

ESC/EAS Guidelines for the management of dyslipidaemias
management of dyslipidaemias of the European Society
European Atherosclerosis Society (EAS)

European Heart Journal

32, 1769-1818

DOI: [10.1093/eurheartj/ehr158](https://doi.org/10.1093/eurheartj/ehr158)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of Neurological Disorders. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 658-658.	0.9	0
2	Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity. Cellular and Molecular Life Sciences, 2004, 61, 2979-2982.	2.4	11
3	The evolution of domain arrangements in proteins and interaction networks. Cellular and Molecular Life Sciences, 2005, 62, 435-445.	2.4	120
4	Poly-ADP-ribosylation in health and disease. Cellular and Molecular Life Sciences, 2005, 62, 739-750.	2.4	115
5	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 fgBT /Overlöck 10 T	10.0	2,331
7	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 2011, 365, 2078-2087.	13.9	731
8	Fenofibrate. Drugs, 2011, 71, 1917-1946.	4.9	124
9	Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Current Medical Research and Opinion, 2011, 27, 2165-2173.	0.9	15
10	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. Clinical Lipidology, 2011, 6, 693-702.	0.4	0
12	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906.	1.0	1,394
13	Introduction. Atherosclerosis Supplements, 2011, 12, 265-266.	1.2	8
14	87 EZETIMIBE/SIMVASTATIN 10/40MG VERSUS ATORVASTATIN 40MG IN HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY. Atherosclerosis Supplements, 2011, 12, 21.	1.2	0
15	HDL-C: Role as a risk modifier. Atherosclerosis Supplements, 2011, 12, 267-270.	1.2	87
16	Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2011, 64, 1090-1095.	0.4	17
17	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
18	Secondary prevention of heart disease and stroke: work to do. Lancet, The, 2011, 378, 1200-1202.	6.3	1
19	Low Density Lipoprotein Cholesterol Target Goal Attainment Rate in Korean Patients with Diabetes. Diabetes and Metabolism Journal, 2011, 35, 578.	1.8	1
20	State of the art papers Lipids, blood pressure, kidney " what was new in 2011?. Archives of Medical Science, 2011, 6, 1055-1066.	0.4	63

#	ARTICLE	IF	CITATIONS
21	Residual cardiovascular risk in secondary prevention. <i>Internal and Emergency Medicine</i> , 2011, 6, 61-68.	1.0	6
22	Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification?. <i>Current Opinion in Lipidology</i> , 2011, 22, 454-459.	1.2	3
23	Intestinal sterol transporters and cholesterol absorption inhibition. <i>Current Opinion in Lipidology</i> , 2011, 22, 467-478.	1.2	24
24	New ESC/EAS Guidelines for the management of dyslipidaemias – any controversies behind the consensus?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 724-727.	3.1	13
25	Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2099-109.	3.8	374
26	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 987-997.	0.6	6
27	The Carotid Artery Atherosclerosis Burden and Its Relation to Cardiovascular Risk Factors in Black and White Africans with Established Rheumatoid Arthritis: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2012, 39, 1798-1806.	1.0	24
28	Conclusion. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 54-55.	0.8	0
29	Adherence to lipid-lowering treatment: the patient perspective. <i>Patient Preference and Adherence</i> , 2012, 6, 805.	0.8	43
30	Lifestyle Change Programs in the Management of Hyperlipidemia. <i>Oman Medical Journal</i> , 2012, 27, 511-511.	0.3	0
31	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
34	Working together in cardiovascular prevention: the common mission of the <i>European Heart Journal</i> and the <i>European Journal of Preventive Cardiology</i> . <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1217-1226.	0.8	4
35	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	0.8	22
36	Postprandial dyslipidaemia and diabetes. <i>Current Opinion in Lipidology</i> , 2012, 23, 303-309.	1.2	21
37	Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 205-215.	0.9	15
38	Statins and Lipid-Lowering Strategies in PD. <i>Contributions To Nephrology</i> , 2012, 178, 106-110.	1.1	3
39	Lipid-Related Markers and Cardiovascular Disease Prediction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2499-506.	3.8	352
42	The Role of Platelets in Athero-Thrombotic Events. <i>Current Pharmaceutical Design</i> , 2012, 18, 5197-5214.	0.9	57

#	ARTICLE	IF	CITATIONS
43	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
44	Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1005-1033.	0.8	223
45	Time to consider an Asian guideline for management of dyslipidemia?. <i>Journal of Diabetes Investigation</i> , 2012, 3, 199-201.	1.1	0
46	Pravastatin and fenofibrate in combination (Pravafenix [®]) for the treatment of high-risk patients with mixed hyperlipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 565-575.	0.6	3
47	A Systematic Review of Xuezhikang, an Extract from Red Yeast Rice, for Coronary Heart Disease Complicated by Dyslipidemia. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-18.	0.5	37
49	Actualizaci3n en el manejo del colesterol hdl bajo. <i>Revista M3dica Cl3nica Las Condes</i> , 2012, 23, 689-692.	0.2	0
50	Stage of chronic kidney disease and severity of coronary heart disease manifestation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 457-460.	0.9	14
51	Conflicts and dilemmas in prevention of cardiovascular disease. The new, Norwegian Guidelines“a new approach to risk management. <i>European Journal of General Practice</i> , 2012, 18, 56-62.	0.9	2
52	Statins Work Just as Well in Women as in Men. <i>Archives of Internal Medicine</i> , 2012, 172, 919-20.	4.3	10
53	Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2012, 5, CMED.S7591.	1.0	15
54	Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. <i>Oman Medical Journal</i> , 2012, 27, 260-260.	0.3	1
55	Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective. <i>Arthritis</i> , 2012, 2012, 1-15.	2.0	57
56	Critical appraisal of trials for validation of “risk-guided” cardiovascular disease prevention therapy. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 33-36.	0.8	2
57	Risk-guided therapy: a first step to personalized medicine. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 5-6.	0.8	8
58	A new approach to managing the 'statin-intolerant' patient?. <i>European Heart Journal</i> , 2012, 33, 1040-1043.	1.0	6
59	The best of the <i>European Heart Journal</i> : look back with pride. <i>European Heart Journal</i> , 2012, 33, 1161-1171.	1.0	10
60	Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?). <i>Current Vascular Pharmacology</i> , 2012, 10, 374-377.	0.8	23
61	4.2 Diabetes und Stoffwechsel. , 0, , .		0

#	ARTICLE	IF	CITATIONS
62	Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. <i>Aids</i> , 2012, 26, 1387-1392.	1.0	64
63	Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function. <i>Current Vascular Pharmacology</i> , 2012, 10, 705-708.	0.8	18
64	Hypertension: Quo Vadis?. <i>Current Vascular Pharmacology</i> , 2012, 10, 739-742.	0.8	2
66	Mutation Screening of the APOA5 Gene in Subjects with Coronary Artery Disease. <i>Journal of Investigative Medicine</i> , 2012, 60, 1015-1019.	0.7	14
67	Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 150-157.	0.4	11
68	Module 15. Statins and their role in the prevention of cardiovascular disease. <i>NursePrescribing</i> , 2012, 10, 1-11.	0.1	0
70	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , 2012, 380, 581-590.	6.3	2,250
71	Mendelian randomisation, lipids, and cardiovascular disease. <i>Lancet, The</i> , 2012, 380, 543-545.	6.3	26
72	Balancing the cardiometabolic benefits and risks of statins. <i>Lancet, The</i> , 2012, 380, 541-543.	6.3	9
74	QRisk superior in diverse South Asian groups - response to Robson et al.. <i>International Journal of Clinical Practice</i> , 2012, 66, 910-910.	0.8	0
75	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. <i>International Journal of Evidence-Based Healthcare</i> , 2012, 10, 211-221.	0.1	25
76	Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. <i>International Journal of Evidence-Based Healthcare</i> , 2012, 10, 181-190.	0.1	8
77	Cardiovascular risk. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 396-410.	1.1	53
78	LDL Apheresis and Inflammation – Implications for Atherosclerosis. <i>Scandinavian Journal of Immunology</i> , 2012, 76, 229-236.	1.3	22
79	Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2497.	3.8	393
80	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2012, 380, 1995-2006.	6.3	319
81	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. <i>Lancet, The</i> , 2012, 380, 2007-2017.	6.3	379
82	Association of total cholesterol/apoB100 with lipid and protein oxidation products in stable angina patients treated with statins. <i>European Journal of Lipid Science and Technology</i> , 2012, 114, 1335-1339.	1.0	1

#	ARTICLE	IF	CITATIONS
85	Statin-Induced Immunomodulation Alters Peripheral Invariant Natural Killer T-cell Prevalence in Hyperlipidemic Patients. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 293-299.	1.3	5
86	Inhibition of Cholesterol Absorption: Targeting the Intestine. <i>Pharmaceutical Research</i> , 2012, 29, 3235-3250.	1.7	15
88	Colesterol de las lipoproteínas de baja densidad <70mg/dl en la enfermedad renal crónica. ¿Ficción o realidad?. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 284-288.	0.4	0
89	Insuficiencia renal crónica y estatinas. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 297-298.	0.4	0
90	News from the literature: Focus on joint ESC/EAS dyslipidemia guidelines. <i>Atherosclerosis</i> , 2012, 220, 42-44.	0.4	1
91	CETP inhibition in perspective. <i>Atherosclerosis</i> , 2012, 220, 325-328.	0.4	2
92	Non-high-density lipoprotein cholesterol is a practical predictor of long-term cardiac death after coronary artery bypass grafting. <i>Atherosclerosis</i> , 2012, 221, 206-211.	0.4	11
93	Controversies in dyslipidaemia management. <i>Atherosclerosis</i> , 2012, 221, 321-324.	0.4	1
94	Non-lipid effects of rosuvastatin+fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. <i>Atherosclerosis</i> , 2012, 221, 169-175.	0.4	14
95	In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. <i>Atherosclerosis</i> , 2012, 221, 478-483.	0.4	3
96	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. <i>Atherosclerosis</i> , 2012, 223, 251-261.	0.4	203
97	A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. <i>Atherosclerosis</i> , 2012, 222, 564-566.	0.4	9
98	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
99	Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level. <i>Clinical Biochemistry</i> , 2012, 45, 1444-1449.	0.8	22
100	Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies. <i>Journal of Clinical Lipidology</i> , 2012, 6, 534-544.	0.6	2
102	Comments on the ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed.)</i> , 2012, 65, 125-130.	0.4	0
103	Metabolic syndrome: What is it and how useful is the diagnosis in clinical practice?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2012, 31, 637-639.	0.2	2
104	Efficacy of a combination of natural lipid-lowering and antioxidant agents in hypercholesterolaemic patients. <i>Nutrafoods</i> , 2012, 11, 145-150.	0.5	2

#	ARTICLE	IF	CITATIONS
105	Medical options to fight mortality in end-stage renal disease: a review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4298-4307.	0.4	25
106	LDL-cholesterol target values and actual values in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic monotherapy: The lipid results of the French ESCALADE survey. <i>Annales D'Endocrinologie</i> , 2012, 73, 503-509.	0.6	1
115	The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S95.	0.4	11
116	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
117	Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 745-758.	1.5	10
118	Food combinations for cholesterol lowering. <i>Nutrition Research Reviews</i> , 2012, 25, 249-266.	2.1	26
119	Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 5-9.	0.3	0
120	Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 49-56.	1.0	12
121	Fenofibrate: a guide to its use in dyslipidaemia. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 5-10.	0.3	0
122	Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3956-3964.	1.8	523
123	The 2012 SEMDSA Guideline for the Management of type 2 Diabetes. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S94.	0.4	54
124	Niacin: another look at an underutilized lipid-lowering medication. <i>Nature Reviews Endocrinology</i> , 2012, 8, 517-528.	4.3	41
125	South African Dyslipidaemia Guideline Consensus Statement:. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, 155-165.	0.4	30
126	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
127	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359
128	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. <i>Revista Española De Cardiología</i> , 2012, 65, 172.e1-172.e57.	0.6	14
130	Comentarios a la guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. <i>Revista Española De Cardiología</i> , 2012, 65, 125-130.	0.6	21
131	Burnt sugarcane harvesting: Particulate matter exposure and the effects on lung function, oxidative stress, and urinary 1-hydroxypyrene. <i>Science of the Total Environment</i> , 2012, 437, 200-208.	3.9	58

#	ARTICLE	IF	CITATIONS
132	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 309-318.	13.9	810
133	One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2012, 110, 356-363.	0.7	219
135	A Suggested Paradigm for Coronary Risk Screening in Asymptomatic Personsâ€”Assessment of Total Coronary Atheromatous Burden. <i>Heart Lung and Circulation</i> , 2012, 21, 449-454.	0.2	2
136	Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: A 15-year follow-up of the Chinese Multi-provincial Cohort Study. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 217-224.	1.1	22
137	Non-every day statin administration â€” A literature review. <i>European Journal of Internal Medicine</i> , 2012, 23, 474-478.	1.0	16
138	Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. <i>BMJ, The</i> , 2012, 345, e5244-e5244.	3.0	108
139	Aragon workersâ€™ health study â€” design and cohort description. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 45.	0.7	70
140	Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983â€”2009. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 68.	0.7	38
141	Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland. <i>BMC Public Health</i> , 2012, 12, 246.	1.2	14
142	What Is the Role of Advanced Lipoprotein Analysis in Practice?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2607-2615.	1.2	19
143	Arterial Erectile Dysfunction and Peripheral Arterial Disease: Reliability of a New Phenotype of Endothelial Progenitor Cells and Endothelial Microparticles. <i>Journal of Andrology</i> , 2012, 33, 1268-1275.	2.0	13
144	Pitavastatin. <i>Drugs</i> , 2012, 72, 565-584.	4.9	27
145	Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160â€”mg/40â€”mg in Patients with Mixed Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 2012, 32, 281-291.	1.1	8
146	Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients. <i>Drugs</i> , 2012, 72, 2365-2373.	4.9	89
148	Severe familial hypercholesterolaemia: Current and future management. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 656-665.	0.7	22
149	Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: An Indian consensus statement. <i>Indian Heart Journal</i> , 2012, 64, 503-507.	0.2	2
150	Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2344-2353.	1.2	461
152	Â¿CuÃ¡les son las diferencias entre las funciones para la evaluaciÃ³n del riesgo cardiovascular?. <i>Cardiocre</i> , 2012, 47, 12-15.	0.0	1

#	ARTICLE	IF	CITATIONS
153	Chronic kidney disease predicts poor prognosis in patients with stable premature coronary artery disease. <i>European Journal of Internal Medicine</i> , 2012, 23, 716-719.	1.0	8
154	Anatomical Predictors of Major Adverse Limb Events after Infrapopliteal Angioplasty for Patients with Critical Limb Ischaemia due to Pure Isolated Infrapopliteal Lesions. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012, 44, 318-324.	0.8	28
155	Gender Differences in Latin-American Patients With Rheumatoid Arthritis. <i>Gender Medicine</i> , 2012, 9, 490-510.e5.	1.4	38
156	Relevancia de la enfermedad arterial periférica en sujetos de edad avanzada. <i>Hipertension Y Riesgo Vascular</i> , 2012, 29, 14-21.	0.3	0
157	A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?. <i>Heart Lung and Circulation</i> , 2012, 21, 543-550.	0.2	16
158	Estimación del riesgo cardiovascular global en pacientes diabéticos. <i>Medicine</i> , 2012, 11, 1050-1054.	0.0	0
160	Tratamiento de las hiperlipidemias. <i>Medicine</i> , 2012, 11, 1145-1152.	0.0	0
161	Statins are better than fibrates in patients with a previous venous thromboembolism. <i>Thrombosis Research</i> , 2012, 130, 831-832.	0.8	0
162	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. <i>Current Cardiology Reports</i> , 2012, 14, 709-720.	1.3	93
163	Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2012, 367, 1891-1900.	13.9	424
170	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	0.8	224
171	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 937.e1-937.e66.	0.6	30
172	Estratificación del riesgo cardiovascular: importancia y aplicaciones. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 8-11.	0.2	2
173	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	0.6	31
175	Update on guidelines for management of hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1239-1249.	0.6	5
176	Interactions Between Cardiovascular and Cerebrovascular Disease. <i>Current Treatment Options in Neurology</i> , 2012, 14, 557-593.	0.7	6
178	Differences in Statin Usage and Target-Goal Achievement between Departments at the Same Hospital. <i>PLoS ONE</i> , 2012, 7, e50466.	1.1	0
179	Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 299-315.	0.9	67

#	ARTICLE	IF	CITATIONS
180	Lipoproteins Impact Increasing Cardiovascular Mortality. , 2012, , .		0
181	Screening for lipid disorders. <i>Pathology</i> , 2012, 44, 115-121.	0.3	4
182	The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. , 2012, , .		12
183	Achieving weight loss and avoiding obesity. <i>South African Medical Journal</i> , 2012, 102, 730.	0.2	1
184	Optimal Range of Triglyceride Values to Estimate Serum Low Density Lipoprotein Cholesterol Concentration in Korean Adults: the Korea National Health and Nutrition Examination Survey, 2009. <i>Journal of Korean Medical Science</i> , 2012, 27, 1530.	1.1	11
185	European guidance on management of dyslipidaemias. <i>British Journal of Cardiac Nursing</i> , 2012, 7, 242-243.	0.0	0
187	South African Dyslipidaemia Guideline Consensus Statement. <i>South African Medical Journal</i> , 2012, 102, 178.	0.2	24
188	How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?. <i>Archives of Medical Science</i> , 2012, 4, 608-613.	0.4	10
189	Editorial [Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough?]. <i>Current Vascular Pharmacology</i> , 2012, 10, 173-177.	0.8	11
190	Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012, 4, 598-600.	0.4	17
191	UP TO DATE STATINS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 538-544.	0.3	0
192	Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. <i>Vascular Health and Risk Management</i> , 2012, 8, 621.	1.0	34
194	Facteurs de risques métaboliques et cardiovasculaires. , 2012, , 245-271.		0
195	Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 810-821.	1.5	167
196	Response to Mildly Decreased Glomerular Filtration Rate Is Associated With Poor Coronary Heart Disease Outcome. <i>Clinical Cardiology</i> , 2012, 35, 315-315.	0.7	2
197	Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy. <i>Clinical Cardiology</i> , 2012, 35, 385-391.	0.7	37
198	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>Clinical Cardiology</i> , 2012, 35, 722-729.	0.7	19
199	Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 501-505.	1.0	12

#	ARTICLE	IF	CITATIONS
201	The Detection of Heterozygous Familial Hypercholesterolemia in Ireland. <i>Advances in Therapy</i> , 2012, 29, 456-463.	1.3	8
203	Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 159-168.	0.9	35
204	Midterm Benefits of Preoperative Statin Therapy in Patients Undergoing Isolated Valve Surgery. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1881-1887.	0.7	9
205	Diabetes mellitus and the heart. <i>International Journal of Clinical Practice</i> , 2012, 66, 640-647.	0.8	29
208	Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. <i>Respirology</i> , 2012, 17, 422-431.	1.3	69
209	Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?. <i>Current Cardiology Reports</i> , 2012, 14, 112-124.	1.3	20
213	Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways. <i>BMC Research Notes</i> , 2013, 6, 52.	0.6	7
214	Statin use among older Finns stratified according to cardiovascular risk. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 261-267.	0.8	17
215	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 453-464.	6.1	156
216	Novel pharmacotherapies of familial hyperlipidemia. , 2013, 139, 301-312.		2
217	Statins in cardiometabolic disease: what makes pitavastatin different?. <i>Cardiovascular Diabetology</i> , 2013, 12, S1.	2.7	17
218	Statin diabetogenicity: guidance for clinicians. <i>Cardiovascular Diabetology</i> , 2013, 12, S3.	2.7	36
219	How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?. <i>Current Cardiology Reports</i> , 2013, 15, 400.	1.3	142
220	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
221	Childhood Obesity Risk Evaluation based on perinatal factors and family sociodemographic characteristics: CORE Index. <i>European Journal of Pediatrics</i> , 2013, 172, 551-555.	1.3	26
222	Left ventricular morphology and function in patients with rheumatoid arthritis. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 233-238.	1.0	15
224	Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. <i>European Journal of Nutrition</i> , 2013, 52, 1843-1852.	1.8	27
225	Role of Colesevelam in Combination Lipid-Lowering Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 315-323.	1.0	26

#	ARTICLE	IF	CITATIONS
226	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 799-807.	1.1	111
227	Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia. <i>Pharmacoeconomics</i> , 2013, 31, 377-391.	1.7	15
228	Heterozygosity for lysosomal acid lipase E85JM mutation and serum lipid concentrations. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 732-736.	1.1	25
229	Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2090-2099.	1.2	191
230	New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 559-567.	1.3	133
232	Associations between the consumption of different kinds of seafood and out-of-hospital cardiac arrests of cardiac origin in Japan. <i>International Journal of Cardiology Heart & Vessels</i> , 2013, 2, 8-14.	0.5	3
233	From the Editor: The future of managing lipoprotein disorders. <i>Journal of Clinical Lipidology</i> , 2013, 7, 535-538.	0.6	0
234	Familial hypercholesterolemia affects microvascular autoregulation in children. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 820-827.	1.5	9
235	Characterization of lipid profile in primary health care users in Portugal. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 987-996.	0.2	11
236	Is type 2 diabetes really a coronary heart disease risk equivalent?. <i>Vascular Pharmacology</i> , 2013, 59, 11-18.	1.0	30
237	A comparison of non-HDL and LDL cholesterol goal attainment in the CHILLAS trial. <i>International Journal of Cardiology</i> , 2013, 168, 4340-4342.	0.8	6
238	Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. <i>International Journal of Cardiology</i> , 2013, 168, 3846-3852.	0.8	140
239	How to control residual cardiovascular risk despite statin treatment: Focusing on HDL cholesterol. <i>International Journal of Cardiology</i> , 2013, 166, 8-14.	0.8	54
240	Advances in Dyslipidemia. , 2013, , .		0
241	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013, 231, 300-307.	0.4	66
242	Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting UNdertreatment of lipids in ACS) Tj ETQq1 10x7843144gBT /Ove		
245	Avian Atherosclerosis: Parrots and Beyond. <i>Journal of Exotic Pet Medicine</i> , 2013, 22, 336-347.	0.2	31
246	Fenofibrate and the kidney: an overview. <i>European Journal of Clinical Investigation</i> , 2013, 43, 522-531.	1.7	46

#	ARTICLE	IF	CITATIONS
248	Protocolo terapéutico del síndrome metabólico. <i>Medicine</i> , 2013, 11, 2434-2437.	0.0	0
249	Caso clínico de dislipidemia mixta. <i>Medicine</i> , 2013, 11, 2438.e1-2438.e2.	0.0	0
251	Protocolo terapéutico de las dislipidemias. <i>Medicine</i> , 2013, 11, 2429-2433.	0.0	0
252	Lipid Imbalance in Individuals Predisposed to Rheumatoid Arthritis: Possible Relationship with Common Infections. <i>Bulletin of Experimental Biology and Medicine</i> , 2013, 155, 778-784.	0.3	0
253	Polypill is not a "vaccine-like" solution for primary cardiovascular disease prevention in all parts of the world. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, 981-982.	2.0	3
254	Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1597-1612.	0.6	4
255	When should we measure lipoprotein (a)? <i>European Heart Journal</i> , 2013, 34, 3268-3276.	1.0	68
256	Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome—Results from the countrywide TARGET study. <i>International Journal of Cardiology</i> , 2013, 168, 922-927.	0.8	30
257	American Association of Clinical Endocrinologists™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
258	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2061.	3.8	568
260	Chronic kidney disease and statin therapy: to treat or not to treat? <i>European Heart Journal</i> , 2013, 34, 1772-1774.	1.0	3
261	Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 285-296.	1.0	26
262	The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER. <i>European Heart Journal</i> , 2013, 34, 1318-1320.	1.0	2
264	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
265	Pitavastatin in cardiometabolic disease: therapeutic profile. <i>Cardiovascular Diabetology</i> , 2013, 12, S2.	2.7	21
266	Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. <i>Annals of the New York Academy of Sciences</i> , 2013, 1290, 37-51.	1.8	80
267	Adverse events of statin+fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 181-188.	0.9	6
268	SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R91.	1.6	40

#	ARTICLE	IF	CITATIONS
269	n-3 Fatty acids and cardiovascular disease: the story is not over yet. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 357-363.	1.4	5
271	First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. <i>Lipids in Health and Disease</i> , 2013, 12, 170.	1.2	12
272	Recent Developments in the Treatment of Familial Hypercholesterolemia: A Review of Several New Drug Classes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 696-705.	0.4	4
273	Evidence that periodontal treatment improves biomarkers and CVD outcomes. <i>Journal of Periodontology</i> , 2013, 84, S85-S105.	1.7	68
274	Demystifying the management of hypertriglyceridaemia. <i>Nature Reviews Cardiology</i> , 2013, 10, 648-661.	6.1	92
275	Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations – A meta-analysis of randomized controlled studies. <i>Atherosclerosis</i> , 2013, 230, 336-346.	0.4	93
276	LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. <i>European Journal of Nutrition</i> , 2013, 52, 547-557.	1.8	44
277	Evidence that periodontal treatment improves biomarkers and CVD outcomes. <i>Journal of Clinical Periodontology</i> , 2013, 40, S85-105.	2.3	156
278	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
279	Are we ready to use oxidative stress in clinical practice?. <i>European Journal of Lipid Science and Technology</i> , 2013, 115, 133-135.	1.0	0
280	Cardiac telerehabilitation: current situation and future challenges. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 12-16.	0.8	50
281	Review of existing experimental approaches for the clinical evaluation of the benefits of plant food supplements on cardiovascular function. <i>Food and Function</i> , 2013, 4, 856.	2.1	6
282	Target cardiovascular risk rather than cholesterol concentration. <i>BMJ, The</i> , 2013, 347, f7110-f7110.	3.0	13
283	Early development of metabolic syndrome in patients subjected to lung transplantation. <i>Clinical Transplantation</i> , 2013, 27, E237-43.	0.8	21
284	Alternate-day Dosing with Statins. <i>American Journal of Medicine</i> , 2013, 126, 99-104.	0.6	17
285	Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2482-2489.	0.8	33
286	Is there a role for thoracic aortic calcium to fine-tune cardiovascular risk prediction?. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 217-219.	0.7	8
287	The prognostic value of carotid intima-media thickness revisited. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 1-3.	0.7	5

#	ARTICLE	IF	CITATIONS
288	Low levels of high-density lipoprotein cholesterol in patients with atherosclerotic stroke: A prospective cohort study. <i>Atherosclerosis</i> , 2013, 228, 472-477.	0.4	36
289	High Intestinal Cholesterol Absorption Is Associated With Cardiovascular Disease and Risk Alleles in ABCG8 and ABO. <i>Journal of the American College of Cardiology</i> , 2013, 62, 291-299.	1.2	93
290	Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1146-1156.	1.2	210
291	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013, 228, 18-28.	0.4	119
293	Management of a 112-year-old patient with STEMI: A case-based short literature review. <i>European Geriatric Medicine</i> , 2013, 4, 112-114.	1.2	0
294	Non-HDL Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1960-1965.	1.2	59
295	How will new medications affect the lipoprotein apheresis situation in Germany?. <i>Atherosclerosis Supplements</i> , 2013, 14, 71-72.	1.2	7
296	Angina estable. <i>Medicine</i> , 2013, 11, 2188-2197.	0.0	0
298	Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 93-102.	0.7	22
299	Phytosterol capsules and serum cholesterol in hypercholesterolemia: A randomized controlled trial. <i>Atherosclerosis</i> , 2013, 228, 421-425.	0.4	30
300	Adequate Cholesterol Levels in Coronary Heart Disease and Diabetic Patients. Analysis According to Medical Specialty and Autonomous Communities. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 748-749.	0.4	1
301	C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population. <i>European Journal of Internal Medicine</i> , 2013, 24, 161-166.	1.0	4
302	Percentiles of Carotid Intima-media Thickness in a Spanish Population With and Without Cardiovascular Risk Factors. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 749-751.	0.4	5
303	¿Qué ha habido de nuevo en riesgo vascular en el año 2012?. <i>Revista Clinica Espanola</i> , 2013, 213, 442-452.	0.2	6
305	Cifras de colesterol adecuadas en pacientes coronarios y diabéticos. Análisis según especialidades médicas y comunidades autónomas. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 748-749.	0.6	10
307	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. <i>Atherosclerosis</i> , 2013, 226, 471-475.	0.4	17
308	Discordance: Can we capitalize on it to better personalize atherosclerosis treatment?. <i>Atherosclerosis</i> , 2013, 229, 504-506.	0.4	7
309	What was new about vascular risk in the year 2012?. <i>Revista Clinica Espanola</i> , 2013, 213, 442-452.	0.3	0

#	ARTICLE	IF	CITATIONS
310	Perfil clnico y pronstico de los pacientes con sndrome coronario agudo y colesterol unido a lipoprotenas de baja densidad < 70mg/dl. Revista Espanola De Cardiologia, 2013, 66, 588-589.	0.6	13
311	Non-obstructive coronary artery disease documented by cardiac computed tomography: Discrepancy between atherosclerotic burden and cardiovascular risk. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Over	1.2	31
312	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology, 2013, 62, 1834-1841.	1.2	42
315	A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. International Journal of Food Sciences and Nutrition, 2013, 64, 882-889.	1.3	30
316	Clinical Profile and Prognosis of Patients With Low-density Lipoprotein Cholesterol <70mg/dL and Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2013, 66, 588-589.	0.4	1
317	Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. Atherosclerosis, 2013, 226, 296-298.	0.4	6
318	Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C. Atherosclerosis, 2013, 230, 106-109.	0.4	26
319	Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. Atherosclerosis Supplements, 2013, 14, 45-50.	1.2	8
320	Changes in serum uric acid levels and cardiovascular events: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 707-714.	1.1	45
321	New EAS Consensus Statement on FH: Improving the care of FH patients. Atherosclerosis, 2013, 231, 69-71.	0.4	9
324	Gua de prctica clnica de la ESH/ESC para el manejo de la hipertensin arterial (2013). Revista Espanola De Cardiologia, 2013, 66, 880.e1-880.e64.	0.6	24
326	Guidelines on CVD prevention: Confusing or complementary?. Atherosclerosis, 2013, 226, 299-300.	0.4	5
327	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	1.2	331
328	Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis, 2013, 231, 401-404.	0.4	38
329	Tratamento com estatina no diabtico tipo 2. Revista Portuguesa De Endocrinologia Diabetes E Metabolismo, 2013, 8, 50-54.	0.1	0
330	Stanowisko dotyczce postpowania w rodzinnej hipercholesterolemii u dzieci i mdzieÅ1/4y. Stanowisko Forum Ekspertw Lipidowych. Pediatria Polska, 2013, 88, 567-574.	0.1	1
331	Lipoprotein apheresis standard for apheresis competence centers â€“ An updated synthesis and amendment to pre-existing standards. Atherosclerosis Supplements, 2013, 14, 57-65.	1.2	11
332	Early Atherosclerosis Detection in Asymptomatic Patients: A Comparison of Carotid Ultrasound, Coronary Artery Calcium Score, and Coronary Computed Tomography Angiography. Canadian Journal of Cardiology, 2013, 29, 1687-1694.	0.8	18

#	ARTICLE	IF	CITATIONS
334	Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. <i>Atherosclerosis</i> , 2013, 229, 415-422.	0.4	13
336	Polymeric bile acid sequestrantsâ€™ Synthesis using conventional methods and new approaches based on â€œcontrolledâ€™ living radical polymerization. <i>Progress in Polymer Science</i> , 2013, 38, 445-461.	11.8	33
337	Lipid control in patients with coronary heart disease treated in primary care or cardiology clinics. <i>Journal of Clinical Lipidology</i> , 2013, 7, 637-641.	0.6	3
338	Arterial erectile dysfunction: Different severities of endothelial apoptosis between diabetic patients â€œrespondersâ€™ and â€œnon respondersâ€™ to sildenafil. <i>European Journal of Internal Medicine</i> , 2013, 24, 234-240.	1.0	23
339	Egg yolk consumption, smoking and carotid plaque: Reply to letters to the Editor by Sean Lucan and T Dylan Olver et Al.. <i>Atherosclerosis</i> , 2013, 227, 189-191.	0.4	7
340	Decreased Tissue Levels of Cyclophilin A, a Cyclosporine A Target and Phospho-ERK1/2 in Simvastatin Patients with Abdominal Aortic Aneurysm. <i>European Journal of Vascular and Endovascular Surgery</i> , 2013, 45, 682-688.	0.8	24
342	Prevalence of Silent Cerebral Ischemia in Paroxysmal and Persistent Atrial Fibrillation and Correlation With Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1990-1997.	1.2	215
343	Comentarios del ComitÃ© EspaÃ±ol Interdisciplinario de PrevenciÃ³n Cardiovascular (CEIPC) a las GuÃ­as Europeas de PrevenciÃ³n Cardiovascular 2012. <i>Hipertension Y Riesgo Vascular</i> , 2013, 30, 143-155.	0.3	22
344	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290.	2.0	3
346	State of the art paper Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation. <i>Archives of Medical Science</i> , 2013, 1, 151-158.	0.4	28
347	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70Âµg/dl or â‰¥50% reduction in high-risk patients: Results from VOYAGER. <i>Atherosclerosis</i> , 2013, 228, 265-269.	0.4	20
348	Aortic stenosis: a general overview of clinical, pathophysiological and therapeutic aspects. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 239-250.	0.6	17
349	Statins for the primary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2021, 2021, CD004816.	1.5	933
350	Novel risk factors for cardiovascular disease in rheumatoid arthritis. <i>Immunologic Research</i> , 2013, 56, 267-286.	1.3	45
352	Nicotinic acid as a lipid-modifying drug â€œ A review. <i>Atherosclerosis Supplements</i> , 2013, 14, 7-13.	1.2	45
353	Current standards in diagnosis and therapy of hyperlipoproteinemia. <i>Atherosclerosis Supplements</i> , 2013, 14, 15-18.	1.2	6
354	Effect of Carotid Plaque Screening Using Contrast-Enhanced Ultrasound on Cardiovascular Risk Stratification. <i>American Journal of Cardiology</i> , 2013, 111, 754-759.	0.7	23
355	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2013, 29, 151-167.	0.8	680

#	ARTICLE	IF	CITATIONS
356	The Role of Statins in the Metabolic Syndrome. , 2013, , 147-153.		0
357	Triglyceride-rich lipoproteins and HDL: What do recent trials tell us?. Atherosclerosis, 2013, 228, 329-331.	0.4	1
358	PCSK9â€™an exciting target for reducing LDL-cholesterol levels. Nature Reviews Endocrinology, 2013, 9, 76-78.	4.3	10
359	LDL cholesterol in CKDâ€™to treat or not to treat?. Kidney International, 2013, 84, 451-456.	2.6	49
360	Is walking to school associated with improved metabolic health?. International Journal of Behavioral Nutrition and Physical Activity, 2013, 10, 12.	2.0	58
361	HDL function and cardiovascular risk: Debate continuesâ€ . Atherosclerosis, 2013, 229, 38-41.	0.4	2
362	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. International Journal of Cardiology, 2013, 167, 2391-2396.	0.8	62
363	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	0.7	355
364	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports, 2013, 15, 391.	1.3	9
365	HIV and Coronary Heart Disease. Journal of the American College of Cardiology, 2013, 61, 511-523.	1.2	234
366	Statins and the risk of developing diabetes. BMJ, The, 2013, 346, f3156-f3156.	3.0	11
367	Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. Journal of Clinical Lipidology, 2013, 7, 217-221.	0.6	28
368	Lipoprotein (a) is independently correlated with coronary artery calcification. European Journal of Internal Medicine, 2013, 24, 75-79.	1.0	51
369	Therapeutic Angiogenesis in Critical Limb Ischemia. Angiology, 2013, 64, 466-480.	0.8	41
370	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
371	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Journal of Clinical Lipidology, 2013, 7, 561-565.	0.6	147
374	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
375	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915

#	ARTICLE	IF	CITATIONS
376	The bumpy road to evidence: why many research findings are lost in translation. <i>European Heart Journal</i> , 2013, 34, 3329-3335.	1.0	20
377	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013, 34, 1818-1825.	1.0	61
381	Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between ≤ 60 and ≥ 75 Years. <i>Obesity Facts</i> , 2013, 6, 9-16.	1.6	11
382	Genes and cardiovascular risk. <i>European Heart Journal</i> , 2013, 34, 949-950.	1.0	3
384	Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children. <i>Journal of Nutritional Science</i> , 2013, 2, e32.	0.7	14
385	ESC Core Curriculum for the General Cardiologist (2013). <i>European Heart Journal</i> , 2013, 34, 2381-2411.	1.0	75
386	An update on the management of comorbid conditions in lupus nephritis. <i>Clinical Investigation</i> , 2013, 3, 281-293.	0.0	0
389	Chapter 2: Pharmacological cholesterol-lowering treatment in adults. <i>Kidney International Supplements</i> , 2013, 3, 271-279.	4.6	16
390	Association between Angiotensin II Type 1 Receptor Polymorphism and Sudden Cardiac Death in Myocardial Infarction. <i>Disease Markers</i> , 2013, 35, 287-293.	0.6	7
391	Intensive risk factor control in stroke prevention. <i>F1000prime Reports</i> , 2013, 5, 42.	5.9	11
392	Lipid-Lowering Pharmacotherapy in Central and Eastern European Countries in Cardiovascular Prevention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 234-242.	1.0	4
393	Atherogenic dyslipidemia. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 969.	0.2	62
394	Diagnosis and treatment of familial hypercholesterolaemia. <i>European Heart Journal</i> , 2013, 34, 962-971.	1.0	212
395	Management of statin intolerance. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 977.	0.2	32
396	Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement. <i>Disease Markers</i> , 2013, 35, 857-862.	0.6	20
397	Traditional coronary risk factors in healthy Turkish military personnel between 20 and 50 years old: focus on high-density lipoprotein cholesterol. <i>Anatolian Journal of Cardiology</i> , 2013, 13, 552-8.	0.4	0
398	Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice?. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 401-416.	0.5	15
399	Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People. <i>Diabetes Care</i> , 2013, 36, S292-S300.	4.3	5

#	ARTICLE	IF	CITATIONS
400	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013, 54, 339-345.	0.2	30
401	Cardiovascular Disease in Latin American Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study and a Systematic Review. <i>Autoimmune Diseases</i> , 2013, 2013, 1-20.	2.7	26
402	Diet and cardiovascular health in asymptomatic normo- and mildly-to-moderately hypercholesterolemic participants – baseline data from the BLOOD FLOW intervention study. <i>Nutrition and Metabolism</i> , 2013, 10, 62.	1.3	2
403	Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. <i>Cardiovascular Diabetology</i> , 2013, 12, 163.	2.7	15
404	Plant sterols and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2013, 24, 12-17.	1.2	31
405	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7
406	Nutraceuticals and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2013, 28, 475-482.	0.8	14
407	Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease. <i>Menopause</i> , 2013, 20, 852-859.	0.8	5
408	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
409	Population-level changes to promote cardiovascular health. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 409-421.	0.8	106
410	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1764-1770.	0.5	123
411	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1080-1087.	0.8	22
412	Guidelines, position papers and critical reviews: differences and similarities. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 3-5.	0.8	9
413	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , 2013, 54, 467-472.	2.0	52
414	Current challenges in the management of patients with familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 217-229.	0.4	0
415	Guidelines on CVD prevention: confusing or complementary?. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 6-8.	0.8	2
416	An Observational Study of Ezetimibe in Cardiac Transplant Recipients Receiving Calcineurin Inhibitors. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1457-1462.	0.9	10
417	Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Events – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 27.	3.8	6

#	ARTICLE	IF	CITATIONS
418	Relationship between Adiponectin and Leptin, and Blood Lipids in Hyperlipidemia Patients Treated with Red Yeast Rice. <i>Research in Complementary Medicine</i> , 2013, 20, 197-203.	2.2	13
419	Triglycerides and cardiovascular risk. <i>Heart</i> , 2013, 99, 1-2.	1.2	15
420	Nonfasting Lipids: There Is the Population and Then There Is the Patient. <i>JAMA Internal Medicine</i> , 2013, 173, 936.	2.6	4
421	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	0.8	22
422	South African Dyslipidaemia Guideline Consensus Statement. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013, 55, 9-18.	0.2	3
423	Very Large Database of Lipids: Rationale and Design. <i>Clinical Cardiology</i> , 2013, 36, 641-648.	0.7	39
424	The safety of statins in children. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2013, 102, 857-862.	0.7	18
425	Adverse events following statin+ fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 219-226.	0.9	17
426	Prevention and Treatment of Cardiovascular Disease in Women: The Obstetric+Gynecologist's Point of View. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 162-168.	0.4	8
427	Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1009-1015.	1.7	27
428	Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2013, 67, 412-419.	0.8	9
429	Channelling of Statin Use towards Low-Risk Population and Patients with Diabetes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 173-178.	1.2	9
430	Management of the patient with diabetes and coronary artery disease: a contemporary review. <i>Future Cardiology</i> , 2013, 9, 387-403.	0.5	8
431	Statins for primary prevention: problems with cardiovascular-risk estimation?. <i>Nature Reviews Cardiology</i> , 2013, 10, 547-547.	6.1	4
432	Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3388-3395.	4.3	46
433	The Role of Statins in Diabetes Treatment. <i>Diabetes Spectrum</i> , 2013, 26, 156-164.	0.4	8
434	Cardiovascular disease and hypertriglyceridemia: a report from the hypertriglyceridemia registry of the Spanish Atherosclerosis Society. <i>Clinical Lipidology</i> , 2013, 8, 525-532.	0.4	4
437	Classification of LDL Phenotypes by 4 Methods of Determining Lipoprotein Particle Size. <i>Journal of Investigative Medicine</i> , 2013, 61, 942-949.	0.7	21

#	ARTICLE	IF	CITATIONS
438	Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 90.	0.7	14
439	Prognostic implications of non-culprit plaques in acute coronary syndrome: non-invasive assessment with coronary CT angiography. <i>European Heart Journal</i> , 2013, 34, 3799-3799.	1.0	0
440	Hyperuricaemia. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 397-402.	0.6	66
441	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
442	Reassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients - A Systematic Review and Meta-Analysis. <i>Review of Diabetic Studies</i> , 2013, 10, 157-170.	0.5	14
443	Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 11.	1.1	13
444	Hemoglobin A1c Can Identify More Cardiovascular and Metabolic Risk Profile in OGTT-Negative Chinese Population. <i>International Journal of Medical Sciences</i> , 2013, 10, 1028-1034.	1.1	16
445	Melatonin and its use in atherosclerosis and dyslipidemia. <i>ChronoPhysiology and Therapy</i> , 0, , 15.	0.5	2
446	Editorial Statin treatment in the elderly: how much do we know?. <i>Archives of Medical Science</i> , 2013, 4, 585-588.	0.4	8
447	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013, 5, 788-795.	0.4	21
448	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	1.0	7
449	Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases. <i>Journal of Lipid and Atherosclerosis</i> , 2013, 2, 53.	1.1	2
451	High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 23-31.	0.9	5
452	Transitioning from population to individualized preventive cardiology. <i>Research Reports in Clinical Cardiology</i> , 0, , 55.	0.2	1
453	The Correlation Between Achilles Tendon Thickness and Cardiovascular Risk Factors. <i>Journal of Lipid and Atherosclerosis</i> , 2013, 2, 77.	1.1	2
455	Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. <i>Vascular Health and Risk Management</i> , 2013, 9, 563.	1.0	71
456	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	1.0	28
457	Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 139-149.	2.2	88

#	ARTICLE	IF	CITATIONS
458	The Effects of Two <i>Lactobacillus plantarum</i> Strains on Rat Lipid Metabolism Receiving a High Fat Diet. <i>Scientific World Journal</i> , The, 2013, 2013, 1-7.	0.8	54
459	A Markov Model of the Cost-Effectiveness of Pharmacist Care for Diabetes in Prevention of Cardiovascular Diseases: Evidence from Kaiser Permanente Northern California. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 102-114.	2.2	67
460	Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 123-133.	0.9	75
461	Carotid Intima-Media Thickness and Plaque in Apparently Healthy Japanese Individuals with an Estimated 10-Year Absolute Risk of CAD Death According to the Japan Atherosclerosis Society (JAS) Guidelines 2012: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 755-766.	0.9	43
462	Subclinical hypothyroidism and vascular risk: An update. <i>Hormones</i> , 2013, 12, 495-506.	0.9	29
463	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3869-3877.	0.9	52
464	REAL PRACTICE OF STATINS USE AND ITS DEPENDENCE ON FOLLOW-UP IN THE SPECIALIZED MEDICAL CENTRE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (ACCORDING TO THE PROFILE REGISTER). <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 362-367.	0.3	8
465	Lowering cholesterol naturally alongside prescribed medication. <i>NursePrescribing</i> , 2013, 11, 609-614.	0.1	1
466	Increased C-reactive Protein Associates with Elevated Carotid Intima-Media Thickness in Chinese Adults with Normal Low Density Lipoprotein Cholesterol Levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 575-584.	0.9	8
467	MEDICAL SUPERVISION IN SPECIALIZED CENTER AND THE QUALITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES (ACCORDING TO THE PROFIL REGISTER). <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 133-137.	0.3	15
468	Editorial paper Statins in rheumatology: revisited. <i>Reumatologia</i> , 2014, 6, 351-353.	0.5	1
469	Clinical management of familial hypercholesterolemia: new insights from international guidelines and recent studies. <i>Neurology International</i> , 2014, 4, .	0.2	0
470	Self-assessed and self-reported lifestyle of people at risk of cardiovascular diseases. <i>Journal of Nursing Education and Practice</i> , 2014, 4, .	0.1	0
471	Use of Targeted Exome Sequencing in Genetic Diagnosis of Chinese Familial Hypercholesterolemia. <i>PLoS ONE</i> , 2014, 9, e94697.	1.1	18
472	Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease. <i>PLoS ONE</i> , 2014, 9, e101082.	1.1	22
473	The Impact of Chronic Kidney Disease on Lipid Management and Goal Attainment in Patients with Atherosclerosis Diseases in Taiwan. <i>International Journal of Medical Sciences</i> , 2014, 11, 381-388.	1.1	12
474	The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin. <i>International Heart Journal</i> , 2014, 55, 39-47.	0.5	11
475	Dyslipidemia in women: etiology and management. <i>International Journal of Women's Health</i> , 2014, 6, 185.	1.1	57

#	ARTICLE	IF	CITATIONS
476	Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 815.	0.9	31
478	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. <i>Vascular Health and Risk Management</i> , 2014, 10, 237.	1.0	12
479	Association between rs1049673 polymorphism in CD36 and premature coronary heart disease. <i>Genetics and Molecular Research</i> , 2014, 13, 7708-7717.	0.3	9
480	Improving medication adherence in hypercholesterolemia: challenges and solutions. <i>Vascular Health and Risk Management</i> , 2014, 10, 615.	1.0	22
481	Optimal treatment of chronic angina in patients with type 2 diabetes mellitus. <i>Research Reports in Clinical Cardiology</i> , 0, , 155.	0.2	0
482	Personalized Estimates of Benefit From Preventive Care Guidelines. <i>Annals of Internal Medicine</i> , 2014, 160, 140.	2.0	2
483	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2014, 160, 142-143.	2.0	3
484	Absolute Systolic Ankle Blood Pressure Versus Ankle-Brachial Index. <i>Annals of Internal Medicine</i> , 2014, 160, 140-141.	2.0	2
485	Personalized Estimates of Benefit From Preventive Care Guidelines. <i>Annals of Internal Medicine</i> , 2014, 160, 140.	2.0	0
486	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. <i>Vascular Health and Risk Management</i> , 2014, 10, 205.	1.0	21
487	Profile of plasma lipids and degree of derangements among the elderly of Morogoro region, Tanzania. <i>Tanzania Journal of Health Research</i> , 2014, 16, 261-8.	0.1	0
488	Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. <i>Vascular Health and Risk Management</i> , 2014, 10, 225.	1.0	10
489	The Role of Carotid Ultrasound for Cardiovascular Risk Stratification beyond Traditional Risk Factors. <i>Yonsei Medical Journal</i> , 2014, 55, 551.	0.9	15
490	Combinaton or Individual Lipid-Lowering Therapy-What Is The Right Direction?. <i>Journal of Cardiovascular Diseases & Diagnosis</i> , 2014, 02, .	0.0	0
491	STATINS IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES: REPETITION OF THE PAST AND OPTIMISM FOR THE FUTURE. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 513-524.	0.3	7
492	The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. <i>Journal of Metabolic Syndrome</i> , 2014, 03, .	0.1	0
493	Current Treatment of Familial Hypercholesterolaemia. <i>European Cardiology Review</i> , 2014, 9, 76.	0.7	16
494	Are the New Guidelines for the Use of Lipid-Lowering Agents Sound, and Should Their Adoption Be Encouraged?. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 246-9.	0.1	4

#	ARTICLE	IF	CITATIONS
495	Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. <i>Vascular Health and Risk Management</i> , 2014, 10, 279.	1.0	8
496	Prevalence and concordance of high cardiovascular disease scores in HIV/AIDS patients from Croatia and Serbia with four international algorithms. <i>Journal of the International AIDS Society</i> , 2014, 17, 19549.	1.2	2
497	Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. <i>Brazilian Journal of Medical and Biological Research</i> , 2014, 47, 432-437.	0.7	29
498	Use of friedewald equation for dyslipidemia in metabolic syndrome. <i>International Journal of Medicine</i> , 2014, 2, 36.	0.1	2
500	Nonalcoholic fatty liver disease and aging: Epidemiology to management. <i>World Journal of Gastroenterology</i> , 2014, 20, 14185.	1.4	227
501	Prevention and management of cardiovascular risk factors. , 2014, , .		0
503	Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. <i>Kidney International</i> , 2014, 85, 416-424.	2.6	41
504	Are add-on agents to statin therapy necessary in hypercholesterolemia?. <i>Clinical Lipidology</i> , 2014, 9, 695-707.	0.4	0
505	Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. <i>Current Medical Research and Opinion</i> , 2014, 30, 775-784.	0.9	36
506	The effects of mipomersen, a second generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2014, 9, 487-503.	0.4	8
507	Unanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish society of internal medicine. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 193.	0.7	11
509	Cholesterol-lowering effects of oat β -glucan: a meta-analysis of randomized controlled trials. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 1413-1421.	2.2	289
510	Consensus statement on management of dyslipidemia in Indian subjects. <i>Indian Heart Journal</i> , 2014, 66, S1-S51.	0.2	47
511	Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 863-868.	1.4	20
512	Fibrates and niacin: is there a place for them in clinical practice?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2673-2680.	0.9	11
513	Dyslipidaemia: what's around the corner?. <i>Clinical Medicine</i> , 2014, 14, s41-s44.	0.8	5
514	Effects of Preventive Acupuncture and Moxibustion on Fat Accumulation, Blood Lipid, and Uterus of Menopause Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-9.	0.5	5
515	Effect of <i>Morinda citrifolia</i> Fruit Extract Capsule on Total Cholesterol Levels in Patients with Hypercholesterolemia. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 1319.	0.2	4

#	ARTICLE	IF	CITATIONS
516	Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials. <i>Global Cardiology Science & Practice</i> , 2014, 2014, 48.	0.3	3
517	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF- κ B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	26
518	Very late stent thrombosis related to incomplete neointimal coverage or neoatherosclerotic plaque rupture identified by optical coherence tomography imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 24-31.	0.5	36
519	Hypertriglyceridemia Induced Pancreatitis (Chylomicronemia Syndrome) Treated with Supportive Care. <i>Case Reports in Critical Care</i> , 2014, 2014, 1-3.	0.2	1
520	A Randomized Study on Lipids Response to Different Exercise Programs in Overweight Older Men. <i>International Journal of Sports Medicine</i> , 2014, 35, 1106-1111.	0.8	6
521	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
522	Effects of Recombinant Human Thyrotropin Administration on 24-Hour Arterial Pressure in Female Undergoing Evaluation for Differentiated Thyroid Cancer. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-8.	0.6	4
523	Prevalence of Hypothyroidism in Patients with Dyslipidemia: Tehran Thyroid Study (TTS). <i>Hormone and Metabolic Research</i> , 2014, 46, 980-984.	0.7	7
524	General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. <i>BMJ Open</i> , 2014, 4, e004812.	0.8	31
525	Reaching hypertriglyceridemia goals. <i>Current Medical Research and Opinion</i> , 2014, 30, 391-393.	0.9	0
526	Dietary supplementation contributes to lifestyle improvement in hypercholesterolemic patients in real-life contexts. <i>Current Medical Research and Opinion</i> , 2014, 30, 1309-1316.	0.9	5
527	Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1957-1965.	0.9	5
528	Achieving optimal lipid goals in the metabolic syndrome: A global health problem. <i>Atherosclerosis</i> , 2014, 237, 191-193.	0.4	3
529	Clinical utility gene card for: Hyperlipoproteinemia, TYPE II. <i>European Journal of Human Genetics</i> , 2014, 22, 953-953.	1.4	10
531	Prognostic implications of non-culprit plaques in acute coronary syndrome: non-invasive assessment with coronary CT angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1231-1237.	0.5	26
532	Predictive factors of achieving therapeutic goals of hypertriglyceridemia. <i>Current Medical Research and Opinion</i> , 2014, 30, 19-26.	0.9	11
533	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 554-561.	0.6	128
534	A Retrospective Case Series of the Lipid Effects of Switching From Omega-3 Fatty Acid Ethyl Esters to Icosapent Ethyl in Hyperlipidemic Patients. <i>Postgraduate Medicine</i> , 2014, 126, 268-273.	0.9	9

#	ARTICLE	IF	CITATIONS
535	Application of the New Cholesterol Guidelines. <i>New England Journal of Medicine</i> , 2014, 371, 77-79.	13.9	6
536	Are We Moving Towards Concordance on the Principle That Lipid Discordance Matters?. <i>Circulation</i> , 2014, 129, 539-541.	1.6	19
537	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. <i>Circulation</i> , 2014, 129, 553-561.	1.6	189
538	Mortality Among Patients With Familial Hypercholesterolemia: A Registry-Based Study in Norway, 1992-2010. <i>Journal of the American Heart Association</i> , 2014, 3, e001236.	1.6	99
539	Self-reported adherence by MARS reflects LDL cholesterol goal achievement among statin users: validation study in the Czech Republic. <i>Journal of Evaluation in Clinical Practice</i> , 2014, 20, 671-677.	0.9	11
540	Update on the efficacy of statin treatment in acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2014, 44, 501-515.	1.7	20
541	New Therapies for Reducing Low-Density Lipoprotein Cholesterol. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 1007-1033.	1.2	35
542	Treatment of homozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2014, 9, 101-118.	0.4	10
543	Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 667-679.	0.6	17
544	Impact of Atherosclerosis Detection by Carotid Ultrasound on Physician Behavior and Risk Factor Management in Asymptomatic Hypertensive Subjects. <i>Clinical Cardiology</i> , 2014, 37, 91-96.	0.7	5
545	Targeting APOC3 in the Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 2200-2206.	13.9	376
546	Functional foods and cardiometabolic diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1272-1300.	1.1	40
547	Psoriatic Arthritis: An Update. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 913-922.	0.2	3
548	Cardiovascular Disease. <i>World Review of Nutrition and Dietetics</i> , 2014, 111, 94-99.	0.1	0
549	Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. <i>American Heart Journal</i> , 2014, 168, 807-811.	1.2	51
550	Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study. <i>International Journal of Clinical Practice</i> , 2014, 68, 1001-1009.	0.8	7
551	The Relationship Between Gamma-Glutamyl Transferase Levels and Coronary Plaque Burdens and Plaque Structures in Young Adults With Coronary Atherosclerosis. <i>Clinical Cardiology</i> , 2014, 37, 552-557.	0.7	16
552	The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 542-549.	0.6	17

#	ARTICLE	IF	CITATIONS
553	PO115 CLINICAL FEATURES OF DIABETIC PATIENTS ATTENDING OUTPATIENT CLINIC KARDINAH DISTRICT HOSPITAL TEGAL, CENTRAL JAVA “ INDONESIA. Diabetes Research and Clinical Practice, 2014, 106, S103-S104.	1.1	0
554	National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology, 2014, 8, S1-S36.	0.6	64
555	Physical Exercise and Health. Revista Espanola De Cardiologia (English Ed), 2014, 67, 748-753.	0.4	22
556	Measuring LDL Cholesterol: for Old and New Calculations, Is There an Optimal Formula?. Clinical Chemistry, 2014, 60, 1466-1468.	1.5	7
557	Impact of cigarette smoking on the plasma fatty acid profile and their interaction in determining the burden of subclinical atherosclerosis. Nutrafoods, 2014, 13, 159-167.	0.5	4
558	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 2014, 14, 121.	0.7	48
559	Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovascular Diabetology, 2014, 13, 135.	2.7	38
560	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. European Journal of Dermatology, 2014, 24, 662-669.	0.3	4
561	Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. Cmaj, 2014, 186, E449-E456.	0.9	29
562	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. European Journal of Preventive Cardiology, 2014, 21, 866-875.	0.8	18
563	Of heart and kidney: a complicated love story. European Journal of Preventive Cardiology, 2014, 21, 840-846.	0.8	11
564	Heart failure in HIV infection. Current Opinion in Cardiology, 2014, 29, 174-179.	0.8	10
565	How to identify HIV-infected individuals at risk for atherosclerotic events?. Aids, 2014, 28, 2153-2155.	1.0	0
566	Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Current Opinion in Lipidology, 2014, 25, 461-467.	1.2	61
567	Comparison of mortality in patients with coronary or peripheral artery disease following the first vascular intervention. Coronary Artery Disease, 2014, 25, 79-82.	0.3	8
568	Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia. Circulation Research, 2014, 114, 233-235.	2.0	25
569	Familial combined hyperlipidemia. Current Opinion in Lipidology, 2014, 25, 176-182.	1.2	26
570	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. Current Opinion in Lipidology, 2014, 25, 413-417.	1.2	2

#	ARTICLE	IF	CITATIONS
571	The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. <i>Current Opinion in Lipidology</i> , 2014, 25, 239-246.	1.2	12
572	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014, 29, 389-395.	0.8	47
573	Inhibition of PCSK9. <i>Coronary Artery Disease</i> , 2014, 25, 353-359.	0.3	11
574	The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1061-1073.	0.4	25
575	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
576	Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1416.	3.8	301
577	Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 377-383.	0.8	24
578	Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 53-59.	0.9	2
579	Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: An alternative equation for accurate estimation and improved cardiovascular risk classification. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 431-439.	0.9	8
580	Statin intolerance: diagnosis, treatment and alternative therapies. <i>Clinical Lipidology</i> , 2014, 9, 355-367.	0.4	3
581	Risikofaktoren für pAVK. <i>Wiener Klinische Wochenschrift</i> Education, 2014, 9, 45-52.	0.0	0
582	Familial Hypercholesterolemia. <i>Deutsches Arzteblatt International</i> , 2014, 111, 523-9.	0.6	62
583	Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. <i>Journal of Lipids</i> , 2014, 2014, 1-13.	1.9	38
584	GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. <i>Global Cardiology Science & Practice</i> , 2014, 2014, 49.	0.3	10
585	Effects of Methanol Extract of Breadfruit (<i>Artocarpus altilis</i>) on Atherogenic Indices and Redox Status of Cellular System of Hypercholesterolemic Male Rats. <i>Advances in Pharmacological Sciences</i> , 2014, 2014, 1-11.	3.7	11
586	Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 60.	0.7	31
587	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. <i>Cardiovascular Diabetology</i> , 2014, 13, 159.	2.7	135
588	LDL Cholesterol Affects Clinical Outcomes in Incident Hemodialysis Patients During the Early Stages of Dialysis. <i>Blood Purification</i> , 2014, 38, 131-139.	0.9	5

#	ARTICLE	IF	CITATIONS
589	Protecting the Brain and the Heart. <i>Angiology</i> , 2014, 65, 372-378.	0.8	1
590	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2014, 63, 222-227.	0.3	7
591	Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20Âmg plus ezetimibe 10Âmg vs. simvastatin 40 or 80Âmg plus ezetimibe 10Âmg in high-risk patients: Results of the GRAVITY randomized study. <i>Atherosclerosis</i> , 2014, 232, 86-93.	0.4	40
592	Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: A caseâ€“control study. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2014, 7, 72-79.	0.2	6
593	The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: A reappraisal. <i>Indian Heart Journal</i> , 2014, 66, 1-4.	0.2	6
594	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
595	The predictive value of elevated neutrophil to lymphocyte ratio for long-term cardiovascular mortality in peripheral arterial occlusive disease. <i>Journal of Cardiology</i> , 2014, 64, 371-376.	0.8	74
596	Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 187-196.	1.6	10
598	LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy. <i>Clinical Therapeutics</i> , 2014, 36, 792-799.	1.1	3
599	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	0.6	98
600	Comments on the ESC Guidelines on Diabetes, Prediabetes, and Cardiovascular Diseases Developed in Collaboration with the European Society for the Study of Diabetes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 87-93.	0.4	4
601	Ischemic heart disease in systemic inflammatory diseases. An appraisal. <i>International Journal of Cardiology</i> , 2014, 170, 286-290.	0.8	30
602	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014, 30, 377-380.	0.8	27
603	Impact of the Albumin to Creatinine Ratio and the Coronary Artery State on Vascular Events. <i>American Journal of Cardiology</i> , 2014, 113, 1616-1620.	0.7	6
604	Cholesterol control according to the presence of metabolic syndrome in coronary and diabetic patients. Relationship with non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2014, 25, 438-443.	1.0	6
605	Maternal diabetes or hypertension and lifestyle factors may be associated with metabolic syndrome: A populationâ€“based study in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 86-93.	0.8	6
606	Is Plant-Based Cardioprotection Evidence-Based?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1142-1144.	0.8	0
607	Plant sterols in food: No consensus in guidelines. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 811-813.	1.0	26

#	ARTICLE	IF	CITATIONS
608	Improving the care of high-risk patients: The potential of PCSK9. <i>Atherosclerosis</i> , 2014, 232, 420-422.	0.4	5
609	The hypolipidaemic effects of <i>Spirulina (Arthrospira platensis)</i> supplementation in a Cretan population: a prospective study. <i>Journal of the Science of Food and Agriculture</i> , 2014, 94, 432-437.	1.7	67
611	Predicting non-adherence in patients with familial hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 391-397.	0.8	25
612	The "New Deadly Quartet" for Cardiovascular Disease in the 21st Century: Obesity, Metabolic Syndrome, Inflammation and Climate Change: How Does Statin Therapy Fit into this Equation?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 380.	2.0	19
613	Bilberries exert an anti-atherosclerotic effect in lipid-loaded macrophages. <i>Open Life Sciences</i> , 2014, 9, 268-276.	0.6	1
614	Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2014, 8, 18-28.	0.6	34
615	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 1-8.	1.6	66
616	Statin therapy and related risk of new-onset type 2 diabetes mellitus. <i>European Journal of Internal Medicine</i> , 2014, 25, 401-406.	1.0	45
617	Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2014, 113, 1099-1104.	0.7	21
618	Bone mineral density, carotid artery intima-media thickness, and Klotho gene polymorphism in postmenopausal women. <i>Open Medicine (Poland)</i> , 2014, 9, 315-324.	0.6	0
619	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149
620	Nurse-led telecoaching of people with type 2 diabetes in primary care: rationale, design and baseline data of a randomized controlled trial. <i>BMC Family Practice</i> , 2014, 15, 24.	2.9	13
623	Trends in statin therapy initiation during the period 2000-2010 in Israel. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 557-564.	0.8	3
625	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. <i>Contemporary Diabetes</i> , 2014, , 239-278.	0.0	0
626	Immunological aspects of atherosclerosis. <i>Seminars in Immunopathology</i> , 2014, 36, 73-91.	2.8	15
627	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 169-175.	1.0	17
628	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014, 233, 508-509.	0.4	2
629	Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG). <i>Reumatologia Clínica (English Edition)</i> , 2014, 10, 68-84.	0.2	9

#	ARTICLE	IF	CITATIONS
630	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
631	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.4	419
633	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 696-697.	1.2	0
634	GuÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃn con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
635	HDL-targeted therapies: progress, failures and future. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 445-464.	21.5	289
636	Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: The FRESCO Study. <i>Preventive Medicine</i> , 2014, 61, 66-74.	1.6	61
637	Effect of smoking and other traditional risk factors on the onset of coronary artery calcification: Results of the Heinz Nixdorf recall study. <i>Atherosclerosis</i> , 2014, 232, 339-345.	0.4	72
638	Targeting LDL: Is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 309-324.	2.2	27
639	Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 188-200.	0.7	15
640	Subclinical atherosclerosis determinants in morbid obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 963-968.	1.1	13
641	Association between waist circumference (WC) values and hypertension, heart disease (HD) and diabetes, reported by the elderly â€“ SABE survey: Health, wellness and aging, 2000 and 2006. <i>Archives of Gerontology and Geriatrics</i> , 2014, 59, 62-68.	1.4	7
642	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. <i>American Journal of Cardiology</i> , 2014, 113, 17-22.	0.7	10
643	Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2014, 129, 77-86.	1.6	212
646	Long-Term Prognostic Implications of Visit-to-Visit Blood Pressure Variability in Patients With Ischemic Stroke. <i>American Journal of Hypertension</i> , 2014, 27, 1486-1494.	1.0	31
648	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1069-1077.	1.1	386
650	Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations. <i>Journal of Rheumatology</i> , 2014, 41, 2315-2322.	1.0	66
652	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 1465-1472.	0.7	42
653	Impact of the New American and British Guidelines on the Management and Treatment of Dyslipidemia in a Spanish Working Population. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 906-911.	0.4	5

#	ARTICLE	IF	CITATIONS
655	Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 913-919.	0.4	5
656	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. <i>BMJ, The</i> , 2014, 348, g3047-g3047.	3.0	23
658	Statins in Heart Failure. <i>Heart Lung and Circulation</i> , 2014, 23, 895-896.	0.2	0
659	Fenofibrate Increases Serum Creatinine in a Patient with Familial Nephropathy Associated to Hyperuricemia. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 181-184.	0.4	7
660	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. <i>Journal of the American College of Cardiology</i> , 2014, 64, 196-206.	1.2	52
661	The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study. <i>Open Heart</i> , 2014, 1, e000096.	0.9	66
662	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 145-151.	1.8	17
663	Ejercicio fásico y salud. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 748-753.	0.6	35
664	Glomerular Filtration Rate is Associated With Burden of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. <i>Angiology</i> , 2014, 65, 350-356.	0.8	10
665	Nutraceuticals for the treatment of hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 592-599.	1.0	74
666	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	0.6	11
667	Blood Pressure, Low-Density Lipoprotein Cholesterol, and Incidences of Coronary Artery Disease and Ischemic Stroke in Japanese: The Suita Study. <i>American Journal of Hypertension</i> , 2014, 27, 1362-1369.	1.0	20
668	Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 715-723.	2.3	8
669	The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. <i>Atherosclerosis</i> , 2014, 237, 314-318.	0.4	20
673	Impacto de las nuevas guías estadounidense y británica en el manejo y el tratamiento de las dislipemias en una población laboral española. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 906-911.	0.6	6
675	Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2014, 237, 140-145.	0.4	37
677	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>Journal of Lipid Research</i> , 2014, 55, 2103-2112.	2.0	165
680	Metrological traceability in mass spectrometry-based targeted protein quantitation: A proof-of-principle study for serum apolipoproteins A-I and B100. <i>Journal of Proteomics</i> , 2014, 109, 143-161.	1.2	31

#	ARTICLE	IF	CITATIONS
681	Carotid Intima-Media Thickness in Patients With Inflammatory Bowel Disease. <i>Angiology</i> , 2014, 65, 284-293.	0.8	25
682	From the Editor: The art of prevention. <i>Journal of Clinical Lipidology</i> , 2014, 8, 359-362.	0.6	1
683	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150Åmg Every Two Weeks Dosing from Phase 2) Tj ETQq0 0 0ogBT /Overlock 10 Tf	0.8	25
684	Association between cardiovascular risk factors and measurements of blood pressure and cholesterol in 27 European countries in 2009. <i>Preventive Medicine</i> , 2014, 67, 71-74.	1.6	9
685	Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 1063-1069.	1.0	17
688	Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. <i>Atherosclerosis</i> , 2014, 236, 237-243.	0.4	22
689	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. <i>Journal of Clinical Lipidology</i> , 2014, 8, 373-380.	0.6	2
690	Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9. <i>Annual Review of Medicine</i> , 2014, 65, 417-431.	5.0	80
691	Triglycerides and cardiovascular disease. <i>Lancet, The</i> , 2014, 384, 626-635.	6.3	1,005
692	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	4.3	50
694	Non-cardiovascular effects associated with statins. <i>BMJ, The</i> , 2014, 349, g3743-g3743.	3.0	137
696	Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 606-611.	0.9	32
697	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	1.1	41
699	A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1257-1278.	1.4	35
700	A Perspective on the New American College of Cardiology/American Heart Association Guidelines for Cardiovascular Risk Assessment. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1244-1256.	1.4	25
701	Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. <i>International Journal of Cardiology</i> , 2014, 176, 1170-1172.	0.8	4
706	Recomendaciones para una prescripci3n segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades cientÍficas (SER-SEC-AEG). <i>ReumatologÍa ClÍnica</i> , 2014, 10, 68-84.	0.2	21
707	Comentarios a la guÍa de prÁctica clÍnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 87-93.	0.6	15

#	ARTICLE	IF	CITATIONS
708	Central Vestibular Disease in a Blue and Gold Macaw (<i>Ara ararauna</i>) With Cerebral Infarction and Hemorrhage. <i>Journal of Avian Medicine and Surgery</i> , 2014, 28, 132-142.	0.6	13
709	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1420-1428.	0.8	39
710	Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 267-269.	1.0	6
711	Primary Prevention of Cardiovascular Disease with Statins in the Elderly. <i>Current Atherosclerosis Reports</i> , 2014, 16, 420.	2.0	28
712	Stable Angina Pectoris. <i>Current Atherosclerosis Reports</i> , 2014, 16, 422.	2.0	19
713	New Risk Markers for Cardiovascular Prevention. <i>Current Atherosclerosis Reports</i> , 2014, 16, 427.	2.0	9
714	Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 367-376.	1.0	37
715	Benefit-Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. <i>Drug Safety</i> , 2014, 37, 481-500.	1.4	4
716	C-reactive protein levels in patients at cardiovascular risk: EURIKA study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 25.	0.7	40
717	Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells. <i>Lipids in Health and Disease</i> , 2014, 13, 78.	1.2	14
718	Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. <i>Atherosclerosis</i> , 2014, 235, 562-569.	0.4	26
719	Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1157-1162.	0.5	186
720	Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: Subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). <i>Atherosclerosis</i> , 2014, 237, 99-105.	0.4	25
721	A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 122, 645-652.	2.5	9
722	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. <i>European Heart Journal</i> , 2014, 35, 3122-3133.	1.0	249
723	Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. <i>Future Cardiology</i> , 2014, 10, 183-199.	0.5	38
724	Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - A pilot study. <i>Atherosclerosis</i> , 2014, 237, 251-258.	0.4	19
725	Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 722-727.	0.5	190

#	ARTICLE	IF	CITATIONS
726	New strategies for the management of patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis Supplements</i> , 2014, 15, 17-18.	1.2	0
727	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. <i>Cor Et Vasa</i> , 2014, 56, e133-e139.	0.1	7
728	Strategies for treating lipids for prevention: Risk stratification models with and without imaging. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 295-307.	2.2	3
729	Cluster of Atherosclerosis in a Captive Population of Black Kites (<i>Milvus migrans</i> subsp.) in France and Effect of Nutrition on the Plasma Lipid Profile. <i>Avian Diseases</i> , 2014, 58, 176-182.	0.4	16
730	Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 36-44.	0.4	7
732	Intestinal Cholesterol Absorption and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 695-696.	1.2	7
733	Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. <i>Journal of Cardiology</i> , 2014, 63, 335-343.	0.8	34
734	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. <i>International Journal of Cardiology</i> , 2014, 172, 403-410.	0.8	36
735	Estado nutricional, ingesta alimentaria y riesgo de enfermedad cardiovascular en individuos con esquizofrenia en el sur de Brasil: estudio de casos-controles. <i>Revista De Psiquiatría Y Salud Mental</i> , 2014, 7, 72-79.	1.0	25
736	Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk. <i>Atherosclerosis</i> , 2014, 234, 95-101.	0.4	83
737	Prescribing Statins for Cardiovascular Disease Prevention in the Old: An Absence of Evidence and an Absence of Guidelines. <i>Heart Lung and Circulation</i> , 2014, 23, 619-624.	0.2	10
738	Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction. <i>Atherosclerosis</i> , 2014, 235, 21-30.	0.4	232
739	La ecografía en manos del internista: ¿el estetoscopio del siglo XXI?. <i>Revista Clinica Espanola</i> , 2014, 214, 155-160.	0.2	15
740	Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 36-44.	0.6	26
741	The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. <i>Atherosclerosis</i> , 2014, 233, 707-712.	0.4	61
743	Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. <i>Journal of Clinical Lipidology</i> , 2014, 8, 173-180.	0.6	30
745	Actualización en artritis psoriásica. <i>Actas Dermo-sifilográficas</i> , 2014, 105, 913-922.	0.2	8
746	Twelve weeks of smoking cessation therapy with varenicline increases the serum levels of apolipoprotein A-I only in the success group. <i>Journal of Cardiology</i> , 2014, 64, 318-323.	0.8	5

#	ARTICLE	IF	CITATIONS
747	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
749	Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 61-67.	0.6	11
750	Running interference to lower cholesterol. <i>Lancet, The</i> , 2014, 383, 10-12.	6.3	7
752	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology,the</i> , 2014, 2, 655-666.	5.5	473
753	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. <i>Current Medical Research and Opinion</i> , 2014, 30, 1701-1705.	0.9	9
754	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	0.6	6
755	Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS). <i>Atherosclerosis</i> , 2014, 235, 463-469.	0.4	76
756	Elevated LDL-C combined with hypertension worsens subclinical vascular impairment and cognitive function. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 550-560.	2.3	16
757	Resistance and intolerance to statins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1057-1066.	1.1	183
758	Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor-Positive Advanced Breast Cancer: Considerations for Oncologists. <i>Clinical Breast Cancer</i> , 2014, 14, 297-308.	1.1	24
759	Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. <i>BMJ Open</i> , 2014, 4, e005402-e005402.	0.8	19
760	PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014, 62, 103-111.	1.0	30
761	Impact of Long-Term Statin Pretreatment on Myocardial Damage in ST Elevation Myocardial Infarction (from the AIDA STEMI CMR Substudy). <i>American Journal of Cardiology</i> , 2014, 114, 503-509.	0.7	11
763	Meta-Analysis of the Effect of Statins on Renal Function. <i>American Journal of Cardiology</i> , 2014, 114, 562-570.	0.7	48
764	A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 455-459.	0.6	7
765	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
767	Mediterranean Diet and Cardiometabolic Risk: A Review. <i>Nutrients</i> , 2014, 6, 3474-3500.	1.7	108
769	Treatment of dyslipidemia. <i>F1000prime Reports</i> , 2014, 6, 17.	5.9	10

#	ARTICLE	IF	CITATIONS
770	Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial. PLoS ONE, 2014, 9, e101978.	1.1	51
771	The Rationale/Design of the Guimarães/Vizela Study. Journal of Investigative Medicine, 2014, 62, 813-820.	0.7	6
772	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Annals of Internal Medicine, 2014, 160, 141-142.	2.0	0
773	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Annals of Internal Medicine, 2014, 160, 143.	2.0	0
774	Compliance with lipid-lowering medication after diagnosis of coronary heart disease. British Journal of Cardiac Nursing, 2014, 9, 244-249.	0.0	0
775	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. IJC Metabolic & Endocrine, 2014, 5, 61-66.	0.5	1
776	Absolute Systolic Ankle Blood Pressure Versus Ankle-Brachial Index. Annals of Internal Medicine, 2014, 160, 141.	2.0	0
777	Temporal Trends in the Use of High-Dose Potent Statins following Acute Coronary Syndrome in Israel. Cardiology, 2014, 128, 266-272.	0.6	2
778	Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease. Endocrine Journal, 2014, 61, 343-351.	0.7	5
779	Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies. Clinical Cardiology, 2014, 37, 597-604.	0.7	41
781	High-density lipoprotein cholesterol increases following a short-term yoga-based lifestyle intervention: a non-pharmacological modulation. Acta Cardiologica, 2014, 69, 543-549.	0.3	18
782	Cardiovascular risk factors: Belgian target achievement. Acta Cardiologica, 2014, 69, 473-481.	0.3	6
783	Cardiac Sequelae of Human Immunodeficiency Virus Disease. American Journal of the Medical Sciences, 2014, 348, 82-86.	0.4	4
784	CHOROIDAL THICKNESS IN DIABETIC RETINOPATHY. Retina, 2014, 34, 1199-1207.	1.0	59
785	Factors involved in the discontinuation of antihypertensive drug therapy. Journal of Hypertension, 2014, 32, 1708-1716.	0.3	62
786	Separate and Joint Effects of Diabetes Mellitus and Chronic Kidney Disease on the Risk of Acute Coronary Syndrome. Medicine (United States), 2014, 93, e261.	0.4	9
787	Pharmacological lipid lowering for prevention of cardiovascular disease in older adults. Clinical Practice (London, England), 2014, 11, 49-58.	0.1	2
788	Atherogenic ratios in patients with recurrent acute coronary syndrome and receiving statin therapy: Clinical usefulness as cardiovascular predictors. Atherosclerosis, 2014, 235, e209.	0.4	0

#	ARTICLE	IF	CITATIONS
789	PCSK9 inhibitors and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2015, 26, 511-520.	1.2	56
790	Lipid-modifying Therapy: The Clinician's Perspective. <i>Clinical Therapeutics</i> , 2015, 37, 2712-2715.	1.1	0
791	Clinical lipidology: A subspecialty whose time has come. <i>Journal of Clinical Lipidology</i> , 2015, 9, 634-639.	0.6	2
792	Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 435-438.	0.2	0
794	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. <i>Journal of Clinical Lipidology</i> , 2015, 9, 758-769.	0.6	390
795	Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 6.	1.6	125
796	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2015, , CD011737.	1.5	329
798	Familial hypercholesterolemia presenting with multiple nodules of the hands and elbow. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 411-414.	0.2	2
799	The influence of a ten-week Nordic walking training-rehabilitation program on the level of lipids in blood in overweight and obese postmenopausal women. <i>Journal of Physical Therapy Science</i> , 2015, 27, 3039-3044.	0.2	7
801	Dyslipidaemia and the military patient. <i>Journal of the Royal Army Medical Corps</i> , 2015, 161, 206-210.	0.8	0
802	Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 19.	0.3	0
803	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 416-421.	0.8	35
804	Primary cardiovascular prevention with statins in type 2 diabetes mellitus. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 ggBT /Overlock 10 Tf 0.1	0.1	0
808	Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. <i>Cardiovascular Diabetology</i> , 2015, 14, 68.	2.7	18
809	PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. <i>Cardiovascular Diabetology</i> , 2015, 14, 115.	2.7	26
810	Effect of phytosterols and inulin-enriched soymilk on LDL-cholesterol in Thai subjects: a double-blinded randomized controlled trial. <i>Lipids in Health and Disease</i> , 2015, 14, 146.	1.2	13
811	The prevalence of dyslipidemia and its relation to other risk factors: a nationwide survey of Lithuania. <i>Clinical Lipidology</i> , 2015, 10, 219-225.	0.4	12
812	A six question screen to facilitate primary cardiovascular disease prevention. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 140.	0.7	2

#	ARTICLE	IF	CITATIONS
813	Hierarchical modelling of blood lipidsâ€™ profile and 10-year (2002â€“2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study. <i>Lipids in Health and Disease</i> , 2015, 14, 108.	1.2	27
814	Regulation of plasma lipid profile by lactobacillus fermentum (probiotic strain ME-3 DSM14241) in a randomised controlled trial of clinically healthy adults. <i>BMC Nutrition</i> , 2015, 1, .	0.6	10
815	Omegaâ€³ fatty acid supplementation candidates can be selected using fatty acid profiling. <i>European Journal of Lipid Science and Technology</i> , 2015, 117, 601-607.	1.0	2
816	Impaired antioxidant HDL function is associated with premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 731-738.	1.7	21
817	New worldwide lipid guidelines. <i>Current Opinion in Cardiology</i> , 2015, 30, 447-453.	0.8	4
818	Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. <i>Coronary Artery Disease</i> , 2015, 26, 396-401.	0.3	38
819	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 215-220.	1.2	13
820	Long-term follow-up of lipid-lowering trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 572-579.	1.2	18
821	Statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 492-501.	1.2	32
822	Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1017-1024.	1.7	34
823	Alpine Skiing with total knee Arthroplasty (<ASWAP>): metabolism, inflammation, and skeletal muscle fiber characteristics. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2015, 25, 40-48.	1.3	8
824	New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies. <i>Cardiovascular Therapeutics</i> , 2015, 33, 329-337.	1.1	10
825	Did we abandon probucol too soon?. <i>Current Opinion in Lipidology</i> , 2015, 26, 304-316.	1.2	47
826	Non-high-density lipoprotein cholesterol. <i>Current Opinion in Lipidology</i> , 2015, 26, 502-510.	1.2	69
827	Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 659.	0.9	9
828	Sex Differences in the Impact of the Mediterranean Diet on LDL Particle Size Distribution and Oxidation. <i>Nutrients</i> , 2015, 7, 3705-3723.	1.7	25
829	Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1859.	2.0	1
830	Serum 25-Hydroxyvitamin D and the Incidence of Peripheral Artery Disease in the Elderly: The Pro.V.A Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 726-734.	0.9	14

#	ARTICLE	IF	CITATIONS
831	Metabolic syndrome resolution by Roux-en-Y gastric bypass in a real world: a case control study. Revista Da Associação Médica Brasileira, 2015, 61, 161-169.	0.3	11
832	Rapid normalization of severe hypercholesterolemia mediated by lipoprotein X after liver transplantation in a patient with cholestasis - a case report. Acta Biochimica Polonica, 2015, 62, 621-623.	0.3	4
834	Phytosterols, Phytostanols, and Lipoprotein Metabolism. Nutrients, 2015, 7, 7965-7977.	1.7	104
835	2015 Korean Guidelines for Management of Dyslipidemia. Journal of Lipid and Atherosclerosis, 2015, 4, 61.	1.1	38
836	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. Italian Journal of Medicine, 2015, 3, 309.	0.2	1
837	Clinical Characteristics of Systemic Lupus Erythematosus Patients with Coronary Artery Disease: A Matched Study. Advances in Pharmacoepidemiology & Drug Safety, 2015, 04, .	0.1	1
838	ANALYSIS OF HYPERCHOLESTEROLEMIA PREVALENCE IN THE OUTPATIENT PRACTICE (ACCORDING TO THE Tj ETQ 0 0 rgBT /Overloc	0.3	27
839	MULTI-CHANNEL VOLUME SPHYGMOGRAPHY IN CARDIOANGIOLOGICAL SCREENING OF THE ADULT POPULATION. Rational Pharmacotherapy in Cardiology, 2015, 11, 371-379.	0.3	3
840	TREATMENT OF PATIENTS WITH SEVERE DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2015, 11, 380-384.	0.3	3
841	Predictors of atherosclerotic lesions of limb arteries according to cardioangiological screening of the adult population. Rational Pharmacotherapy in Cardiology, 2015, 11, 470-476.	0.3	3
842	Three-year dynamics and unsolved problems of lipid-lowering therapy. Rational Pharmacotherapy in Cardiology, 2015, 11, 504-509.	0.3	0
843	Lipid Lowering Therapy and Endothelial Function in Patients with Metabolic Syndrome. Interdisciplinary Journal of Microinflammation, 2015, 02, .	0.1	1
844	Combination pharmacotherapy in lipid management. Journal of the Korean Medical Association, 2015, 58, 745.	0.1	0
845	Association of neutrophil/lymphocyte ratio with obstructive coronary artery disease and coronary artery calcium score detected by multislice computed tomography in type 2 diabetes mellitus patients. Patient Preference and Adherence, 2015, 9, 1023.	0.8	14
846	Cholesterol confusion and statin controversy. World Journal of Cardiology, 2015, 7, 404.	0.5	51
847	Increased Cardio-ankle Vascular Index in Hyperlipidemic Patients without Diabetes or Hypertension. Journal of Atherosclerosis and Thrombosis, 2015, 22, 272-283.	0.9	31
848	Dyslipidemia in Older Adults and Management of Dyslipidemia in Older Patients. Journal of Lipid and Atherosclerosis, 2015, 4, 1.	1.1	3
849	Role of Nutraceuticals in Hypolipidemic Therapy. Frontiers in Cardiovascular Medicine, 2015, 2, 22.	1.1	22

#	ARTICLE	IF	CITATIONS
850	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. <i>Lipids in Health and Disease</i> , 2015, 14, 45.	1.2	13
851	Potential of PCSK9 as a new target for the management of LDL cholesterol. <i>Research Reports in Clinical Cardiology</i> , 0, , 73.	0.2	6
852	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 353.	1.8	272
853	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 189.	1.1	41
854	Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. <i>Clinical Epidemiology</i> , 2015, 7, 213.	1.5	46
855	Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 555.	0.7	7
856	Medical management of chronic stable angina. <i>Australian Prescriber</i> , 2015, 38, 131-136.	0.5	15
857	Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4735.	2.0	7
858	Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital. <i>Vascular Health and Risk Management</i> , 2015, 11, 563.	1.0	3
859	Association of Small Dense LDL Serum Levels and Circulating Monocyte Subsets in Stable Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0123367.	1.1	33
860	Influence of Retirement on Adherence to Statins in the Insurance Medicine All-Sweden Total Population Data Base. <i>PLoS ONE</i> , 2015, 10, e0130901.	1.1	11
861	Inter-Ethnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. <i>PLoS ONE</i> , 2015, 10, e0131977.	1.1	13
862	Ethnicity Modifies Associations between Cardiovascular Risk Factors and Disease Severity in Parallel Dutch and Singapore Coronary Cohorts. <i>PLoS ONE</i> , 2015, 10, e0132278.	1.1	28
863	The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0132307.	1.1	31
864	Managing comorbidities in COPD. <i>International Journal of COPD</i> , 2015, 10, 95.	0.9	139
865	Profile of evolocumab and its potential in the treatment of hyperlipidemia. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3073.	2.0	19
866	High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1310-1321.	1.8	74
867	The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-7.	1.0	47

#	ARTICLE	IF	CITATIONS
868	Omega-3 Polyunsaturated Fatty Acids: Structural and Functional Effects on the Vascular Wall. <i>BioMed Research International</i> , 2015, 2015, 1-14.	0.9	46
869	Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	38
870	GPS™ Perceptions of Cardiovascular Risk and Views on Patient Compliance: A Qualitative Interview Study. <i>International Journal of Family Medicine</i> , 2015, 2015, 1-7.	1.2	9
871	Optimal Use of Plant Stanol Ester in the Management of Hypercholesterolemia. <i>Cholesterol</i> , 2015, 2015, 1-6.	1.6	10
872	Relationship of Genetic Polymorphisms of the Chemokine, CCL5, and Its Receptor, CCR5, with Coronary Artery Disease in Taiwan. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	10
873	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
874	Treatment Options for Statin-Associated Muscle Symptoms. <i>Deutsches A&#x0308;rzteblatt International</i> , 2015, 112, 748-55.	0.6	65
875	<i>GDF15(MIC1)</i> Polymorphism Does Not Influence Cardiovascular Disease in a Latin American Population with Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	4
876	The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review. <i>Cholesterol</i> , 2015, 2015, 1-5.	1.6	4
877	Impact of predictors upon the reduction of lipid parameters in family medicine practice. <i>Sao Paulo Medical Journal</i> , 2015, 133, 428-434.	0.4	0
878	PCSK9: from discovery to therapeutic perspectives. <i>Sang Thrombose Vaisseaux</i> , 2015, 27, 77-83.	0.1	0
879	Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 949-957.	0.9	4
880	Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients. <i>Chinese Medical Journal</i> , 2015, 128, 259-266.	0.9	18
881	Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
882	Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. <i>British Journal of Pharmacology</i> , 2015, 172, 721-736.	2.7	21
883	Deciphering Unexplained Familial Dyslipidemias. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 250-252.	5.1	3
884	Lipid lowering for primary prevention of stroke in older adults?. <i>BMJ, The</i> , 2015, 350, h2568-h2568.	3.0	0
885	Cortical Ischemic Lesion Burden Measured by DIR Is Related to Carotid Artery Disease Severity. <i>Cerebrovascular Diseases</i> , 2015, 39, 23-30.	0.8	8

#	ARTICLE	IF	CITATIONS
886	Genetic Testing in Hyperlipidemia. <i>Cardiology Clinics</i> , 2015, 33, 267-275.	0.9	7
887	Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2015, 166, 1377-1384.e3.	0.9	56
888	Lipid-modifying therapy in the elderly. <i>Vascular Health and Risk Management</i> , 2015, 11, 251.	1.0	17
889	Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS). <i>Primary Care Diabetes</i> , 2015, 9, 283-289.	0.9	1
890	Dyslipidemia and Cardiovascular Disease in Women. <i>Current Cardiology Reports</i> , 2015, 17, 609.	1.3	62
891	Cardiovascular Prevention: The Role of Second Generation of Nutraceuticals. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 155-157.	1.0	2
892	Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 199-201.	1.0	20
893	Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet on Cardiometabolic Factors: A Multi-Center, Cross-Sectional, Clinical Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 389-394.	1.0	110
894	A possible relationship between renal impairment and complications development in type 2 diabetes mellitus: a prospective, observational study in Italy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 771-775.	1.2	4
895	Statin treatment decreases serum angiostatin levels in patients with ischemic heart disease. <i>Life Sciences</i> , 2015, 134, 22-29.	2.0	6
896	Efecto a largo plazo de los estanoles vegetales en el perfil lipídico de pacientes con hipercolesterolemia. Ensayo clínico aleatorizado. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 665-671.	0.6	15
897	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. <i>Atherosclerosis</i> , 2015, 241, 62-68.	0.4	18
898	Saroglitazar for the treatment of dyslipidemia in diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 597-606.	0.9	59
899	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.4	133
900	Hypertension and Dyslipidemia in Patients with Pre-Diabetes. , 2015, , 157-179.		1
901	Dietary Intervention for Dyslipidemia in Human Immunodeficiency Virus Infection. , 2015, , 419-439.		0
902	Impaired Femoral Vascular Compliance and Endothelial Dysfunction in 30 Healthy Male Soccer Players. <i>Sports Health</i> , 2015, 7, 335-340.	1.3	8
903	From prevention to plaque rupture and infarction. <i>European Heart Journal</i> , 2015, 36, 1003-1004.	1.0	0

#	ARTICLE	IF	CITATIONS
904	Lipoproteins and Cardiovascular Disease Risk. <i>Contemporary Endocrinology</i> , 2015, , 57-65.	0.3	0
905	Prevention in high-risk patients: a long-term committment. <i>European Heart Journal</i> , 2015, 36, 1137-1139.	1.0	0
906	Diagnostic utility of carotid artery duplex ultrasonography in the evaluation of syncope: a good test ordered for the wrong reason. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 621-5.	0.5	7
907	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	0.8	60
908	Lipid Management in Diabetes with a Focus on Emerging Therapies. <i>Canadian Journal of Diabetes</i> , 2015, 39, S183-S190.	0.4	8
909	Imaging, prevention, and rehabilitation. <i>European Heart Journal</i> , 2015, 36, 1489-1491.	1.0	0
910	The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. <i>European Heart Journal</i> , 2015, 36, 2446-2453.	1.0	49
911	Cholesterol production, accumulation, reverse transport, and excretion: opportunities for statins, PPAR- α agonists, and PCSK9 inhibitors. <i>European Heart Journal</i> , 2015, 36, 2965-2967.	1.0	1
912	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. <i>Clinical Therapeutics</i> , 2015, 37, 2732-2750.	1.1	7
913	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	0.6	430
915	Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2015, 9, 533-541.	0.6	37
916	Considering gender in prescribing statins: what do physicians need to know?. <i>Clinical Lipidology</i> , 2015, 10, 499-512.	0.4	11
917	Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients. <i>Clinical Lipidology</i> , 2015, 10, 243-250.	0.4	4
918	Increased serum soluble corin in dyslipidemia: A cross-sectional study. <i>Clinica Chimica Acta</i> , 2015, 450, 310-315.	0.5	10
919	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. <i>Clinical Therapeutics</i> , 2015, 37, 2798-2810.	1.1	6
920	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	0.6	9
921	Renopulmonary syndrome, importance of an early diagnosis. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 430-431.	0.1	0
922	Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 426-433.	1.1	25

#	ARTICLE	IF	CITATIONS
923	Is the Guideline Process Replicable and, if Not, What Does This Mean?. Progress in Cardiovascular Diseases, 2015, 58, 3-9.	1.6	2
924	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. Cardiology, 2015, 131, 225-227.	0.6	14
925	Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans. Cardiology, 2015, 131, 228-235.	0.6	23
926	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Current Medical Research and Opinion, 2015, 31, 221-228.	0.9	25
927	Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease. American Journal of Cardiology, 2015, 115, 441-446.	0.7	16
928	The year in cardiology 2014: prevention. European Heart Journal, 2015, 36, 214-218.	1.0	5
930	Drug adherence in chronic kidney diseases and dialysis. Nephrology Dialysis Transplantation, 2015, 30, 39-44.	0.4	93
931	Alipogene Tiparovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency. Drugs, 2015, 75, 175-182.	4.9	107
932	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. Metabolic Syndrome and Related Disorders, 2015, 13, 1-21.	0.5	26
933	The Predictive Value of Admission Fragmented QRS Complex for In-Hospital Cardiovascular Mortality of Patients with Type 1 Acute Aortic Dissection. Annals of Noninvasive Electrocardiology, 2015, 20, 454-463.	0.5	8
934	Control de factores de riesgo cardiovascular en pacientes diab�ticos revascularizados: un suban�lisis del estudio ICP-Bypass. Revista Espanola De Cardiologia, 2015, 68, 115-120.	0.6	9
935	Plasma triglyceride determination can identify increased risk of statin-induced type 2 diabetes: A hypothesis. Atherosclerosis, 2015, 239, 401-404.	0.4	5
936	Preoperative Statin Therapy Decreases Early Mortality in Patients Undergoing Isolated Valve Surgery: Result From a Meta-Analysis. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 107-114.	0.6	8
937	Control of Cardiovascular Risk Factors in Revascularized Patients With Diabetes: A Subanalysis of the ICP-Bypass Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 115-120.	0.4	2
938	Novedades cardiovasculares 2013/2014. Revista Clinica Espanola, 2015, 215, 33-42.	0.2	0
939	Hormones, herbal preparations and nutraceuticals for a better life after the menopause: part I. Climacteric, 2015, 18, 358-363.	1.1	14
940	The Assessment of Relationship between Fragmented QRS Complex and Left Ventricular Wall Motion Score Index in Patients with ST Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. Annals of Noninvasive Electrocardiology, 2015, 20, 148-157.	0.5	21
941	Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. Clinical Biochemistry, 2015, 48, 495-502.	0.8	11

#	ARTICLE	IF	CITATIONS
942	Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 111-116.	0.2	12
943	Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. <i>Current Therapeutic Research</i> , 2015, 77, 1-6.	0.5	43
945	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. <i>Atherosclerosis</i> , 2015, 239, 93-100.	0.4	65
947	Cardiovascular news 2013/2014. <i>Revista Clínica Espanola</i> , 2015, 215, 33-42.	0.3	0
949	Does coronary calcium scoring with a SCORE better predict significant coronary artery stenosis than without? Correlation with computed tomography coronary angiography. <i>European Radiology</i> , 2015, 25, 776-784.	2.3	13
950	Imaging and prevention. <i>European Heart Journal</i> , 2015, 36, 189-190.	1.0	0
951	The Role of Cystatin C in the Prognosis of Adverse Outcomes after the Coronary Artery Bypass Graft Surgery During Hospitalisation. <i>Heart Lung and Circulation</i> , 2015, 24, 193-199.	0.2	4
952	Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. <i>Clinical Therapeutics</i> , 2015, 37, 804-815.	1.1	2
953	Current Drug Treatment of Hyperlipidemia in Older Adults. <i>Drugs and Aging</i> , 2015, 32, 127-138.	1.3	10
954	Myocardial Infarction Among Danish HIV-Infected Individuals: Population-Attributable Fractions Associated With Smoking. <i>Clinical Infectious Diseases</i> , 2015, 60, 1415-23.	2.9	96
955	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet</i> , 2015, 385, 1397-1405.	6.3	1,112
957	Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. <i>Journal of the Saudi Heart Association</i> , 2015, 27, 179-191.	0.2	23
958	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 1186-1194.	1.0	344
959	Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. <i>Pituitary</i> , 2015, 18, 525-534.	1.6	16
961	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <i>Internal and Emergency Medicine</i> , 2015, 10, 115-117.	1.0	1
962	The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. <i>Internal and Emergency Medicine</i> , 2015, 10, 119-122.	1.0	1
963	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 471-475.	1.5	25
964	Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias. <i>Clinical Research in Cardiology Supplements</i> , 2015, 10, 2-7.	2.0	8

#	ARTICLE	IF	CITATIONS
965	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. <i>Genetics in Medicine</i> , 2015, 17, 980-988.	1.1	35
966	Lipid Management. , 2015, , .		1
967	Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 127.	0.9	19
968	Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (<i>Amazona ventralis</i>). <i>Journal of Avian Medicine and Surgery</i> , 2015, 29, 18-24.	0.6	13
969	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2015, 12, 565-575.	6.1	101
970	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1059-1066.	0.6	5
971	Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. <i>European Heart Journal</i> , 2015, 36, ehv340.	1.0	71
972	Statines et risque de diab�te : quelles �vidences ?. <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 273-278.	0.1	0
973	Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 568-575.	0.6	31
974	A combination of palm oil tocotrienols and citrus peel polymethoxylated flavones does not influence elevated LDL cholesterol and high-sensitivity C-reactive protein levels. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 1209-1214.	1.3	4
975	Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). <i>Atherosclerosis</i> , 2015, 238, 336-343.	0.4	83
976	Is albuminuria a myocardial infarction risk equivalent for atherothrombotic events?. <i>Atherosclerosis</i> , 2015, 240, 21-25.	0.4	12
977	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1215-1223.	1.5	68
979	Lost in translation: dietary management of cardiovascular risk factors is seldom implemented. <i>Preventive Medicine</i> , 2015, 76, 68-73.	1.6	8
980	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. <i>Canadian Journal of Cardiology</i> , 2015, 31, 585-587.	0.8	8
981	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. <i>Clinical Science</i> , 2015, 129, 63-79.	1.8	21
982	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	1.6	41
983	Safety considerations with fenofibrate/simvastatin combination. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1481-1493.	1.0	21

#	ARTICLE	IF	CITATIONS
984	Visualization of Coronary Artery Calcification: Influence on Risk Modification. American Journal of Medicine, 2015, 128, 1023.e23-1023.e31.	0.6	15
985	The New Pooled Cohort Equations Risk Calculator. Canadian Journal of Cardiology, 2015, 31, 613-619.	0.8	67
986	Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Croatian Medical Journal, 2015, 56, 14-23.	0.2	20
988	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 2015, 36, 2438-2445.	1.0	129
989	Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials. Journal of the American Heart Association, 2015, 4, e001937.	1.6	66
990	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3140-3148.	1.8	198
991	Authorised EU health claims for phytosterols. , 2015, , 31-47.		5
992	A paradigm shift in the treatment of atherosclerosis. Archives of Cardiovascular Diseases, 2015, 108, 337-339.	0.7	1
993	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs, 2015, 75, 1201-1228.	4.9	18
994	Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk. Advances in Therapy, 2015, 32, 680-690.	1.3	24
996	Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open, 2015, 5, e008017.	0.8	20
997	Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with) trial. European Heart Journal Supplements, 2015, 17, B47-B56.	0.784314	10
998	Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). Clinical and Experimental Hypertension, 2015, 37, 116-121.	0.5	5
999	Clinical Evaluation. , 2015, , 157-169.		0
1000	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Cardiovascular Drugs and Therapy, 2015, 29, 295-308.	1.3	18
1001	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015, 241, 409-418.	0.4	87
1002	Actual situation of lipoprotein apheresis in Saxony in 2013. Atherosclerosis Supplements, 2015, 18, 215-225.	1.2	19
1003	Association and Interaction of PPAR α , PPAR γ and PPAR δ Gene Polymorphisms with Low-Density Lipoprotein-Cholesterol in a Chinese Han Population. Genetic Testing and Molecular Biomarkers, 2015, 19, 379-386.	0.3	17

#	ARTICLE	IF	CITATIONS
1004	The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015, 36, 2212-2218.	1.0	61
1005	Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. <i>European Heart Journal</i> , 2015, 36, 3404-3412.	1.0	354
1006	Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial. <i>American Heart Journal</i> , 2015, 170, 46-54.e2.	1.2	13
1007	Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). <i>Atherosclerosis</i> , 2015, 241, 597-606.	0.4	34
1008	Microalbuminuria and Prediction of Cardiovascular Complications in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus after CABG Surgery. <i>Heart Lung and Circulation</i> , 2015, 24, 951-959.	0.2	6
1009	Dyslipidemia testing: Why, for whom and when. <i>Maturitas</i> , 2015, 81, 442-445.	1.0	4
1010	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. <i>Clinical Chemistry</i> , 2015, 61, 1156-1163.	1.5	53
1011	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	1.3	32
1012	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. <i>Diabetologia</i> , 2015, 58, 1494-1502.	2.9	29
1013	Family history of premature myocardial infarction, life course socioeconomic position and coronary heart disease mortality – A Cohort of Norway (CONOR) study. <i>International Journal of Cardiology</i> , 2015, 190, 302-307.	0.8	10
1014	Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review. <i>Heart Lung and Circulation</i> , 2015, 24, 495-502.	0.2	1
1017	IMPROVE-IT clinical implications. Should the “high-intensity cholesterol-lowering therapy” strategy replace the “high-intensity statin therapy”? <i>Atherosclerosis</i> , 2015, 240, 161-162.	0.4	64
1018	The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study. <i>EBioMedicine</i> , 2015, 2, 356-364.	2.7	1
1019	Statin treatment: can genetics sharpen the focus?. <i>Lancet, The</i> , 2015, 385, 2227-2229.	6.3	10
1020	Combining detection of Notch1 and tumor necrosis factor- α converting enzyme is a reliable biomarker for the diagnosis of abdominal aortic aneurysms. <i>Life Sciences</i> , 2015, 127, 39-45.	2.0	13
1022	Variation of lipoprotein(a) plasma levels after premature myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 186, 5-6.	0.8	4
1023	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	2.0	357
1024	Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2129.	2.0	12

#	ARTICLE	IF	CITATIONS
1025	Genetic and immunologic susceptibility to statin-related myopathy. <i>Atherosclerosis</i> , 2015, 240, 260-271.	0.4	33
1026	Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade?. <i>European Journal of Internal Medicine</i> , 2015, 26, 268-272.	1.0	20
1028	2013 ACC/AHA cholesterol treatment guidelines. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S15-S20.	0.1	0
1030	Optimizing statin treatment. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 226-227.	2.3	0
1031	Estatinas en pacientes con sÃndrome coronario agudo. MÃ¡s allÃ de las lipoproteÃnas de baja densidad. <i>Revista Espanola De Cardiologia Suplementos</i> , 2015, 15, 28-33.	0.2	0
1033	Impact of fibrates therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials. <i>Atherosclerosis</i> , 2015, 240, 284-296.	0.4	11
1036	Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq0 0 0 rgBT /Overlap 10 Tf 5	0.1	0
1037	GuÃas de prÃctica clÃnica de manejo de la dislipemia en diabÃticos y otros grupos de riesgo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2015, 15, 8-13.	0.2	0
1038	Evolocumab (AMG 145) for primary hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 477-488.	0.6	50
1039	Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 489-499.	0.6	2
1040	Costâ€effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. <i>Journal of Medical Economics</i> , 2015, 18, 565-572.	1.0	13
1041	Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1539-1548.	1.2	156
1042	Cardiovascular disease (CVD) risk factors in older adults â€ Perception and reality. <i>Archives of Gerontology and Geriatrics</i> , 2015, 61, 88-92.	1.4	29
1043	Role for Combination Therapy in Diabetic Dyslipidemia. <i>Current Cardiology Reports</i> , 2015, 17, 32.	1.3	26
1044	Effects of a New Combination of Nutraceuticals with <i>Morus alba</i> on Lipid Profile, Insulin Sensitivity and Endotelial Function in Dyslipidemic Subjects. A Cross-Over, Randomized, Double-Blind Trial. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 149-154.	1.0	38
1045	Is anemia a new cardiovascular risk factor?. <i>International Journal of Cardiology</i> , 2015, 186, 117-124.	0.8	62
1046	Statin intolerance â€ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
1047	Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 8.	0.7	6

#	ARTICLE	IF	CITATIONS
1048	Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. <i>AAPS Journal</i> , 2015, 17, 881-890.	2.2	17
1049	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509.	13.9	1,352
1050	Prevalence of dyslipidaemia and associated risk factors among Balearic Islands adolescents, a Mediterranean region. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 722-728.	1.3	6
1052	Practical recommendations for the management of hyperlipidemia. <i>Atherosclerosis Supplements</i> , 2015, 18, 194-198.	1.2	25
1053	Statin Reloading before Noncardiac Surgery: A Simple, Safe and Effective Approach for Reducing the Risk of Perioperative Myocardial Infarction. <i>Cardiology</i> , 2015, 131, 51-52.	0.6	1
1054	Lipoproteins and diabetes. <i>European Heart Journal</i> , 2015, 36, 529-531.	1.0	2
1055	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 19-31.	1.6	46
1056	Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". <i>Circulation</i> , 2015, 131, e473.	1.6	1
1057	Cardiovascular risk assessment: a global perspective. <i>Nature Reviews Cardiology</i> , 2015, 12, 301-311.	6.1	94
1058	Comparison of equations for the calculation of LDL-cholesterol in hospitalized patients. <i>Clinica Chimica Acta</i> , 2015, 444, 137-142.	0.5	37
1059	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1354-1362.	0.8	81
1060	Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study. <i>Atherosclerosis</i> , 2015, 240, 90-97.	0.4	43
1061	Relationship between serum visfatin levels and coronary slow-flow phenomenon. <i>Herz</i> , 2015, 40, 921-928.	0.4	13
1062	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. <i>American Journal of Cardiology</i> , 2015, 116, 481-484.	0.7	16
1063	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. <i>Journal of Clinical Lipidology</i> , 2015, 9, 226-233.	0.6	22
1064	Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2015, 9, 201-209.	0.6	26
1065	PCSK9 inhibitors. <i>Swiss Medical Weekly</i> , 2015, 145, w14094.	0.8	13
1066	Cholesterol-lowering therapy: Old evidence, new guidelines "Which one to follow? A critical appraisal. <i>Atherosclerosis Supplements</i> , 2015, 18, 176-179.	1.2	1

#	ARTICLE	IF	CITATIONS
1067	Serum Adropin Level in Patients with Stable Coronary Artery Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 975-979.	0.2	36
1068	Lipids, blood pressure and kidney update 2014. <i>Pharmacological Research</i> , 2015, 95-96, 111-125.	3.1	77
1069	Strategies to overcome statin intolerance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 851-855.	1.5	13
1070	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial. <i>Atherosclerosis</i> , 2015, 240, 408-414.	0.4	36
1071	Long-term Effects of Plant Stanols on the Lipid Profile of Patients With Hypercholesterolemia. A Randomized Clinical Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 665-671.	0.4	12
1072	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. <i>International Urology and Nephrology</i> , 2015, 47, 805-813.	0.6	14
1073	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
1074	Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. <i>Journal of Cardiology</i> , 2015, 66, 353-358.	0.8	11
1075	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. <i>Cardiology and Therapy</i> , 2015, 4, 25-38.	1.1	59
1076	HDL particle subpopulations: Focus on biological function. <i>BioFactors</i> , 2015, 41, 67-77.	2.6	47
1077	A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. <i>American Journal of Cardiology</i> , 2015, 115, 1760-1766.	0.7	80
1078	Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: a 50% reduction from baseline versus <70mg/dL. <i>International Journal of Cardiology</i> , 2015, 187, 478-485.	0.8	12
1079	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 299-312.	1.0	6
1080	Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 769-779.	0.2	130
1082	Carotid thin fluttering bands: A new element of arterial wall remodelling? An ultrasound study. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1393-1400.	0.7	1
1083	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
1084	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.4	587
1086	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). <i>INCARDIO (Indicadores)</i> Tj ETQq1 1 0,784314 rBT /Over <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 976-995.e10.	0.4	15

#	ARTICLE	IF	CITATIONS
1087	Treating lipid disorders and diabetes with novel and established drugs. <i>European Heart Journal</i> , 2015, 36, 2405-2407.	1.0	0
1088	The Role of Omega-3 Fatty Acids in Dyslipidemias. , 2015, , 45-64.		1
1089	Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. <i>Atherosclerosis</i> , 2015, 242, 340-345.	0.4	14
1090	Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 794-800.	0.6	18
1091	Nonstatin Low-Density Lipoprotein Lowering Therapy and Cardiovascular Risk Reduction Statement From the American College of Cardiology Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2269-2280.	1.1	58
1092	Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000132.	1.2	8
1093	Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study. <i>BMC Research Notes</i> , 2015, 8, 294.	0.6	3
1094	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. <i>Current Cardiology Reports</i> , 2015, 17, 109.	1.3	28
1095	Dyslipidemia in Obesity. , 2015, , 1-18.		1
1096	Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. <i>Pharmacological Research</i> , 2015, 102, 168-175.	3.1	5
1097	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. <i>Journal of Medicinal Food</i> , 2015, 18, 1270-1273.	0.8	17
1098	Prevention and Control of Cardiovascular Diseases: What Works?. , 2015, , 207-217.		0
1099	Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium. <i>Current Cardiology Reports</i> , 2015, 17, 110.	1.3	20
1100	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 618-626.	1.6	94
1101	Genetic considerations in the treatment of familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2015, 10, 387-403.	0.4	2
1102	Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 55.	0.7	4
1103	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2015, 170, 865-871.	1.2	20
1104	Lipophilic Statins in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 816-817.	0.4	0

#	ARTICLE	IF	CITATIONS
1105	Should we consider ezetimibe to reach even lower LDL-C targets?. <i>Current Medical Research and Opinion</i> , 2015, 31, 459-460.	0.9	5
1106	Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design. <i>Current Medical Research and Opinion</i> , 2015, 31, 595-602.	0.9	9
1108	Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study. <i>BMC Neurology</i> , 2015, 15, 120.	0.8	26
1109	The prognostic value of admission red cell distribution width-to-platelet ratio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 597-606.	0.2	14
1110	Evaluating the Heart Through the Breasts: A Feasible Strategy?. <i>Journal of Women's Health</i> , 2015, 24, 787-788.	1.5	0
1111	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate+statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
1112	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1505-1515.	1.5	11
1113	PCSK9 inhibitors – past, present and future. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1517-1521.	1.5	37
1114	Prevention of Cardiovascular Diseases. , 2015, , .		1
1115	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015, 36, ehv370.	1.0	395
1116	Poor agreement between chart-based and objectively identified comorbidities of COPD. <i>European Respiratory Journal</i> , 2015, 46, 1492-1495.	3.1	29
1117	Coronary artery disease in the military patient. <i>Journal of the Royal Army Medical Corps</i> , 2015, 161, 211-222.	0.8	10
1118	Carotid atherosclerosis severity in relation to glycemic status: A cross-sectional population study. <i>Atherosclerosis</i> , 2015, 242, 377-382.	0.4	42
1119	LDL Cholesterol, Statins And PCSK 9 Inhibitors. <i>Indian Heart Journal</i> , 2015, 67, 419-424.	0.2	13
1120	Nonfasting Lipid Profiles: The Way of the Future. <i>Clinical Chemistry</i> , 2015, 61, 1123-1125.	1.5	23
1121	Meta-analysis Comparing the Effects of Rosuvastatin Versus Atorvastatin on Regression of Coronary Atherosclerotic Plaques. <i>American Journal of Cardiology</i> , 2015, 116, 1521-1526.	0.7	27
1122	Fasting plasma triglyceride concentration: A possible approach to identify increased risk of statin-induced type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 373-376.	0.9	3
1124	The Atherogenicity of Plant Sterols: The Evidence from Genetics to Clinical Trials. <i>Journal of AOAC INTERNATIONAL</i> , 2015, 98, 742-749.	0.7	26

#	ARTICLE	IF	CITATIONS
1125	Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. <i>Journal of Lipid Research</i> , 2015, 56, 2381-2392.	2.0	47
1126	Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database. <i>Journal of Medical Economics</i> , 2015, 18, 655-665.	1.0	8
1127	The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant Sterols (INVEST) study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 733-741.	2.2	48
1128	Estatinas lipófilas en la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 816-817.	0.6	4
1129	The prognostic value of admission red cell distribution width-to-platelet ratio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 597-606.	0.2	7
1130	Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. <i>Vascular Pharmacology</i> , 2015, 72, 197-208.	1.0	14
1131	An evaluation of alirocumab for the treatment of hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1307-1323.	0.6	21
1132	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). <i>Journal of Clinical Lipidology</i> , 2015, 9, 377-383.	0.6	37
1134	2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 340-347.	2.3	18
1136	The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels. <i>Pharmacological Reports</i> , 2015, 67, 305-309.	1.5	6
1137	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , 2015, 238, 182-184.	0.4	3
1138	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6
1139	Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 472.	2.0	32
1140	Mediterranean-Style Diet Is Associated With Reduced Blood Pressure Variability and Subsequent Stroke Risk in Patients With Coronary Artery Disease. <i>American Journal of Hypertension</i> , 2015, 28, 501-507.	1.0	33
1142	Cardiovascular risk and lifestyle habits of consumers of a phytosterol-enriched yogurt in a real-life setting. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 226-235.	1.3	3
1143	Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 762-770.	0.8	32
1144	The New Dyslipidemia Guidelines: What Is the Debate?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 605-612.	0.8	46
1145	Serum lipoprotein(a) concentrations do not change significantly in the immediate seven-day period post myocardial infarction. <i>Annals of Clinical Biochemistry</i> , 2015, 52, 502-505.	0.8	0

#	ARTICLE	IF	CITATIONS
1147	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
1148	Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. International Journal of Obesity, 2015, 39, 265-269.	1.6	21
1149	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	1.0	142
1150	Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 87-94.	0.6	7
1151	Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. European Journal of Preventive Cardiology, 2016, 23, 88-110.	0.8	58
1152	Comentarios del Comit�o Espa�ol Interdisciplinario de Prevenci�n Cardiovascular (CEIPC) a las Gu�as Europeas de Prevenci�n Cardiovascular 2012. Neurolog�a, 2016, 31, 195-207.	0.3	0
1153	LIPID-LOWERING THERAPY IN OUTPATIENT PRACTICE (ACCORDING TO THE ARGO-2 STUDY). Rational Pharmacotherapy in Cardiology, 2016, 12, 147-153.	0.3	8
1154	High and low impact aerobic exercise as a method of early prevention of hypercholesterolaemia development among young women. Human Movement, 2016, 17, 242-249.	0.5	0
1155	Drug treatment of dyslipidemia. Journal of the Korean Medical Association, 2016, 59, 366.	0.1	6
1157	Comparison of Formulas for Calculating Low-density Lipoprotein Cholesterol in General Population and High-risk Patients with Cardiovascular Disease. Korean Circulation Journal, 2016, 46, 688.	0.7	21
1158	Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. Medical Devices: Evidence and Research, 2016, Volume 9, 349-360.	0.4	19
1159	Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study. Endocrinology and Metabolism, 2016, 31, 402.	1.3	4
1160	Use of fibrates in the metabolic syndrome: A review. World Journal of Diabetes, 2016, 7, 74.	1.3	47
1161	Art�riopathie des membres inf�rieurs asymptomatique. , 2016, , 251-253.		0
1162	Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country. Therapeutics and Clinical Risk Management, 2016, 12, 353.	0.9	1
1163	EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY. Rational Pharmacotherapy in Cardiology, 2016, 12, 351-358.	0.3	0
1164	The Correlation between LDL-C and Non-HDL-C Levels and Cardiovascular Events in Patients with Metabolic Syndrome. Endocrinology & Metabolic Syndrome: Current Research, 2016, 05, .	0.3	1
1165	New concept of treatment guideline of dyslipidemia. Journal of the Korean Medical Association, 2016, 59, 349.	0.1	0

#	ARTICLE	IF	CITATIONS
1166	Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland. Archives of Medical Science, 2016, 4, 687-696.	0.4	37
1167	The Effectiveness of a Bioactive Food Compound in the Lipid Control of Individuals with HIV/AIDS. Nutrients, 2016, 8, 598.	1.7	3
1168	Vascular Pathobiology. , 2016, , 85-124.		9
1169	Cholesterol: until which age 'the lower the better'?. Monaldi Archives for Chest Disease, 2016, 84, 749.	0.3	0
1170	International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?. Journal of Atherosclerosis and Thrombosis, 2016, 23, 505-519.	0.9	29
1171	Efectos del consumo del beta-glucano de la avena sobre el colesterol sanguíneo: una revisión. Revista Espanola De Nutricion Humana Y Dietetica, 2016, 20, 127.	0.1	0
1172	Clinical Inertia in the Management of Hypercholesterolemia: What Clinicians Need to do. Journal of Atherosclerosis and Thrombosis, 2016, 23, 552-553.	0.9	4
1173	Cardiovascular risk factor control is insufficient in young patients with coronary artery disease. Vascular Health and Risk Management, 2016, 12, 219.	1.0	7
1174	Validity of a Novel Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Diabetic Patients. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1355-1364.	0.9	42
1175	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 685-698.	0.5	55
1176	Relationship between Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol in the General Population:. Journal of Atherosclerosis and Thrombosis, 2016, 23, 477-490.	0.9	26
1177	Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants. Medical Science Monitor, 2016, 22, 2133-2143.	0.5	11
1178	Overview of guidelines for the management of dyslipidemia: EU perspectives. Vascular Health and Risk Management, 2016, Volume 12, 357-369.	1.0	16
1179	Diet management for dyslipidemia. Journal of the Korean Medical Association, 2016, 59, 358.	0.1	4
1180	Treatment of Homozygous Familial Hypercholesterolemia: Challenges and Latest Development. , 0, , .		0
1181	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones, 2016, 15, 8-14.	0.9	28
1182	Canada acute coronary syndrome score was a stronger baseline predictor than age ≥75 years of in-hospital mortality in acute coronary syndrome patients in western Romania. Clinical Interventions in Aging, 2016, 11, 481.	1.3	8
1183	Linking CD11b ⁺ Dendritic Cells and Natural Killer T Cells to Plaque Inflammation in Atherosclerosis. Mediators of Inflammation, 2016, 2016, 1-12.	1.4	18

#	ARTICLE	IF	CITATIONS
1184	Cardiometabolic Risk in Hyperlipidemic Men and Women. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-8.	0.6	6
1185	Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-12.	1.0	36
1186	Rationale and Design of the PROSPECTIVE Trial: Probuocol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 746-756.	0.9	15
1187	High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. <i>Clinics</i> , 2016, 71, 235-242.	0.6	78
1188	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	1.0	166
1189	2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). <i>Korean Circulation Journal</i> , 2016, 46, 275.	0.7	106
1190	Spirulina as a functional ingredient in broiler chicken diets. <i>South African Journal of Animal Sciences</i> , 2016, 46, 94.	0.2	48
1191	Combined Treatment with Amlodipine and Atorvastatin Calcium Reduces Circulating Levels of Intercellular Adhesion Molecule-1 and Tumor Necrosis Factor- α in Hypertensive Patients with Prediabetes. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 206.	1.7	6
1193	The Contribution of GWAS Loci in Familial Dyslipidemias. <i>PLoS Genetics</i> , 2016, 12, e1006078.	1.5	48
1194	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. <i>World Journal of Cardiology</i> , 2016, 8, 201.	0.5	47
1195	Postprandial dysmetabolism: Too early or too late?. <i>Hormones</i> , 2016, 15, 321-344.	0.9	24
1196	Statin myopathy. <i>Current Opinion in Cardiology</i> , 2016, 31, 417-425.	0.8	7
1197	Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?. <i>Current Cardiology Reports</i> , 2016, 18, 67.	1.3	74
1198	Advances in Lipid Testing: A Practical Step Forward. <i>Clinical Chemistry</i> , 2016, 62, 905-906.	1.5	5
1199	Comparison and Validation of 10 Equations Including a Novel Method for Estimation of LDL-cholesterol in a 168,212 Asian Population. <i>Medicine (United States)</i> , 2016, 95, e3230.	0.4	17
1200	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. <i>JAMA Cardiology</i> , 2016, 1, 700.	3.0	13
1201	Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 858-863.	1.0	6
1202	Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland. <i>Journal of Hypertension</i> , 2016, 34, 532-538.	0.3	31

#	ARTICLE	IF	CITATIONS
1203	The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. <i>Obesity Reviews</i> , 2016, 17, 553-572.	3.1	33
1204	Plasma cholesterol is related to menstrual status in adolescent girls with eating disorders and weight loss. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2016, 105, 317-323.	0.7	3
1205	Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: A retrospective study. <i>Journal of Clinical Apheresis</i> , 2016, 31, 571-578.	0.7	56
1206	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. <i>Joint Bone Spine</i> , 2016, 83, 501-509.	0.8	39
1207	Nurses' Role in Cardiovascular Risk Assessment and Management in People with Inflammatory Arthritis: A European Perspective. <i>Musculoskeletal Care</i> , 2016, 14, 133-151.	0.6	16
1208	Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: A two-center registry study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 508-514.	0.7	22
1209	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2016, 118, 647-655.	0.7	21
1210	Metabolic Control in Older Dependent People: Need for Improvement?. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 777-778.	1.2	0
1211	Newer Therapies for Management of Stable Ischemic Heart Disease With Focus on Refractory Angina. <i>American Journal of Therapeutics</i> , 2016, 23, e1842-e1856.	0.5	2
1212	Serum Lipid Profile, Prevalence of Dyslipidaemia, and Associated Risk Factors Among Northern Mexican Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 544-549.	0.9	16
1213	Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. <i>Lipids in Health and Disease</i> , 2016, 15, 116.	1.2	3
1214	Multicenter Cohort Study of Acute Myocardial Infarction in Korea – Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. <i>Circulation Journal</i> , 2016, 80, 1427-1436.	0.7	166
1215	Cardiovascular complications of diabetes. <i>InnovAIT</i> , 2016, 9, 694-701.	0.0	1
1217	Resistance training reduces systolic blood pressure in metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials. <i>British Journal of Sports Medicine</i> , 2016, 50, 1438-1442.	3.1	75
1218	Dietary cholesterol and egg yolk should be avoided by patients at risk of vascular disease. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 20-24.	1.0	25
1219	Lower extremity and carotid artery disease in COPD. <i>ERJ Open Research</i> , 2016, 2, 00037-2016.	1.1	11
1220	β-Blockers and Vascular Hemodynamics in Patients With Peripheral Arterial Disease. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1244-1249.	1.0	2
1224	Management standards for stable coronary artery disease in India. <i>Indian Heart Journal</i> , 2016, 68, S31-S49.	0.2	11

#	ARTICLE	IF	CITATIONS
1225	Niacin is still beneficial. Implications from an updated meta-regression analysis. <i>Acta Cardiologica</i> , 2016, 71, 463-472.	0.3	5
1226	Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000275.	1.2	27
1227	6.4 LARGE AND SMALL ARTERY CROSSTALK IN PATIENTS WITH TYPE 2 DIABETES. <i>Artery Research</i> , 2016, 16, 60.	0.3	0
1228	The year in cardiology 2015: prevention. <i>Egyptian Heart Journal</i> , 2016, 68, 291-300.	0.4	0
1229	Trastornos del metabolismo lipídico. <i>Medicine</i> , 2016, 12, 1059-1071.	0.0	0
1230	Protocolo diagnóstico de las dislipidemias. <i>Medicine</i> , 2016, 12, 1107-1110.	0.0	0
1233	Mutation detection in Chinese patients with familial hypercholesterolemia. <i>SpringerPlus</i> , 2016, 5, 2095.	1.2	3
1234	Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study. <i>Nefrologia</i> , 2016, 36, 679-686.	0.2	0
1235	Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science. <i>Circulation</i> , 2016, 133, 1302-1331.	1.6	198
1236	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
1237	A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. <i>Journal of Clinical Lipidology</i> , 2016, 10, 228-239.	0.6	5
1238	Quality of life in patients treated with lipoprotein apheresis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 323-329.e6.	0.6	18
1239	Increases in plasma plant sterols stabilize within four weeks of plant sterol intake and are independent of cholesterol metabolism. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 302-309.	1.1	18
1240	Diabetic dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2016, 27, 313-322.	1.2	42
1241	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2016, 62, 930-946.	1.5	145
1242	Provider understanding of the 2013 ACC/AHA cholesterol guideline. <i>Journal of Clinical Lipidology</i> , 2016, 10, 497-504.e4.	0.6	61
1243	Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. <i>Current Medical Research and Opinion</i> , 2016, 32, 1633-1638.	0.9	17
1244	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	1.0	5,370

#	ARTICLE	IF	CITATIONS
1246	How Well Can We Control Dyslipidemias Through Lifestyle Modifications?. <i>Current Cardiology Reports</i> , 2016, 18, 66.	1.3	29
1247	Non-“high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf. <i>Journal of Clinical Lipidology</i> , 2016, 10, 368-377.	0.6	14
1248	Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 931-938.	0.6	72
1250	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1424-1430.	4.3	31
1251	Synthesis of tailor-made bile acid sequestrants by supplemental activator and reducing agent atom transfer radical polymerization. <i>RSC Advances</i> , 2016, 6, 52143-52153.	1.7	13
1253	Vascular Age Versus Cardiovascular Risk: Clarifying Concepts. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 243-246.	0.4	23
1254	Comparison of statin eligibility according to the Adult Treatment Panel III, ACC/AHA blood cholesterol guideline, and presence of carotid plaque by ultrasound in Mexican mestizo patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2823-2827.	1.0	6
1255	Relationship between serum triglyceride levels and endothelial function in a large community-based study. <i>Atherosclerosis</i> , 2016, 249, 70-75.	0.4	36
1256	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.0	71
1257	Abnormal left ventricular relaxation and symptoms of heart failure. <i>Journal of Echocardiography</i> , 2016, 14, 113-119.	0.4	1
1258	Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. <i>Clinical Research in Cardiology</i> , 2016, 105, 783-790.	1.5	43
1259	Patients with dyslipidemia on a self-reported diet have a healthier dietary intake than the general population. The CoLaus study. <i>Clinical Nutrition ESPEN</i> , 2016, 11, e33-e39.	0.5	5
1260	Statin therapy in the primary prevention of early atrial fibrillation after coronary artery bypass grafting. <i>Indian Heart Journal</i> , 2016, 68, 792-797.	0.2	12
1261	A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study. <i>International Journal of Cardiology</i> , 2016, 217, 183-189.	0.8	5
1262	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. <i>Nature Reviews Endocrinology</i> , 2016, 12, 467-484.	4.3	28
1263	Association between metabolic syndrome and 10-year risk of developing cardiovascular disease in a Nigerian population. <i>International Health</i> , 2016, 8, 354-359.	0.8	13
1264	Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 931-938.	0.4	14
1265	Screening for Asymptomatic Carotid Plaques with Ultrasound. <i>European Journal of Vascular and Endovascular Surgery</i> , 2016, 52, 309-312.	0.8	14

#	ARTICLE	IF	CITATIONS
1266	Lipid-modifying effects of nutraceuticals: An evidence-based approach. <i>Nutrition</i> , 2016, 32, 1179-1192.	1.1	157
1267	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
1268	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. <i>Atherosclerosis</i> , 2016, 244, 138-146.	0.4	163
1269	Rosuvastatin: Beyond the cholesterol-lowering effect. <i>Pharmacological Research</i> , 2016, 107, 1-18.	3.1	57
1270	The metabolic vascular syndrome - guide to an individualized treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 5-17.	2.6	29
1271	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. <i>Endocrine</i> , 2016, 54, 588-601.	1.1	58
1272	Diabetes Dyslipidemia. <i>Diabetes Therapy</i> , 2016, 7, 203-219.	1.2	259
1273	Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. <i>Future Cardiology</i> , 2016, 12, 449-466.	0.5	11
1275	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1202-1210.	0.8	42
1276	Nonfasting for Routine Lipid Testing. <i>JAMA Internal Medicine</i> , 2016, 176, 1005.	2.6	38
1277	Toxic hepatitis due to a food supplement: "Natural" is no synonym for "harmless". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, e38-e43.	0.7	6
1278	LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors. <i>European Heart Journal</i> , 2016, 37, 1337-1340.	1.0	3
1279	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 117-127.	2.6	5
1280	Recent Update to the US Cholesterol Treatment Guidelines. <i>Circulation</i> , 2016, 133, 1795-1806.	1.6	89
1281	Effects of K-877, a novel selective PPAR α modulator (SPPARM α), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. <i>Atherosclerosis</i> , 2016, 249, 36-43.	0.4	146
1282	Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2016, 200, 235-242.	2.0	104
1283	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1109-1123.	1.5	363
1284	Ascending Aortic Dimensions in Hypertensive Subjects: Reference Values for Two-Dimensional Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 827-837.	1.2	23

#	ARTICLE	IF	CITATIONS
1285	Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Review of Cardiovascular Therapy, 2016, 14, 953-962.	0.6	26
1286	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. European Heart Journal, 2016, 37, 3588-3595.	1.0	174
1287	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189
1288	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology, 2016, 223, 750-757.	0.8	54
1289	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 1624-1630.	0.7	52
1290	Relationship Among Risk Score Systems and Coronary Atherosclerosis Determined by Multislice Computed Tomography. Clinical Cardiology, 2016, 39, 603-607.	0.7	4
1291	Long-Term Effects of Radiotherapy on Arterial Stiffness in Breast Cancer Women. American Journal of Cardiology, 2016, 118, 771-776.	0.7	16
1293	Clinical considerations of lipid target and goal in dyslipidemia control. Chronic Diseases and Translational Medicine, 2016, 2, 3-6.	0.9	1
1295	Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). Preventive Medicine Reports, 2016, 4, 192-198.	0.8	3
1301	Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA. Nefrología, 2016, 36, 679-686.	0.2	2
1302	Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study. Nicotine and Tobacco Research, 2016, 19, ntw235.	1.4	13
1303	Should we individualize lipid profiling in women with polycystic ovary syndrome?. Human Reproduction, 2016, 31, 2791-2795.	0.4	9
1304	Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care. Advances in Therapy, 2016, 33, 2049-2058.	1.3	4
1305	Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data in Brief, 2016, 9, 616-620.	0.5	18
1306	Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 180-191.	1.2	19
1307	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. Clinica Chimica Acta, 2016, 462, 193-200.	0.5	7
1308	Validation of the european SCORE risk chart in the healthy middle-aged Japanese. Atherosclerosis, 2016, 252, 116-121.	0.4	9
1311	Under-Recognised and Underestimated: The Cardiovascular Health Burden of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2016, 25, 1045-1047.	0.2	1

#	ARTICLE	IF	CITATIONS
1312	The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. <i>Lipids in Health and Disease</i> , 2016, 15, 118.	1.2	131
1315	Statin use and risk of cholecystectomy – A case-control analysis using Swiss claims data. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1577-1582.	1.0	5
1316	Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. <i>Revista Española De Cardiología (English Ed)</i> , 2016, 69, 1083-1087.	0.4	4
1317	Consensus statement on the management of dyslipidaemias in adults. <i>Diabetes and Metabolism</i> , 2016, 42, 398-408.	1.4	18
1318	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	1.0	142
1319	Unmet Needs in LDL-C Lowering: When Statins Won't Do!. <i>Drugs</i> , 2016, 76, 1175-1190.	4.9	57
1320	Dyslipidaemia in the Middle East: Current status and a call for action. <i>Atherosclerosis</i> , 2016, 252, 182-187.	0.4	37
1321	Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1412-1443.	1.1	36
1322	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2066-2074.	1.0	12
1323	Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis). <i>Journal of the American College of Cardiology</i> , 2016, 67, 1077-1085.	1.0	10
1324	Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 222, 119-129.	0.8	23
1325	Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2016, 252, 50-60.	0.4	50
1326	Cholesterol Guidelines: More Similar Than Different. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 190-199.	1.6	2
1327	The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 145-152.	1.6	21
1328	The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. <i>American Heart Journal</i> , 2016, 181, 35-42.	1.2	35
1329	Chronic ischaemic heart disease in the elderly. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 372.e1-372.e10.	0.1	0
1330	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , 2016, 134, 698-709.	1.6	99
1331	Statin Use and Its Facility Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. <i>Clinical Cardiology</i> , 2016, 39, 185-191.	0.7	43

#	ARTICLE	IF	CITATIONS
1332	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
1333	Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 170-179.	0.7	29
1334	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	1.0	2,393
1335	Clinical Case 1: Patient with Essential Hypertension and Metabolic Syndrome. Practical Case Studies in Hypertension Management, 2016, , 1-16.	0.0	0
1336	Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 217-230.	1.0	31
1337	Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies. International Journal of Cardiology, 2016, 222, 793-794.	0.8	13
1338	Clinical Case 2: Adult Patient with Hypertension and Diabetes. Practical Case Studies in Hypertension Management, 2016, , 17-32.	0.0	0
1339	Inhibition of HMG-CoA reductase activity and cholesterol permeation through Caco-2 cells by caffeoylquinic acids from Vernonia condensata leaves. Revista Brasileira De Farmacognosia, 2016, 26, 738-743.	0.6	27
1340	Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy, 2016, 14, 1263-1271.	0.6	8
1341	Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study. Clinical Chemistry, 2016, 62, 1372-1379.	1.5	17
1342	Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovascular Diabetology, 2016, 15, 104.	2.7	49
1343	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
1344	Gender-related impact on outcomes of high density lipoprotein in acute ST-elevation myocardial infarction. Atherosclerosis, 2016, 251, 460-466.	0.4	8
1345	Safety of atorvastatin in Asian patients within clinical trials. Cardiovascular Therapeutics, 2016, 34, 431-440.	1.1	15
1346	Effect of Tai Chi exercise on blood lipid profiles: a meta-analysis of randomized controlled trials. Journal of Zhejiang University: Science B, 2016, 17, 640-648.	1.3	23
1347	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1257-1272.	2.4	19
1348	Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statinsâ€”â€” ODYSSEY JAPAN Randomized Controlled Trial â€œ. Circulation Journal, 2016, 80, 1980-1987.	0.7	92
1349	ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. European Heart Journal, 2016, 38, ehw426.	1.0	45

#	ARTICLE	IF	CITATIONS
1350	Non-High-Density Lipoprotein Cholesterol Levels on the Risk of Asymptomatic Intracranial Arterial Stenosis: A Result from the APAC Study. <i>Scientific Reports</i> , 2016, 6, 37410.	1.6	9
1351	Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2016, 165, 560.	2.0	33
1352	Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16082.	18.1	585
1354	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160Âmg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 473-483.	1.3	160
1355	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. <i>Heart Lung and Circulation</i> , 2016, 25, 975-981.	0.2	43
1356	Statins and their role in the secondary prevention of coronary heart disease. <i>British Journal of Cardiac Nursing</i> , 2016, 11, 446-452.	0.0	0
1357	Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. <i>Atherosclerosis</i> , 2016, 255, 200-209.	0.4	88
1358	Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 498-509.	1.0	12
1359	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	71
1360	PCSK9 Inhibitors. <i>Journal of Pharmacy Technology</i> , 2016, 32, 201-209.	0.5	1
1361	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.4	415
1362	A phase III randomized trial evaluating alirocumab 300Âmg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. <i>Atherosclerosis</i> , 2016, 254, 254-262.	0.4	91
1363	Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 1508-1516.	2.9	103
1364	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1263-1282.	0.8	775
1365	The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2016, 17, 1329-1340.	3.1	55
1367	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. <i>Cardiovascular Diabetology</i> , 2016, 15, 95.	2.7	52
1368	Remembering Statins: Do Statins Have Adverse Cognitive Effects?. <i>Diabetes Care</i> , 2016, 39, S253-S259.	4.3	29
1369	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 323-336.	1.0	18

#	ARTICLE	IF	CITATIONS
1370	The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. <i>Journal of Medical Economics</i> , 2016, 19, 1167-1174.	1.0	7
1372	Non-HDL-C vs. LDL-C in Predicting the Severity of Coronary Atherosclerosis. <i>Heart Lung and Circulation</i> , 2016, 25, 953-954.	0.2	14
1373	Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. <i>Atherosclerosis</i> , 2016, 251, 248-254.	0.4	61
1374	Real life validation of the European Atherosclerosis Society Consensus Panel lipoprotein(a) threshold of 50mg/dL. <i>International Journal of Cardiology</i> , 2016, 221, 537-538.	0.8	4
1376	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	0.8	17
1377	HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort. <i>Scientific Reports</i> , 2016, 6, 30741.	1.6	17
1378	Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. <i>International Journal of Clinical Practice</i> , 2016, 70, 886-897.	0.8	20
1379	Risk burdens of modifiable risk factors incorporating lipoprotein (a) and low serum albumin concentrations for first incident acute myocardial infarction. <i>Scientific Reports</i> , 2016, 6, 35463.	1.6	15
1380	A competing-risk-based score for predicting twenty-year risk of incident diabetes: the Beijing Longitudinal Study of Ageing study. <i>Scientific Reports</i> , 2016, 6, 37248.	1.6	10
1381	Cardiovascular Risk Assessment. <i>Annals of Internal Medicine</i> , 2016, 165, 713.	2.0	55
1382	Risk factors and quality of life of dyslipidemic patients in Lebanon: A cross-sectional study. <i>Journal of Epidemiology and Global Health</i> , 2016, 6, 315.	1.1	18
1383	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	1.6	110
1384	Statins and their role in the secondary prevention of coronary heart disease. <i>NursePrescribing</i> , 2016, 14, 496-501.	0.1	0
1385	Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1344-1352.	0.6	32
1386	Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk. <i>Scientific Reports</i> , 2016, 6, 34268.	1.6	6
1387	Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016, 176, 1834.	2.6	194
1388	Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. <i>Atherosclerosis</i> , 2016, 254, 215-227.	0.4	23
1391	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2016, 24, .	0.0	6

#	ARTICLE	IF	CITATIONS
1392	Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. <i>BMJ, The</i> , 2016, 352, i721.	3.0	93
1393	ST-segment elevation in lead aVR in the setting of acute coronary syndrome. <i>Acta Cardiologica</i> , 2016, 71, 47-54.	0.3	8
1394	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	1.8	32
1395	Two new lipid-regulating drugs:. <i>Drug and Therapeutics Bulletin</i> , 2016, 54, 18-21.	0.3	3
1396	Observations in relation to myocardial infarction: Are there three different Mexicos?. <i>Medicina Universitaria</i> , 2016, 18, 181-184.	0.1	0
1397	Systematic screening for cardiovascular risk at pharmacies. <i>Open Heart</i> , 2016, 3, e000497.	0.9	7
1398	Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 49.	1.2	2
1400	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. <i>BMC Family Practice</i> , 2016, 17, 110.	2.9	12
1401	Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. <i>BMC Family Practice</i> , 2016, 17, 144.	2.9	14
1402	Nutritional management of a patient with obesity and pulmonary embolism: a case report. <i>Nutrition Journal</i> , 2016, 15, 90.	1.5	1
1404	Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1171-1176.	0.8	15
1406	What to say and how to say it. <i>Current Opinion in Cardiology</i> , 2016, 31, 537-544.	0.8	28
1407	Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. <i>Cardiovascular Diabetology</i> , 2016, 15, 81.	2.7	17
1409	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 216-228.	1.0	8
1410	A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. <i>American Journal of Cardiology</i> , 2016, 117, 495-500.	0.7	20
1411	Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 241-253.	1.0	12
1412	Application of cavitation system to accelerate aqueous enzymatic extraction of seed oil from <i>Cucurbita pepo</i> L. and evaluation of hypoglycemic effect. <i>Food Chemistry</i> , 2016, 212, 403-410.	4.2	30
1414	Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 355-364.	0.6	6

#	ARTICLE	IF	CITATIONS
1415	Cardiovascular risk assessment in women – an update. <i>Climacteric</i> , 2016, 19, 329-336.	1.1	62
1416	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points – a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , 2016, 37, 1944-1958.	1.0	542
1417	Stroke: Changing Risk Factor Profile and Unaltered Mean Age in a Developing Country. A Retrospective Study and Literature Review. <i>European Neurology</i> , 2016, 75, 229-235.	0.6	4
1418	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. <i>American Journal of Cardiology</i> , 2016, 117, 1928-1933.	0.7	92
1419	Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance. <i>Clinical Biochemistry</i> , 2016, 49, 868-872.	0.8	11
1420	Pilot study of safety and efficacy of polyphenols in combination with coenzyme Q10 in patients with statin-induced myopathy. <i>Medicina (Lithuania)</i> , 2016, 52, 171-179.	0.8	7
1422	Effectiveness of a diet with low advanced glycation end products, in improving glycoxidation and lipid peroxidation: a long-term investigation in patients with chronic renal failure. <i>Endocrine</i> , 2016, 54, 552-555.	1.1	8
1423	New agents for hypercholesterolemia. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 172-177.	0.1	1
1424	Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique. <i>American Journal of Medicine</i> , 2016, 129, 906-912.	0.6	6
1425	Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy. <i>Journal of Clinical Lipidology</i> , 2016, 10, 587-593.	0.6	10
1426	Predictors of first-year statin medication discontinuation: A cohort study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 987-995.	0.6	25
1427	Impaired metabolic profile is a predictor of capillary rarefaction in a population of hypertensive and normotensive individuals. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 640-646.	2.3	14
1428	Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a). <i>Annals of Pharmacotherapy</i> , 2016, 50, 609-615.	0.9	7
1429	Lack of evidence and standardization in care pathway documents for patients with ST-elevated myocardial infarction. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, e45-e51.	0.4	8
1430	Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 74.	0.7	27
1431	Clinical and metabolic characteristics of treated hyperlipidemic patients additionally affected by subclinical hyperglycemia. <i>Lipids in Health and Disease</i> , 2016, 15, 10.	1.2	3
1432	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. <i>Lipids in Health and Disease</i> , 2016, 15, 28.	1.2	36
1433	Expert opinion: the therapeutic challenges faced by statin intolerance. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1497-1507.	0.9	43

#	ARTICLE	IF	CITATIONS
1435	The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. <i>Contemporary Clinical Trials</i> , 2016, 49, 47-56.	0.8	2
1436	Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11. <i>BMC Public Health</i> , 2016, 16, 240.	1.2	21
1437	Uncontrolled risk factors and worsening perfusion pattern on SPECT myocardial perfusion imaging in medically treated patients with stable chronic ischaemic heart disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1513-1521.	3.3	0
1439	Skeletal muscle ultrastructure and function in statin-tolerant individuals. <i>Muscle and Nerve</i> , 2016, 53, 242-251.	1.0	17
1440	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
1441	Identifying familial hypercholesterolemia in acute coronary syndrome. <i>Current Opinion in Lipidology</i> , 2016, 27, 375-381.	1.2	18
1442	Chronotropic response during treadmill exercise and subclinical carotid atherosclerosis after adjusting for the calibrated SCORE risk classification: a cross-sectional study. <i>Heart and Vessels</i> , 2016, 31, 129-136.	0.5	7
1443	Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 275-281.	0.8	8
1444	Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2016, 63, 756-763.	0.6	12
1445	Quality markers in cardiology: measures of outcomes and clinical practice—a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. <i>European Heart Journal</i> , 2016, 37, 12-23.	1.0	14
1446	Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia. <i>Blood Purification</i> , 2016, 41, 270-276.	0.9	5
1447	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries — Findings from the EUROASPIRE IV survey. <i>Atherosclerosis</i> , 2016, 246, 243-250.	0.4	173
1448	Fibrinogen and the Severity of Coronary Atherosclerosis among Adults with and without Statin Treatment: Lipid as a mediator. <i>Heart Lung and Circulation</i> , 2016, 25, 558-567.	0.2	8
1449	Five-year results of laparoscopic sleeve gastrectomy: effects on gastroesophageal reflux disease symptoms and co-morbidities. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 960-968.	1.0	43
1450	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 433-441.	2.3	7
1451	Cardiovascular risk profile and use of statins at the age of 70 years: a comparison of two Finnish birth cohorts born 20 years apart. <i>Age and Ageing</i> , 2016, 45, 84-90.	0.7	7
1452	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. <i>American Journal of Medicine</i> , 2016, 129, 384-391.	0.6	37
1453	Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. <i>Atherosclerosis</i> , 2016, 249, 116-124.	0.4	58

#	ARTICLE	IF	CITATIONS
1454	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 275-281.	0.9	9
1455	Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis at aortic tissue with reflection in plasma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 725-732.	1.8	35
1456	No evidence to support high-intensity statin in Chinese patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2016, 204, 57-58.	0.8	19
1457	Current Management of Hyperlipidemia in Patients Discharged With a Diagnosis of Acute Coronary Syndrome. <i>Revista Española De Cardiología (English Ed)</i> , 2016, 69, 83-84.	0.4	0
1458	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	1.0	120
1459	Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 83-92.	1.0	10
1460	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. <i>European Heart Journal</i> , 2016, 37, 3569-3575.	1.0	30
1461	Utility of repeat serum cholesterol measurements for assessment of cardiovascular risk in primary prevention. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 628-635.	0.8	4
1462	Reduction of LDL-cholesterol: important at all ages. <i>European Heart Journal</i> , 2016, 37, 1982-1984.	1.0	5
1465	Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	0
1467	From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 44-53.	1.4	30
1468	Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors. <i>BMC Cancer</i> , 2016, 16, 234.	1.1	56
1469	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 212, 160-168.	0.8	51
1471	High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. <i>Atherosclerosis</i> , 2016, 247, 58-63.	0.4	21
1472	Genetic Testing in Hyperlipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 129-140.	1.2	4
1473	The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 109-113.	1.1	3
1474	Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward. <i>Atherosclerosis</i> , 2016, 247, 225-282.	0.4	67
1475	The year in cardiology 2015: prevention. <i>European Heart Journal</i> , 2016, 37, 510-519.	1.0	13

#	ARTICLE	IF	CITATIONS
1476	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. <i>Journal of Clinical Lipidology</i> , 2016, 10, 240-264.	0.6	3
1477	Cholesterol absorption and synthesis markers in Portuguese hypercholesterolemic adults: A cross-sectional study. <i>European Journal of Internal Medicine</i> , 2016, 28, 85-90.	1.0	6
1478	Plasma Cholesterol-Lowering Activity of Lard Functionalized with Mushroom Extracts Is Independent of Niemann-Pick C1-like 1 Protein and ABC Sterol Transporter Gene Expression in Hypercholesterolemic Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 1686-1694.	2.4	14
1479	Saroglitazar: The revolution in India. <i>Journal of Indian College of Cardiology</i> , 2016, 6, 105-108.	0.1	2
1480	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. <i>Circulation Research</i> , 2016, 118, 547-563.	2.0	701
1481	Rationale for Strengthening Muscle to Prevent Falls and Fractures: A Review of the Evidence. <i>Calcified Tissue International</i> , 2016, 98, 531-545.	1.5	65
1482	Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1451-1465.	1.3	30
1485	Inflammation, High-sensitivity C-reactive Protein, and Persistent Patent Ductus Arteriosus in Preterm Infants. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 84-85.	0.4	5
1486	Manejo actual de la hiperlipemia en pacientes dados de alta con el diagnóstico de síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 83-84.	0.6	2
1487	Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 105, 198-209.	3.1	53
1488	Dyslipidemia in Obesity. , 2016, , 525-540.		4
1489	Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2016, 248, 76-83.	0.4	74
1490	Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016, 117, 1088-1094.	0.7	19
1492	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. <i>Future Cardiology</i> , 2016, 12, 149-157.	0.5	7
1494	Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. <i>European Heart Journal</i> , 2016, 37, 1398-1405.	1.0	73
1495	Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. <i>Current Medical Research and Opinion</i> , 2016, 32, 417-426.	0.9	7
1496	Gemfibrozil in Combination with Statins—Is It Really Contraindicated?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 18.	2.0	10
1497	HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 565-576.	1.6	42

#	ARTICLE	IF	CITATIONS
1498	Alirocumab: A Review in Hypercholesterolemia. American Journal of Cardiovascular Drugs, 2016, 16, 141-152.	1.0	10
1499	National Lipid Association Annual Summary of Clinical Lipidology 2016. Journal of Clinical Lipidology, 2016, 10, S1-S43.	0.6	99
1500	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. BMC Infectious Diseases, 2016, 16, 114.	1.3	12
1501	Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. Journal of Clinical Lipidology, 2016, 10, 627-634.	0.6	17
1502	La edad vascular frente al riesgo cardiovascular: aclarando conceptos. Revista Espanola De Cardiologia, 2016, 69, 243-246.	0.6	30
1504	Statin therapy with or without ezetimibe and the progression to diabetes. Journal of Clinical Lipidology, 2016, 10, 306-313.	0.6	37
1505	Improving cardiovascular protection: focus on a cardiovascular polypill. Future Cardiology, 2016, 12, 181-196.	0.5	6
1506	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. European Journal of Clinical Pharmacology, 2016, 72, 349-357.	0.8	11
1507	Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 123-133.	1.1	8
1508	Visible aging signs as risk markers for ischemic heart disease: Epidemiology, pathogenesis and clinical implications. Ageing Research Reviews, 2016, 25, 24-41.	5.0	25
1509	Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. European Journal of Preventive Cardiology, 2016, 23, 744-747.	0.8	47
1510	The long-term impact of biliopancreatic diversion on glycemic control in the severely obese with type 2 diabetes mellitus in relation to preoperative duration of diabetes. Surgery for Obesity and Related Diseases, 2016, 12, 345-349.	1.0	16
1511	Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry. European Journal of Preventive Cardiology, 2016, 23, 340-348.	0.8	58
1512	Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China. Journal of Clinical Lipidology, 2016, 10, 150-160.	0.6	61
1513	Relationship between glycosylated hemoglobin A1c and cognitive function in nondemented elderly patients with type 2 diabetes. Metabolic Brain Disease, 2016, 31, 347-353.	1.4	15
1514	Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. European Heart Journal, 2016, 37, 177-185.	1.0	108
1515	Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception, 2016, 94, 280-287.	0.8	26
1516	Statin tolerability: In defence of placebo-controlled trials. European Journal of Preventive Cardiology, 2016, 23, 891-896.	0.8	32

#	ARTICLE	IF	CITATIONS
1517	Statinâ€Ezetimibe Combination Therapy In Diabetic Individuals. <i>Angiology</i> , 2016, 67, 507-509.	0.8	6
1519	Carotid Plaques Correlates in Patients With Familial Hypercholesterolemia. <i>Angiology</i> , 2016, 67, 471-477.	0.8	10
1520	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. <i>American Journal of Hypertension</i> , 2016, 29, 158-162.	1.0	23
1522	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 474-485.	0.8	12
1523	Polychlorinated biphenyls and links to cardiovascular disease. <i>Environmental Science and Pollution Research</i> , 2016, 23, 2160-2172.	2.7	91
1524	Guideline Confusion for the Clinician. <i>Angiology</i> , 2016, 67, 5-9.	0.8	4
1525	Assessment of Drugâ€Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 309-318.	0.6	16
1526	Individualized lipid-lowering therapy to further reduce residual cardiovascular risk. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 169, 198-201.	1.2	8
1528	Statin Eligibility Under American and European Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2017, 2, 459.	3.0	1
1529	Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 301-311.	2.8	17
1530	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. <i>Journal of Clinical Lipidology</i> , 2017, 11, 12-23.e1.	0.6	33
1531	Documento de consenso del uso clÃnico de la Polypill en la prevenciÃn secundaria del riesgo cardiovascular. <i>Medicina ClÃnica</i> , 2017, 148, 139.e1-139.e15.	0.3	6
1534	Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. <i>International Journal of Angiology</i> , 2017, 26, 073-077.	0.2	4
1535	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.5	38
1536	Consensus statement on the management of dyslipidaemias in adults. <i>Annales D'Endocrinologie</i> , 2017, 78, 43-53.	0.6	3
1537	Predictors of Nonuse of a Highâ€Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladibâ€Thrombolysis in Myocardial Infarction 52 (SOLIDâ€TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
1538	Interarm blood pressure differences predict target organ damage in type 2 diabetes. <i>Journal of Clinical Hypertension</i> , 2017, 19, 472-478.	1.0	16
1539	Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. <i>BMJ Open</i> , 2017, 7, e011684.	0.8	21

#	ARTICLE	IF	CITATIONS
1540	Evidence-based goals in LDL-C reduction. <i>Clinical Research in Cardiology</i> , 2017, 106, 237-248.	1.5	69
1541	PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. <i>Heart Lung and Circulation</i> , 2017, 26, 786-798.	0.2	2
1543	Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. <i>Indian Heart Journal</i> , 2017, 69, 458-463.	0.2	94
1544	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	1.5	74
1545	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: sub-analysis of ODYSSEY COMBO II. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 989-996.	2.2	46
1546	Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 747-754.	0.9	24
1547	Appropriate use of cholesterol-lowering therapy. <i>Atherosclerosis</i> , 2017, 262, 198-199.	0.4	1
1549	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. <i>BMJ Open</i> , 2017, 7, e013255.	0.8	32
1550	Ezetimibe: an update on its clinical usefulness in specific patient groups. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 4-11.	1.1	44
1551	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 139.e1-139.e15.	0.1	2
1553	Cholesterol-lowering drugs: science and marketing. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 57-64.	1.1	7
1554	Classical rather than genetic risk factors account for high cardiovascular disease prevalence in Lithuania: A cross-sectional population study. <i>Advances in Medical Sciences</i> , 2017, 62, 121-128.	0.9	8
1555	Statin use and all-cause and cancer mortality: BioBank Japan cohort. <i>Journal of Epidemiology</i> , 2017, 27, S84-S91.	1.1	25
1556	Collecte et prise en charge de certaines comorbidités et facteurs de risque associés dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. <i>Revue Du Rhumatisme (Edition Française)</i> , 2017, 84, 123-131.	0.0	0
1557	Percutaneous coronary intervention vs. cardiac surgery in diabetic patients. Where are we now and where should we be going?. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 178-189.	0.4	18
1558	Recanalization of peripheral chronic total occlusions: no fancy devices, just a crossing catheter™. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 221-225.	0.6	5
1559	Plant sterol enriched functional food and atherosclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 1281-1289.	2.7	45
1560	Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome. <i>Clinical Endocrinology</i> , 2017, 86, 784-790.	1.2	1

#	ARTICLE	IF	CITATIONS
1561	Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 167-178.	0.7	18
1562	Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 413-421.e3.	0.6	12
1563	The genetic spectrum of familial hypercholesterolemia in the central south region of China. <i>Atherosclerosis</i> , 2017, 258, 84-88.	0.4	22
1564	Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management. <i>Clinical Rheumatology</i> , 2017, 36, 1387-1393.	1.0	8
1565	Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 473-503.	1.1	28
1567	Progression of a lesion with nodular calcification. <i>Coronary Artery Disease</i> , 2017, 28, 266-267.	0.3	2
1568	PCSK9 as a therapeutic target for cardiovascular disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 810-814.	0.8	15
1569	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <scp>STATIPLAT</scp> randomized study. <i>Clinical Cardiology</i> , 2017, 40, 605-611.	0.7	9
1570	Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1461-1478.	1.6	41
1571	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. <i>Atherosclerosis Supplements</i> , 2017, 26, 2-15.	1.2	31
1573	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24.	1.2	24
1574	Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 911-924.	1.4	6
1575	The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients. <i>Journal of the American College of Nutrition</i> , 2017, 36, 287-294.	1.1	8
1576	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 313-329.	1.0	9
1577	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 919-926.	1.0	4
1578	Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease. <i>Internal and Emergency Medicine</i> , 2017, 12, 1121-1129.	1.0	9
1579	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the <scp>REACH</scp> Registry. <i>Clinical Cardiology</i> , 2017, 40, 710-718.	0.7	33
1580	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2017, 33, 1-5.	1.3	160

#	ARTICLE	IF	CITATIONS
1581	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 53-65.	3.1	67
1582	Prooxidant-antioxidant balance, hsTnI and hsCRP: mortality prediction in haemodialysis patients, two-year follow-up. <i>Renal Failure</i> , 2017, 39, 491-499.	0.8	16
1584	Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1297-1307.	0.8	31
1585	Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. <i>Rheumatology</i> , 2017, 56, 1102-1110.	0.9	100
1586	Dislipidemia en las personas de edad muy avanzada. <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-10.	0.0	0
1587	Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 13-19.	0.1	0
1589	Cardiovascular Risk and Lipid Management Reimbursement Between Patients with Stage 3-5 Chronic Kidney Disease and Those with Diabetes Mellitus. <i>International Journal of Gerontology</i> , 2017, 11, 51-52.	0.7	2
1590	The association between dietary cholesterol intake and subclinical atherosclerosis in Korean adults: The Kangbuk Samsung Health Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 432-441.e3.	0.6	14
1592	Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities: BioBank Japan. <i>Journal of Epidemiology</i> , 2017, 27, S77-S83.	1.1	3
1593	Chronic kidney disease and dyslipidaemia. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 22-35.	0.1	6
1595	Effect of prompt revascularization on outcomes in diabetic patients with stable ischemic heart disease and previous myocardial infarction in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. <i>Coronary Artery Disease</i> , 2017, 28, 301-306.	0.3	2
1596	Mid-term outcome of biolimus-eluting stents with biodegradable polymer. <i>Coronary Artery Disease</i> , 2017, 28, 457-464.	0.3	2
1597	Clinical utility of the HEART score in patients admitted with chest pain to an inner-city hospital in the USA. <i>Coronary Artery Disease</i> , 2017, 28, 336-341.	0.3	14
1598	Dyslipidemia in diabetes mellitus and cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 27-32.	0.8	41
1599	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	0.8	5
1600	Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. <i>Clinical Therapeutics</i> , 2017, 39, 819-827.e1.	1.1	38
1601	Long-term Low-Density Lipoprotein Cholesterol Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. <i>JAMA Cardiology</i> , 2017, 2, 598.	3.0	137
1602	Statin associated myopathy in clinical practice. Results of DAMA study. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 7-12.	0.1	2

#	ARTICLE	IF	CITATIONS
1603	A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. <i>International Journal of Cardiology</i> , 2017, 235, 49-55.	0.8	24
1604	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 401-411.	6.1	257
1605	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMATology study project. <i>Journal of Clinical Lipidology</i> , 2017, 11, 749-756.e3.	0.6	30
1606	Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 81.	0.7	13
1607	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
1608	Statins and mortality: the untold story. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 938-941.	1.1	4
1609	Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. <i>Clinical Therapeutics</i> , 2017, 39, 107-117.	1.1	37
1610	Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 539-546.	1.8	11
1611	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 343-349.	0.8	16
1612	Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014. <i>Atherosclerosis</i> , 2017, 257, 9-15.	0.4	19
1613	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
1614	Statin potency and the risk of hospitalization for community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1319-1327.	1.1	9
1615	Prognostic Implications of Raphe in Bicuspid Aortic Valve Anatomy. <i>JAMA Cardiology</i> , 2017, 2, 285.	3.0	101
1616	Vascular Diseases for the Non-Specialist. , 2017, , .		3
1617	Glucosaminan- and glucosaminan plus spirulina-enriched pork affect liver fatty acid profile, LDL receptor expression and antioxidant status in Zucker fa/fa rats fed atherogenic diets. <i>Food and Nutrition Research</i> , 2017, 61, 1264710.	1.2	8
1618	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)®. <i>Patient</i> , 2017, 10, 321-334.	1.1	9
1619	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 169-181.	1.0	19
1621	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. <i>Advances in Therapy</i> , 2017, 34, 300-323.	1.3	37

#	ARTICLE	IF	CITATIONS
1622	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , 2017, 112, 1832-1839.	0.2	109
1623	Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2017, 7, e017587.	0.8	6
1624	Adiposity measures and arterial stiffness in primary care: the MARK prospective observational study. <i>BMJ Open</i> , 2017, 7, e016422.	0.8	15
1625	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
1626	Prise en charge des dyslipidémies: quelles nouvelles recommandations?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2017, 2017, 3-8.	0.0	2
1627	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. <i>BMJ Open</i> , 2017, 7, e014150.	0.8	34
1628	Endothelial Dysfunction Markers in Low Cardiovascular Risk Individuals: Comparison of Males and Females. <i>Journal of Medical Biochemistry</i> , 2017, 36, 62-72.	0.7	13
1629	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
1630	Clinician performed ultrasound in fetal growth restriction: fetal, neonatal and pediatric aspects. <i>Journal of Perinatology</i> , 2017, 37, 1251-1258.	0.9	7
1631	Using the McSweeney Acute and Prodromal Myocardial Infarction Symptom Survey to Predict the Occurrence of Short-Term Coronary Heart Disease Events in Women. <i>Women's Health Issues</i> , 2017, 27, 660-665.	0.9	11
1632	Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. <i>Atherosclerosis</i> , 2017, 266, 158-166.	0.4	96
1633	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. <i>Progress in Lipid Research</i> , 2017, 68, 57-82.	5.3	63
1634	Dyslipidemia. <i>Physician Assistant Clinics</i> , 2017, 2, 633-650.	0.1	3
1635	Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. <i>Scientific Reports</i> , 2017, 7, 9179.	1.6	37
1636	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. <i>Scientific Reports</i> , 2017, 7, 8422.	1.6	15
1637	Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. <i>Journal of Clinical Apheresis</i> , 2017, 32, 574-578.	0.7	7
1638	Effect of exclusive cigarette smoking and in combination with waterpipe smoking on lipoproteins. <i>Journal of Epidemiology and Global Health</i> , 2017, 7, 269.	1.1	19
1639	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. <i>Current Opinion in Lipidology</i> , 2017, 28, 495-501.	1.2	31

#	ARTICLE	IF	CITATIONS
1640	Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. <i>BMJ Open</i> , 2017, 7, e014427.	0.8	5
1641	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. <i>Clínica E Investigaci3n En Arteriosclerosis (English) Tj ETQq1 1 0.784314 rgBT2/Overlo</i>	0.8	4
1642	Efficacy of lipid reduction with DALI and MONET. <i>Atherosclerosis Supplements</i> , 2017, 30, 217-224.	1.2	5
1643	The FOURIER study: The profound study of Nature is the most fertile source of discovery. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 146-147.	0.4	3
1644	Knowns and unknowns in the care of pediatric familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2017, 58, 1765-1776.	2.0	39
1645	Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism. <i>Atherosclerosis Supplements</i> , 2017, 30, 63-71.	1.2	4
1646	Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients. <i>Integrative Medicine Research</i> , 2017, 6, 240-244.	0.7	14
1648	Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. <i>International Journal of Clinical Practice</i> , 2017, 71, e12979.	0.8	11
1649	Nutrition in Stroke Prevention. <i>Seminars in Neurology</i> , 2017, 37, 259-266.	0.5	8
1650	Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke. <i>Seminars in Neurology</i> , 2017, 37, 286-293.	0.5	1
1651	Trans fatty acids and plaque vulnerability: Research continues. <i>Atherosclerosis</i> , 2017, 265, 244-245.	0.4	0
1652	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. <i>Coronary Artery Disease</i> , 2017, 28, 190-197.	0.3	19
1653	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	1.2	7
1654	Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. <i>Cardiovascular Endocrinology</i> , 2017, 6, 81-85.	0.8	6
1656	Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. <i>Clinical Cardiology</i> , 2017, 40, 1291-1296.	0.7	10
1657	Risk of vascular events in different manifestations of cerebral small vessel disease: A 2-year follow-up study with a control group. <i>Heliyon</i> , 2017, 3, e00455.	1.4	13
1658	Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. <i>Complementary Therapies in Medicine</i> , 2017, 35, 140-144.	1.3	12
1659	Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1769555.	0.4	0

#	ARTICLE	IF	CITATIONS
1660	Dyslipidemia in children as a risk factor for cardiovascular diseases. <i>Biotechnology and Biotechnological Equipment</i> , 2017, 31, 1192-1197.	0.5	2
1661	Safety aspects of lipidapheresis using DALI and MONET â€“ Multicenter observational study. <i>Atherosclerosis Supplements</i> , 2017, 30, 225-231.	1.2	7
1662	Time to change the SCORE?. <i>European Heart Journal</i> , 2017, 38, 595-597.	1.0	4
1663	Sexâ€Based Differences in the Performance of the HEART Score in Patients Presenting to the Emergency Department With Acute Chest Pain. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
1664	Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. <i>Circulation</i> , 2017, 136, 1087-1098.	1.6	79
1665	Increasing the Bile Acid Sequestration Performance of Cationic Hydrogels by Using an Advanced/Controlled Polymerization Technique. <i>Pharmaceutical Research</i> , 2017, 34, 1934-1943.	1.7	6
1666	The gene-diet associations in postmenopausal women with newly diagnosed dyslipidemia. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 1031-1037.	1.5	3
1667	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 58.	0.4	16
1668	Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 54.	0.7	18
1669	Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 127.	0.7	14
1670	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	2.3	38
1671	Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. <i>Lipids in Health and Disease</i> , 2017, 16, 49.	1.2	7
1672	Identification of the main determinants of abdominal aorta size: a screening by Pocket Size Imaging Device. <i>Cardiovascular Ultrasound</i> , 2017, 15, 2.	0.5	13
1673	Presenting symptoms, pre-hospital delay time and 28-day case fatality in patients with peripheral arterial disease and acute myocardial infarction from the MONICA/KORA Myocardial Infarction Registry. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 265-273.	0.8	13
1674	A systematic review of the effect of yogurt consumption on chronic diseases risk markers in adults. <i>European Journal of Nutrition</i> , 2017, 56, 1375-1392.	1.8	25
1676	Plaque imaging to refine indications for emerging lipid-lowering drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 58-67.	1.4	26
1677	Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: A population based study. <i>International Journal of Cardiology</i> , 2017, 228, 52-57.	0.8	20
1678	Green synthesis of Î²-sitostanol esters catalyzed by the versatile lipase/sterol esterase from <i>Ophiostoma piceae</i> . <i>Food Chemistry</i> , 2017, 221, 1458-1465.	4.2	29

#	ARTICLE	IF	CITATIONS
1679	Translation and adaptation of the French version of the Heart Disease Fact Questionnaire "Rheumatoid Arthritis (HDFQ-RA 1&2). Joint Bone Spine, 2017, 84, 693-698.	0.8	2
1680	Acute myocardial infarction. Lancet, The, 2017, 389, 197-210.	6.3	869
1681	Obstructive sleep apnea is associated with visit-to-visit variability in low-density lipoprotein-cholesterol in patients with coronary artery disease. Sleep and Breathing, 2017, 21, 271-278.	0.9	8
1682	The high-risk criteria low-attenuation plaque <math><lt;60\text{ HU}</math> and the napkin-ring sign are the most powerful predictors of MACE: a long-term follow-up study. European Heart Journal Cardiovascular Imaging, 2017, 18, 772-779.	0.5	95
1683	Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial. Journal of Human Hypertension, 2017, 31, 178-188.	1.0	7
1684	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	1.5	23
1685	Plasma fat-soluble vitamin and carotenoid concentrations after plant sterol and plant stanol consumption: a meta-analysis of randomized controlled trials. European Journal of Nutrition, 2017, 56, 909-923.	1.8	33
1686	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries. Diabetes, Obesity and Metabolism, 2017, 19, 61-69.	2.2	9
1687	Metabolic syndrome and its components in postmenopausal women living in southern Italy, Apulia region. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 43-46.	1.8	11
1688	Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Atherosclerosis, 2017, 256, 134-145.	0.4	9
1689	Enfermedad del hÃgado graso no alcohÃlico, asociaciÃn con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hÃgado graso no alcohÃlico. ClÃnica E InvestigaciÃn En Arteriosclerosis, 2017, 29, 185-200.	0.4	6
1691	The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland. Pharmacological Reports, 2017, 69, 6-12.	1.5	5
1694	Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein and lipoprotein particle levels compared with extra-virgin olive oil. European Journal of Clinical Nutrition, 2017, 71, 33-38.	1.3	32
1695	Nutraceuticals in hypercholesterolaemia: an overview. British Journal of Pharmacology, 2017, 174, 1450-1463.	2.7	86
1696	Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients. Egyptian Rheumatologist, 2017, 39, 89-92.	0.5	5
1697	Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. International Journal of Cardiology, 2017, 228, 754-760.	0.8	18
1698	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. Journal of Clinical Lipidology, 2017, 11, 70-79.e1.	0.6	38
1699	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism, 2017, 19, 98-107.	2.2	60

#	ARTICLE	IF	CITATIONS
1700	A Review of the Efficacy, Safety, and Clinical Implications of Naturally Derived Dietary Supplements for Dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 27-35.	1.0	4
1701	Pharmacological secondary prevention in patients with mesenteric artery atherosclerosis and arterial embolism. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 105-109.	1.0	4
1702	The need for a new classification of cholesterol lowering therapies. <i>Current Medical Research and Opinion</i> , 2017, 33, 67-69.	0.9	0
1703	Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study. <i>BMC Geriatrics</i> , 2017, 17, 294.	1.1	39
1704	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	1.0	41
1705	EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1191-1204.	0.5	63
1707	Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. <i>Oncotarget</i> , 2017, 8, 12333-12341.	0.8	8
1708	Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia. <i>Circulation Journal</i> , 2017, 81, 1686-1692.	0.7	1
1709	13. Hyperlipoproteinemia. <i>Amie.</i> , 2017, , 207-222.		0
1710	ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 301-308.	0.3	0
1711	Vascular parkinsonism and vascular dementia are associated with an increased risk of vascular events or death. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017, 2, 16-23.	0.5	23
1712	Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 583-599.	0.9	39
1713	Determination of Sphingosine-1-Phosphate in Human Plasma Using Liquid Chromatography Coupled with Q-ToF Mass Spectrometry. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1800.	1.8	9
1714	A Mini-Review on the Effect of Docosahexaenoic Acid (DHA) on Cerulein-Induced and Hypertriglyceridemic Acute Pancreatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2239.	1.8	20
1715	Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017, 2, 68-75.	0.5	4
1716	Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1498.	1.8	49
1717	Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 4-13.	0.6	95
1718	Enriching Diet with n-3 PUFAs to Help Prevent Cardiovascular Diseases in Healthy Adults: Results from Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1552.	1.8	31

#	ARTICLE	IF	CITATIONS
1719	Evaluation of Cardiometabolic Parameters among Obese Women Using Oral Contraceptives. <i>Frontiers in Endocrinology</i> , 2017, 8, 256.	1.5	3
1720	Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	1.9	139
1721	The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke. <i>Archives of Medical Science</i> , 2017, 5, 1049-1056.	0.4	21
1722	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
1723	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. <i>Archives of Medical Science</i> , 2017, 1, 1-45.	0.4	70
1724	Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease. <i>Archives of Medical Science</i> , 2017, 5, 1078-1085.	0.4	5
1725	Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans. <i>Yonsei Medical Journal</i> , 2017, 58, 975.	0.9	3
1726	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 29-41.	1.0	20
1727	Is there a relationship between blood lipids and lumbar disc herniation in young Turkish adults?. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017, 2, 24-28.	0.5	3
1728	Statin escape phenomenon: Fact or fiction?. <i>World Journal of Experimental Medicine</i> , 2017, 7, 25.	0.9	1
1729	Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2277-2285.	2.0	3
1730	Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0174656.	1.1	38
1731	Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries. <i>PLoS ONE</i> , 2017, 12, e0183235.	1.1	25
1732	Fish oil omega-3 polyunsaturated fatty acids attenuate oxidative stress-induced DNA damage in vascular endothelial cells. <i>PLoS ONE</i> , 2017, 12, e0187934.	1.1	125
1733	Machine Learning in Healthcare. , 2017, , 279-291.		77
1734	Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 264.	0.7	22
1735	Double product reflects the association of heart rate with MACEs in acute coronary syndrome patients treated with percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 284.	0.7	7
1736	Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. <i>Cardiovascular Diabetology</i> , 2017, 16, 156.	2.7	18

#	ARTICLE	IF	CITATIONS
1737	Effects of aerobic exercise on lipids and lipoproteins. <i>Lipids in Health and Disease</i> , 2017, 16, 132.	1.2	232
1738	Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2017, 16, 229.	1.2	9
1739	Racial Differences in the Cholesterol-Lowering Effect of Statin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 19-25.	0.9	78
1740	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017, 17, 551.	1.3	112
1741	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
1743	Evaluation of endothelial function and cardiovascular risk in non-obese patients with slight degree of obstructive sleep apnea syndrome. <i>Monaldi Archives for Chest Disease</i> , 2017, 87, 822.	0.3	4
1744	ASSOCIATION OF LIPID FRACTIONS LEVELS WITH CARDIOVASCULAR DISEASE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 180.	0.3	2
1745	The role of nutraceuticals in the prevention of cardiovascular disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S21-S31.	0.7	81
1746	Management of stable coronary artery disease: from evidence to clinical practice. <i>Italian Journal of Medicine</i> , 2017, 11, 114.	0.2	1
1747	Non-Alcoholic Steatohepatitis, Liver Cirrhosis and Hepatocellular Carcinoma: The Molecular Pathways. , 0, , .		5
1748	Lifestyle and Dietary Determinants of Serum Apolipoprotein A1 and Apolipoprotein B Concentrations: Cross-Sectional Analyses within a Swedish Cohort of 24,984 Individuals. <i>Nutrients</i> , 2017, 9, 211.	1.7	39
1749	Statin Intolerance: Diagnosis and Management. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2017, 02, 014-020.	0.1	0
1750	Unmasking of severe hypertriglyceridaemia associated with antipsychotic therapy by atypical eruptive xanthomas. <i>Postepy Dermatologii I Alergologii</i> , 2017, 5, 507-509.	0.4	1
1751	Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction. <i>Korean Circulation Journal</i> , 2017, 47, 31.	0.7	11
1752	Usefulness of the platelet-to-lymphocyte ratio in predicting long-term cardiovascular mortality in patients with peripheral arterial occlusive disease. <i>Postepy W Kardiologii Interwencyjnej</i> , 2017, 1, 32-38.	0.1	13
1753	New European Society of Cardiology/European Atherosclerosis Society Guideline for the Management of Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2017, 6, 8.	1.1	0
1754	Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. <i>American Journal of Case Reports</i> , 2017, 18, 1238-1241.	0.3	18
1755	ADVERSE EFFECTS AND SIDE EFFECTS ON VITAMIN THERAPY: A REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 19.	0.3	4

#	ARTICLE	IF	CITATIONS
1756	Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. <i>BMJ Open</i> , 2017, 7, e016604.	0.8	14
1757	Change in <sc>ALT</sc> levels after administration of <sc>HMG</sc>â€CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12324.	1.1	5
1758	Exercise electrocardiogram in middle-aged and older leisure time sportsmen: 100 exercise tests would be enough to identify one silent myocardial ischemia at risk for cardiac event. <i>International Journal of Cardiology</i> , 2018, 257, 16-23.	0.8	4
1759	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. <i>Atherosclerosis</i> , 2018, 271, 120-127.	0.4	31
1760	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. ERÖMOT study. <i>ClÄnica E InvestigaciÄ³n En Arteriosclerosis (English Edition)</i> , 2018, 30, 1-9.	0.1	4
1761	Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. <i>Journal of Clinical Lipidology</i> , 2018, 12, 685-692.e2.	0.6	35
1762	Predictors of a successful statin reattempt after an adverse reaction. <i>Journal of Clinical Lipidology</i> , 2018, 12, 643-651.	0.6	7
1764	Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1491-1500.	0.9	39
1765	Estimates of Medication Expenditure for Ischemic Heart Disease Accompanying Chronic Obstructive Pulmonary Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1114, 49-55.	0.8	3
1766	Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort. <i>ClÄnica E InvestigaciÄ³n En Arteriosclerosis (English Edition)</i> , 2018, 30, 64-71.	0.1	5
1767	The additive effect of adherence to multiple healthy lifestyles on subclinical atherosclerosis: Insights from the AWHs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 615-625.	0.6	15
1768	Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 174-182.	1.1	20
1769	The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1441-1447.	0.9	8
1770	Post stroke depression: The sequelae of cerebral stroke. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 104-114.	2.9	176
1771	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. <i>Cardiology Clinics</i> , 2018, 36, 287-298.	0.9	13
1772	Transitions from Ideal to Intermediate Cholesterol Levels may vary by Cholesterol Metric. <i>Scientific Reports</i> , 2018, 8, 2782.	1.6	1
1773	Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 277-291.e3.	0.6	19
1774	Suboptimal lipid management before and after ischaemic stroke and TIAâ€”the North Dublin Population Stroke Study. <i>Irish Journal of Medical Science</i> , 2018, 187, 739-746.	0.8	5

#	ARTICLE	IF	CITATIONS
1775	Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low-density lipoprotein cholesterol in diabetic patients with coronary artery disease. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22399.	0.9	3
1776	Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 241.	3.8	711
1777	Sense of Coherence, Smoking Status, Biochemical Cardiovascular Risk Factors and Body Mass in Blue Collar Workers—Short Report. <i>American Journal of Men's Health</i> , 2018, 12, 894-899.	0.7	6
1778	Menopause and cardiovascular disease. <i>Post Reproductive Health</i> , 2018, 24, 44-49.	0.3	89
1779	Valoración del colesterol no HDL como predictor de episodios cardiovasculares no mortales en una cohorte prospectiva de origen poblacional. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 64-71.	0.4	8
1780	An update on the safety of nutraceuticals and effects on lipid parameters. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 303-313.	1.0	19
1781	Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. <i>Clinical Research in Cardiology</i> , 2018, 107, 380-388.	1.5	59
1782	Validation of the Friedewald formula for the estimation of low density lipoprotein cholesterol in a sub-Saharan African population. <i>Clinical Biochemistry</i> , 2018, 53, 25-30.	0.8	7
1783	Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study. <i>Atherosclerosis</i> , 2018, 269, 106-116.	0.4	22
1784	¿Qué objetivos debemos conseguir con el tratamiento hipolipemiante tras un síndrome coronario agudo?. <i>CardiCore</i> , 2018, 53, 11-13.	0.0	1
1785	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 197-205.	1.1	34
1786	Cumplimiento terapéutico del tratamiento con estatinas: medicina de precisión para optimizar la adherencia. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 4-5.	0.6	3
1787	Authorised EU health claim for chitosan. , 2018, , 161-178.		2
1788	A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 44-55.	0.6	15
1789	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. <i>Acta Diabetologica</i> , 2018, 55, 209-218.	1.2	32
1790	Peripheral arterial disease is associated with higher mortality in patients with incident acute myocardial infarction. <i>European Journal of Internal Medicine</i> , 2018, 51, 46-52.	1.0	11
1791	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. <i>Drugs</i> , 2018, 78, 215-229.	4.9	33
1792	Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. <i>International Journal of Cardiology</i> , 2018, 253, 167-173.	0.8	47

#	ARTICLE	IF	CITATIONS
1793	Prevention of cardiovascular disease: Much more is needed. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1083-1086.	0.8	11
1794	Effect of blood pressure and total cholesterol measurement on risk prediction using the Systematic COronary Risk Evaluation (SCORE). <i>BMC Cardiovascular Disorders</i> , 2018, 18, 84.	0.7	1
1795	Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 24.	1.5	10
1796	Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 580-592.	0.9	13
1797	Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China. <i>Lipids in Health and Disease</i> , 2018, 17, 37.	1.2	109
1798	Lipid profiles in French West Indies sickle cell disease cohorts, and their general population. <i>Lipids in Health and Disease</i> , 2018, 17, 38.	1.2	13
1799	Association between the PPP1R3B polymorphisms and serum lipid traits, the risk of coronary artery disease and ischemic stroke in a southern Chinese Han population. <i>Nutrition and Metabolism</i> , 2018, 15, 27.	1.3	11
1800	Inhibition of miR-486 and miR-92a decreases liver and plasma cholesterol levels by modulating lipid-related genes in hyperlipidemic hamsters. <i>Molecular Biology Reports</i> , 2018, 45, 497-509.	1.0	18
1801	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. <i>Cardiology</i> , 2018, 140, 30-34.	0.6	5
1802	A new perspective on lipid research in age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2018, 67, 56-86.	7.3	162
1803	Lipid Parameters are Independently Associated with Cardiovascular Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 621-633.	0.9	26
1804	High-Intensity Statin Therapy Is Too Much, Thus Not Indicated for Very Elderly Patients. <i>Pulse</i> , 2018, 6, 19-31.	0.9	3
1805	Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study. <i>Atherosclerosis</i> , 2018, 274, 54-60.	0.4	17
1806	Longitudinal association between egg consumption and the risk of cardiovascular disease: interaction with type 2 diabetes mellitus. <i>Nutrition and Diabetes</i> , 2018, 8, 20.	1.5	18
1807	Family Health History and Health Risk Assessment For Cardiovascular Disease in Health Care. , 2018, , 1-16.		4
1808	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 958-971.	5.4	27
1810	Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 15-22.	1.4	48
1811	HEART score performance in Asian and Caucasian patients presenting to the emergency department with suspected acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 591-601.	0.4	10

#	ARTICLE	IF	CITATIONS
1812	Evaluation of the Predictive Value of CHA ₂ DS ₂ -VASc Score for In-Stent Restenosis. <i>Angiology</i> , 2018, 69, 38-42.	0.8	14
1814	Need for hyperlipidemia management policy reform in China: learning from the global experience. <i>Current Medical Research and Opinion</i> , 2018, 34, 197-207.	0.9	5
1815	Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 33-41.	0.4	7
1818	Eficacia de una estrategia combinada para mejorar el control del colesterol unido a lipoproteínas de baja densidad en pacientes con hipercolesterolemia. Ensayo clínico aleatorizado. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 33-41.	0.6	6
1819	¿Qué papel juega la actividad de la enfermedad en el riesgo cardiovascular de la artritis reumatoide?. <i>Reumatología Clínica</i> , 2018, 14, 339-345.	0.2	4
1820	Improvement in the Management of Dyslipidemia in a Clinical Practice Population at Very High Cardiovascular Risk. The COLIPAR Project. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 979-980.	0.4	0
1821	Uric acid and obesity-related phenotypes in postmenopausal women. <i>Molecular and Cellular Biochemistry</i> , 2018, 443, 111-119.	1.4	9
1822	Causas de no consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de Lápidos y Riesgo Vascular. Estudio EROMOT. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 1-9.	0.4	8
1823	Extended Serum Lipid Profile Predicting Long-Term Survival in Patients Treated for Abdominal Aortic Aneurysms. <i>World Journal of Surgery</i> , 2018, 42, 1200-1207.	0.8	1
1824	Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry. <i>Heart and Vessels</i> , 2018, 33, 102-112.	0.5	11
1825	Mejora del tratamiento de la dislipemia para pacientes con muy alto riesgo cardiovascular en la práctica clínica. Proyecto COLIPAR. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 979-980.	0.6	2
1826	Eryptosis and oxidative damage in hypertensive and dyslipidemic patients. <i>Molecular and Cellular Biochemistry</i> , 2018, 440, 105-113.	1.4	22
1828	Traduction et adaptation de la version française du Heart Disease Fact Questionnaire-Rheumatoid Arthritis (HDFQ-RA 1&2). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 255-260.	0.0	0
1830	Spanish consensus on treat to target for osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 489-499.	1.3	13
1831	Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. <i>Atherosclerosis</i> , 2018, 268, 99-107.	0.4	53
1832	Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. <i>Pharmacoeconomics</i> , 2018, 36, 115-126.	1.7	8
1833	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. <i>Nature Reviews Nephrology</i> , 2018, 14, 57-70.	4.1	192
1834	Evaluation of lipid-lowering effect of <i>Cynara scolymus</i> extract-loaded mesoporous silica nanoparticles on ultra-lipid-fed mice. <i>Comparative Clinical Pathology</i> , 2018, 27, 513-518.	0.3	0

#	ARTICLE	IF	CITATIONS
1835	Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data in Brief, 2018, 16, 369-375.	0.5	5
1836	Preventing recurrent events in survivors of acute coronary syndromes in Australia: consensus recommendations using the Delphi process. Current Medical Research and Opinion, 2018, 34, 551-558.	0.9	0
1837	Dynamic changes of the composition of plasma <sc>HDL</sc> particles in patients with cardiac disease: Spotlight on sphingosine-1-phosphate/serum amyloid A ratio. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 319-325.	0.9	3
1838	Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry. Journal of Cardiology, 2018, 71, 259-267.	0.8	2
1840	To Persist or Not to Persist: Learning From Precision Medicine to Optimize Statin Adherence. Revista Espanola De Cardiologia (English Ed), 2018, 71, 4-5.	0.4	0
1841	Apolipoprotein B is not superior to non-high-density lipoprotein cholesterol for dyslipidemic classification of glycosylated hemoglobin-defined diabetic patients. Medicine (United States), 2018, 97, e12896.	0.4	0
1842	Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 1823-1873.	1.7	17
1843	Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective. Global & Regional Health Technology Assessment, 2018, 2018, 228424031878148.	0.2	0
1844	A Comparative Study of Muscle Symptoms of Atorvastatin with Rosuvastatin in Patients of Atherosclerotic Cardiovascular Disease. University Heart Journal, 2018, 14, 9-20.	0.0	0
1845	Lipid Measurements. , 2018, , 88-97.		0
1846	Screening for Atherosclerotic Cardiovascular Disease in Asymptomatic Individuals. , 2018, , 459-478.		2
1848	Associations Between Gun Shows and Firearm Deaths and Injuries. Annals of Internal Medicine, 2018, 169, 65.	2.0	0
1849	Associations Between Gun Shows and Firearm Deaths and Injuries. Annals of Internal Medicine, 2018, 169, 66.	2.0	0
1850	CURRENT SCENARIO OF HYPERLIPIDAEMIA AND ITS MANAGEMENT WITH DRUGS: A REVIEW. International Journal of Research in Ayurveda and Pharmacy, 2018, 9, 185-193.	0.0	0
1851	Management of coronary artery disease. IOP Conference Series: Earth and Environmental Science, 2018, 125, 012125.	0.2	0
1852	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2018, 39, 697-704.	0.5	3
1853	Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism. Chinese Journal of Natural Medicines, 2018, 16, 572-579.	0.7	6
1854	Rheumatoid arthritis; a systemic disease with an under-estimated cardiovascular risk. Revista Colombiana De ReumatologÃa (English Edition), 2018, 25, 92-98.	0.1	0

#	ARTICLE	IF	CITATIONS
1855	Validity of ambulatory blood pressure monitoring in daily primary healthcare practice in France. <i>Blood Pressure Monitoring</i> , 2018, 23, 288-293.	0.4	2
1856	49 Hyperlipoproteinämien. , 2018, , .		0
1857	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. <i>Korean Circulation Journal</i> , 2018, 48, 1097.	0.7	15
1858	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3426.	1.8	78
1859	The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. <i>European Journal of Medical Research</i> , 2018, 23, 57.	0.9	40
1860	Metabolism of Natural Highly Unsaturated Fatty Acid, Tetracosahexaenoic Acid (24:6n-3), in C57BL/KsJ- <i>db</i> Mice. <i>Journal of Oleo Science</i> , 2018, 67, 1597-1607.	0.6	11
1861	Different age-independent effects of nutraceutical combinations on endothelium-mediated coronary flow reserve. <i>Immunity and Ageing</i> , 2018, 15, 30.	1.8	5
1862	Associations Between Gun Shows and Firearm Deaths and Injuries. <i>Annals of Internal Medicine</i> , 2018, 169, 65.	2.0	0
1863	Associations Between Gun Shows and Firearm Deaths and Injuries. <i>Annals of Internal Medicine</i> , 2018, 169, 65.	2.0	2
1864	Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. <i>BMC Health Services Research</i> , 2018, 18, 900.	0.9	10
1865	Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania. <i>Atherosclerosis</i> , 2018, 277, 267-272.	0.4	5
1866	Is hypertriglyceridemia atherogenic?. <i>Presse Medicale</i> , 2018, 47, 757-763.	0.8	6
1867	Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009835.	1.6	109
1868	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , 2018, 277, 334-340.	0.4	33
1869	Comparison of ELISA and flow cytometry for measurement of interleukin-1 beta, interleukin-6 and tumor necrosis factor- α . <i>Biyokimya Dergisi</i> , 2018, 43, 540-548.	0.1	6
1870	Latvian registry of familial hypercholesterolemia: The first report of three-year results. <i>Atherosclerosis</i> , 2018, 277, 347-354.	0.4	11
1871	Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 10.	0.6	59
1872	The Relationship Between Psychosocial Status and Hypertensive Condition. <i>Current Hypertension Reports</i> , 2018, 20, 102.	1.5	7

#	ARTICLE	IF	CITATIONS
1873	Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes. <i>Personalized Medicine</i> , 2018, 15, 521-529.	0.8	9
1874	Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. <i>Folia Medica</i> , 2018, 60, 389-396.	0.2	4
1875	Impact of self-reported fasting duration on lipid profile variability, cardiovascular risk stratification and metabolic syndrome diagnosis. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 187-192.	0.3	2
1876	CRP-Based Cardiovascular Risk Assessment: New Conventional CRP Assay Fit for Purpose?. <i>Journal of Applied Laboratory Medicine</i> , 2018, 2, 952-959.	0.6	7
1877	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
1878	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	0.8	50
1879	Attainment of low-density lipoprotein cholesterol target in patients with coronary heart disease: Still a long way to go. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1947-1949.	0.8	1
1880	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2018, 41, 1075-1083.	0.7	7
1881	Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 707-715.	1.0	4
1882	Comparison of the application of treatment Panel III and American College of Cardiology/American Heart Association guidelines for blood cholesterol treatment in Saudi Arabia. <i>Journal of the Saudi Heart Association</i> , 2018, 30, 349-355.	0.2	2
1883	Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1950-1963.	0.8	28
1884	Practice setting and secondary prevention of coronary artery disease. <i>Archives of Medical Science</i> , 2018, 14, 979-987.	0.4	27
1885	Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome. <i>Egyptian Heart Journal</i> , 2018, 70, 129-134.	0.4	4
1886	PPARGgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 463-472.	1.3	6
1887	Statins decrease leptin expression in human white adipocytes. <i>Physiological Reports</i> , 2018, 6, e13566.	0.7	31
1888	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International Cholesterol management Practice Study (ICLPS). <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1087-1094.	0.8	86
1889	Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan – A Retrospective Database Analysis –. <i>Circulation Journal</i> , 2018, 82, 1605-1613.	0.7	10
1890	Differential Diagnosis of HyperCKemia. <i>Neurology International Open</i> , 2018, 02, E72-E83.	0.4	7

#	ARTICLE	IF	CITATIONS
1892	Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4683-4688.	0.8	7
1893	PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 844-848.	0.6	1
1894	Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
1895	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2018, 12, 972-980.e1.	0.6	16
1896	Alirocumab as add-on therapy to statins: current evidence and clinical potential. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 191-202.	1.0	4
1897	High body fat percentage among adult women in Malaysia: the role of lifestyle. <i>Journal of Fundamental and Applied Sciences</i> , 2018, 9, 905.	0.2	1
1898	Validity of a Novel Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Cardiovascular Disease Patients Treated with Statins. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 643-652.	0.9	19
1900	Lipidstoffwechselstörungen. , 2018, , 1639-1656.		0
1901	Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. <i>International Journal of General Medicine</i> , 2018, Volume 11, 313-322.	0.8	33
1902	Comparison of Five Major Guidelines for Statin Use in Primary Prevention. <i>Annals of Internal Medicine</i> , 2018, 169, 66.	2.0	0
1903	Natural History of Cervical Artery Fibromuscular Dysplasia and Associated Neurovascular Events. <i>Cerebrovascular Diseases</i> , 2018, 46, 33-39.	0.8	21
1904	Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 126.	0.7	8
1905	Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. <i>Circulation Journal</i> , 2018, 82, 183-191.	0.7	0
1906	Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 20-22.	0.3	3
1907	Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. <i>BMC Medicine</i> , 2018, 16, 115.	2.3	19
1908	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. <i>Frontiers in Pharmacology</i> , 2018, 9, 707.	1.6	31
1909	Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. <i>International Journal of Cardiology</i> , 2018, 268, 195-199.	0.8	24
1910	Comparison of Five Major Guidelines for Statin Use in Primary Prevention. <i>Annals of Internal Medicine</i> , 2018, 169, 67.	2.0	4

#	ARTICLE	IF	CITATIONS
1911	Firearm-Related Injury and Death. <i>Annals of Internal Medicine</i> , 2018, 169, 64.	2.0	0
1912	Comparisons of three different doses of alirocumab application in patients with hypercholesterolemia: a meta-analysis. <i>Minerva Medica</i> , 2018, 109, 229-238.	0.3	1
1913	Secondary Prevention of Coronary Artery Disease. , 2018, , 479-487.		1
1914	Could Lipid Profile be Used as a Marker of Autonomous Cortisol Secretion in Patients with Adrenal Incidentalomas?. <i>Hormone and Metabolic Research</i> , 2018, 50, 551-555.	0.7	7
1915	Association between circulating full-length angiotensin-like protein 8 and non-high-density lipoprotein cholesterol levels in Chinese non-diabetic individuals: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2018, 17, 161.	1.2	7
1916	DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke. <i>Lipids in Health and Disease</i> , 2018, 17, 30.	1.2	21
1917	Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. <i>Biomarkers</i> , 2018, 23, 647-653.	0.9	20
1918	Non-fasting versus fasting cholesterol measurement. <i>Nurse Practitioner</i> , 2018, 43, 16-20.	0.2	1
1919	Consistent LDLâ€œ response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335.	0.7	25
1920	Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population. <i>CardioRenal Medicine</i> , 2018, 8, 311-320.	0.7	4
1921	Statin treatment reduces matrix degradation capacity of proinflammatory polarized macrophages. <i>Vascular Pharmacology</i> , 2018, 110, 49-54.	1.0	8
1922	What Role Does Rheumatoid Arthritis Disease Activity Have in Cardiovascular Risk?. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2018, 14, 339-345.	0.2	2
1923	Cardiovascular events in patients under age fifty with early findings of elevated lipid and glucose levels â€œ The AMORIS study. <i>PLoS ONE</i> , 2018, 13, e0201972.	1.1	8
1924	Non-fasting lipid profile determination in presumably healthy children: Impact on the assessment of lipid abnormalities. <i>PLoS ONE</i> , 2018, 13, e0198433.	1.1	7
1925	The Association of Dietary Cholesterol and Fatty Acids with Dyslipidemia in Chinese Metropolitan Men and Women. <i>Nutrients</i> , 2018, 10, 961.	1.7	14
1926	Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. <i>Transfusion and Apheresis Science</i> , 2018, 57, 661-664.	0.5	17
1927	Comparison of Five Major Guidelines for Statin Use in Primary Prevention. <i>Annals of Internal Medicine</i> , 2018, 169, 67.	2.0	2
1928	Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice. <i>Clinical Therapeutics</i> , 2018, 40, 1484-1495.e22.	1.1	6

#	ARTICLE	IF	CITATIONS
1929	The overlap between regeneration and fibrosis in injured skeletal muscle is regulated by phosphatidylinositol 3-kinase/Akt signaling pathway - A bioinformatic analysis based on lncRNA microarray. <i>Gene</i> , 2018, 672, 79-87.	1.0	19
1930	Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. <i>International Journal of Cardiology</i> , 2018, 270, 21-27.	0.8	16
1931	Pharmacological Targets for Correction of Dyslipidemias. Opportunities and Prospects of Therapeutic Use. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2018, 12, 96-113.	0.2	2
1932	Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention. <i>Current Pharmaceutical Design</i> , 2018, 24, 442-450.	0.9	1
1933	Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II. <i>International Journal of Cardiology</i> , 2018, 265, 1-5.	0.8	10
1934	The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 537-546.	0.6	35
1935	Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. <i>Data in Brief</i> , 2018, 18, 1937-1940.	0.5	6
1936	APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in ApoE atherosclerotic mice. <i>International Journal of Cardiology</i> , 2018, 271, 233-239.	0.8	11
1937	Prevention of Dementia. , 0, , 120-139.		0
1938	A quasi-experimental study for inappropriate laboratory utilization from a payer perspective in Cyprus. <i>Health Policy and Technology</i> , 2018, 7, 137-141.	1.3	2
1939	Hypercholesterolemie familiale: mise au point pratique. <i>Perfectionnement En Pdiatrie</i> , 2018, 1, 113-118.	0.0	1
1940	Building a Foundation of Training: Community Collaboration to Make Cardiovascular Care Work. <i>Global Heart</i> , 2019, 13, 101.	0.9	0
1941	Association of macronutrient consumption with arterial aging in adults without clinically overt cardiovascular disease: a 5-year prospective cohort study. <i>European Journal of Nutrition</i> , 2019, 58, 2305-2314.	1.8	0
1942	Animal models to study bile acid metabolism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 895-911.	1.8	141
1943	A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 3-8.	0.7	12
1944	Acute and residual effects of aerobic exercise on fructose-induced postprandial lipemia on lean male subjects. <i>European Journal of Nutrition</i> , 2019, 58, 2293-2303.	1.8	5
1945	Metabolic Syndrome in Adult Congenital Heart Disease. <i>Korean Circulation Journal</i> , 2019, 49, 691.	0.7	24
1946	Effects of Moderate Chronic Food Restriction on the Development of Postprandial Dyslipidemia with Ageing. <i>Nutrients</i> , 2019, 11, 1865.	1.7	8

#	ARTICLE	IF	CITATIONS
1947	Hospitalisation of Type 2 diabetes mellitus patients with and without major depressive disorder in a private managed healthcare organisation. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2019, 24, 70-76.	0.4	1
1948	The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-30.	1.9	30
1949	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019, 13, 735-743.	0.6	1
1950	Association of metabolic syndrome with atherogenic index of plasma in an urban Chinese population: A 15-year prospective study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1214-1219.	1.1	34
1951	Detection of stroke risk factors over the decade in the polish population of ischemic stroke patients. <i>Postepy Psychiatrii I Neurologii</i> , 2019, 28, 83-87.	0.2	3
1952	A multi-scale model for low-density lipoprotein cholesterol (LDL-C) regulation in the human body: Application to quantitative systems pharmacology. <i>Computers and Chemical Engineering</i> , 2019, 130, 106507.	2.0	8
1953	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. <i>Current Atherosclerosis Reports</i> , 2019, 21, 41.	2.0	53
1954	<p>Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 495-508.	1.5	13
1955	Diagnosis and management of familial hypercholesterolaemia. <i>The Prescriber</i> , 2019, 30, 28-31.	0.1	0
1956	The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction. <i>International Urology and Nephrology</i> , 2019, 51, 2235-2242.	0.6	17
1957	Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial. <i>Cell Transplantation</i> , 2019, 28, 1632-1640.	1.2	4
1958	Changing trends in the prevalence of diabetic retinopathy in type 1 diabetes mellitus from 1990 to 2018: A retrospective study in a Portuguese population. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107891.	1.1	5
1959	The curative treatment of familial hypercholesterolemia: Liver transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13730.	0.8	10
1960	Coronary artery calcium score in female rheumatoid arthritis patients: Associations with apolipoproteins and disease biomarkers. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1841-1856.	0.9	7
1961	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78.	1.1	100
1962	Cardiovascular Health of Retired Field-Based Athletes: A Systematic Review and Meta-analysis. <i>Orthopaedic Journal of Sports Medicine</i> , 2019, 7, 232596711986275.	0.8	14
1963	Ambient air pollution and lipid profile: Systematic review and meta-analysis. <i>Environmental Pollution</i> , 2019, 254, 113036.	3.7	67
1965	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753

#	ARTICLE	IF	CITATIONS
1966	Speckle tracking derived reference values of myocardial deformation and impact of cardiovascular risk factors – Results from the population-based STAAB cohort study. PLoS ONE, 2019, 14, e0221888.	1.1	5
1967	Association Between HDL Cholesterol and QTc Interval: A Population-Based Epidemiological Study. Journal of Clinical Medicine, 2019, 8, 1527.	1.0	9
1968	Worldwide Dyslipidemia Guidelines. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	17
1969	Abordaje del paciente con insuficiencia renal crónica. FMC Formacion Medica Continuada En Atencion Primaria, 2019, 26, 1-26.	0.0	0
1970	Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service. PLoS ONE, 2019, 14, e0210498.	1.1	7
1972	Association between awareness of nutrition labeling and high-density lipoprotein cholesterol concentration in cancer survivors and the general population: The Korean National Health and Nutrition Examination Survey (KNHANES) 2010–2016. BMC Cancer, 2019, 19, 16.	1.1	3
1973	Predictive value of non-HDL cholesterol for cardiovascular disease in a population in far western Algeria with type 2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 826-829.	1.8	0
1974	Impact of Percent Body Fat on All-Cause Mortality among Adequate Dialysis Patients with and without Insulin Resistance: A Multi-Center Prospective Cohort Study. Nutrients, 2019, 11, 1304.	1.7	2
1975	Dietary Hyperlipidemia and Retinal Microaneurysms. , 2019, , 73-84.		0
1976	Impact of pharmacist's intervention on reducing cardiovascular risk in obese patients. International Journal of Clinical Pharmacy, 2019, 41, 1099-1109.	1.0	4
1977	Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International Cholesterol management Practice Study. Journal of Clinical Lipidology, 2019, 13, 594-600.	0.6	17
1978	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. Archives of Medical Science, 2019, 15, 821-831.	0.4	8
1979	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. AIDS Research and Therapy, 2019, 16, 11.	0.7	13
1980	Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids in Health and Disease, 2019, 18, 131.	1.2	15
1981	Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care. Lancet Public Health, The, 2019, 4, e256-e264.	4.7	37
1982	Determinant of postprandial triglyceride levels in healthy young adults. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1917-1921.	1.8	4
1983	Metabolic Syndrome and Male Fertility. World Journal of Men's Health, 2019, 37, 113.	1.7	61
1984	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.4	227

#	ARTICLE	IF	CITATIONS
1985	A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. <i>Journal of Nutrition</i> , 2019, 149, 968-981.	1.3	83
1986	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019, 285, 40-48.	0.4	39
1987	Association between non-high-density lipoprotein cholesterol levels and asymptomatic vulnerable carotid atherosclerotic plaques. <i>European Journal of Neurology</i> , 2019, 26, 1433-1438.	1.7	14
1988	Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1172-1181.	1.1	31
1989	A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS). <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 210-221.	0.5	5
1990	Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026603.	0.8	15
1991	Intermediate-Term Efficacy and Tolerance of Statins in Children. <i>Journal of Pediatrics</i> , 2019, 210, 161-165.	0.9	20
1992	Is There a Need to Revise Goals in the Management of Dyslipidemias?. <i>Current Cardiology Reports</i> , 2019, 21, 51.	1.3	6
1993	Dietary Patterns in Relation to Components of Dyslipidemia and Fasting Plasma Glucose in Adults with Dyslipidemia and Elevated Fasting Plasma Glucose in Taiwan. <i>Nutrients</i> , 2019, 11, 845.	1.7	21
1994	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COHoRtE (DIACORE) study. <i>PLoS ONE</i> , 2019, 14, e0213157.	1.1	8
1995	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	1.9	101
1996	Gender differences in cardiovascular risk assessment in elderly adults in Ecuador: evidence from a national survey. <i>Journal of Investigative Medicine</i> , 2019, 67, 736-742.	0.7	3
1997	Management of atherogenic dyslipidemia according to current treatment guidelines: DESPEGA study in real clinical practice. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 192-199.	0.3	0
1998	Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study. <i>Atherosclerosis</i> , 2019, 284, 31-36.	0.4	27
1999	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. <i>Current Atherosclerosis Reports</i> , 2019, 21, 14.	2.0	15
2000	Dyslipidemia and associated factors among women using hormonal contraceptives in Harar town, Eastern Ethiopia. <i>BMC Research Notes</i> , 2019, 12, 120.	0.6	16
2001	Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1455-1463.	2.2	24
2003	Do self-reported data accurately measure health inequalities in risk factors for cardiovascular disease?. <i>International Journal of Public Health</i> , 2019, 64, 721-729.	1.0	0

#	ARTICLE	IF	CITATIONS
2004	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmacology Reports</i> , 2019, 5, 210-213.	1.5	0
2006	Development of an intelligent decision support system for ischemic stroke risk assessment in a population-based electronic health record database. <i>PLoS ONE</i> , 2019, 14, e0213007.	1.1	22
2007	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
2008	Drugs for Treatment of Dyslipidemia Available in the USA. , 2019, , 171-195.		0
2009	Lipid Disorders and Familial Hypercholesterolaemia. , 2019, , 1101-1120.		1
2010	High-Resolution Regulatory Maps Connect Vascular Risk Variants to Disease-Related Pathways. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002353.	1.6	13
2012	Blood Pressure Variability Is Associated with Hearing and Hearing Loss: A Population-Based Study in Males. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	0.5	7
2013	Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes. <i>Journal of Clinical and Translational Endocrinology</i> , 2019, 15, 76-80.	1.0	5
2014	Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 223-231.	0.5	9
2015	Effect of Magnesium Supplementation on Lipid Profile: A Systematic Review of Randomized Clinical Trials. , 2019, , 277-286.		0
2016	Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. <i>Advances in Therapy</i> , 2019, 36, 608-620.	1.3	10
2017	Dietary patterns in relation to major cardiovascular diseases risk factors. <i>Nutrition and Food Science</i> , 2019, 50, 921-935.	0.4	4
2018	2018 Guidelines for the management of dyslipidemia. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 723-771.	0.7	144
2019	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6
2020	Prevalence and pattern of dyslipidemia in patients with type 2 diabetes mellitus in Zaria, Northwestern Nigeria. <i>Pan African Medical Journal</i> , 2019, 34, 123.	0.3	14
2021	Prevalence of Dyslipidemia and Goal Attainment with Lipid-Lowering Therapy: Insights from Thai Multicenter Study and Overview of the Major Guidelines. , 2019, , .		0
2022	A Validated Method for Cholesterol Determination in Turkey Meat Products Using Relative Response Factors. <i>Foods</i> , 2019, 8, 684.	1.9	7
2023	Microbiome and metabonomics study of quercetin for the treatment of atherosclerosis. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 545-560.	0.7	30

#	ARTICLE	IF	CITATIONS
2024	Sequence analysis and variant identification at the APOC3 gene locus indicates association of rs5218 with BMI in a sample of Kuwaiti™s. <i>Lipids in Health and Disease</i> , 2019, 18, 224.	1.2	1
2027	The Effect of Hypertension Duration and the Age of Onset on CV Risk Factors Expression in Perimenopausal Women. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	0.5	4
2028	Low-Density Lipoprotein Cholesterol and Risk of Hemorrhagic Stroke: a Systematic Review and Dose-Response Meta-analysis of Prospective Studies. <i>Current Atherosclerosis Reports</i> , 2019, 21, 52.	2.0	19
2029	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. <i>Current Diabetes Reports</i> , 2019, 19, 146.	1.7	5
2030	Lipoprotein apheresis in Germany " Still more commonly indicated than implemented. How can patients in need access therapy?. <i>Atherosclerosis Supplements</i> , 2019, 40, 23-29.	1.2	7
2031	Is hypertriglyceridemia atherogenic?. <i>Current Opinion in Lipidology</i> , 2019, 30, 291-299.	1.2	11
2032	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2019, 8, e013225.	1.6	114
2033	Mid-arm circumference, body fat, nutritional and inflammatory biomarkers, blood glucose, dialysis adequacy influence all-cause mortality in hemodialysis patients. <i>Medicine (United States)</i> , 2019, 98, e14930.	0.4	17
2034	The Secrets of the Mediterranean Diet. Does [Only] Olive Oil Matter?. <i>Nutrients</i> , 2019, 11, 2941.	1.7	158
2035	Carotid ultrasound findings in rheumatoid arthritis and control subjects: A case-control study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 25-31.	0.9	16
2036	Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases. <i>Saudi Journal of Biological Sciences</i> , 2019, 26, 334-339.	1.8	19
2037	Survey of family doctors' attitudes towards statin treatment in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 81-92.	1.1	0
2038	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <i>Cardiology and Therapy</i> , 2019, 8, 5-20.	1.1	17
2039	Update on the diagnosis, treatment and management of rare genetic lipid disorders. <i>Pathology</i> , 2019, 51, 193-201.	0.3	14
2040	Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study. <i>Atherosclerosis</i> , 2019, 280, 1-6.	0.4	31
2041	Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines. <i>Clinical Cardiology</i> , 2019, 42, 101-110.	0.7	12
2042	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , 2019, 282, 169-175.	0.4	27
2043	Enquête "Un jour donn" sur les modalit"s de prescription des statines dans un centre hospitalier g"n"ral fran"ais. <i>Pharmacien Hospitalier Et Clinicien</i> , 2019, 54, 109-115.	0.3	0

#	ARTICLE	IF	CITATIONS
2044	Drug Therapy of Dyslipidemia in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 321-340.	1.3	22
2045	Genetic Risk, Adherence to a Healthy Lifestyle, and Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2019, 21, 1.	1.3	37
2046	Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. <i>IJC Heart and Vasculature</i> , 2019, 22, 73-77.	0.6	12
2047	Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates. <i>International Journal of Biological Sciences</i> , 2019, 15, 265-276.	2.6	94
2048	Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 249-253.	0.4	9
2049	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	0.8	36
2050	Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 408-431.	0.9	6
2051	Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor. <i>Cardiology in Review</i> , 2019, 27, 49-56.	0.6	26
2052	General practice preventive health care in non-obstructive coronary artery disease determined by coronary computed tomography angiography. <i>International Journal of Cardiology</i> , 2019, 278, 14-21.	0.8	4
2053	Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 559-572.	0.9	7
2054	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , 2019, 17, 376-378.	0.8	2
2055	Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea. <i>Frontiers of Medicine</i> , 2019, 13, 713-722.	1.5	1
2056	Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. <i>Clinical Research in Cardiology</i> , 2019, 108, 487-509.	1.5	19
2057	Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. <i>Current Medical Research and Opinion</i> , 2019, 35, 829-835.	0.9	11
2058	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	0.9	30
2060	Can the ESC/EAS LDL-cholesterol target in patients with diabetes and high cardiovascular risk be achieved in clinical practice? Results from an ambulatory multidisciplinary diabetes center cohort. <i>Diabetes and Metabolism</i> , 2019, 45, 592-595.	1.4	0
2061	Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol. <i>Herz</i> , 2020, 45, 594-602.	0.4	16
2062	Cardiac computed tomography in asymptomatic siblings of patients with premature coronary disease: illustrations and current knowledge. <i>Acta Cardiologica</i> , 2020, 75, 107-115.	0.3	0

#	ARTICLE	IF	CITATIONS
2063	Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. <i>Heart Lung and Circulation</i> , 2020, 29, 405-413.	0.2	2
2064	Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 112-120.	4.3	7
2065	Registry of the Egyptian specialized hypertension clinics: patient risk profiles and geographical differences. <i>Journal of Human Hypertension</i> , 2020, 34, 520-527.	1.0	7
2066	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
2067	Decreased glomerular filtration rate in patients with at least 5 years of type 2 diabetes in Ho Chi Minh City, Vietnam: Prevalence and associated factors. <i>Primary Care Diabetes</i> , 2020, 14, 173-180.	0.9	4
2068	Effects of pomegranate on lipid profiles: A systematic review of randomised controlled trials. <i>Complementary Therapies in Medicine</i> , 2020, 48, 102236.	1.3	6
2069	A Novel Risk Score for Type 2 Diabetes Containing Sleep Duration: A 7-Year Prospective Cohort Study among Chinese Participants. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-13.	1.0	9
2070	Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 376-382.	0.4	2
2071	Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 453-465.	1.2	1
2072	Optimal Blood Pressure Control Improves Left Ventricular Torsional Deformation and Vascular Function in Newly Diagnosed Hypertensives: a 3-Year Follow-up Study. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 814-825.	1.1	15
2073	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	0.5	3
2074	C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 427.	0.7	16
2075	Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1469-1479.	1.0	5
2076	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. <i>European Heart Journal Supplements</i> , 2020, 22, J21-J33.	0.0	7
2077	Morning blood pressure surge and diastolic dysfunction in patients with masked hypertension. <i>Blood Pressure Monitoring</i> , 2020, 25, 121-125.	0.4	4
2078	Effects of Two Community-Based Exercise Programs on Adherence, Cardiometabolic Markers, and Body Composition in Older People with Cardiovascular Risk Factors: A Prospective Observational Cohort Study. <i>Journal of Personalized Medicine</i> , 2020, 10, 176.	1.1	1
2079	Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. <i>Computers in Biology and Medicine</i> , 2020, 126, 104043.	3.9	34
2080	Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 617-629.	0.7	3

#	ARTICLE	IF	CITATIONS
2081	Myocardial work - correlation patterns and reference values from the population-based STAAB cohort study. <i>PLoS ONE</i> , 2020, 15, e0239684.	1.1	38
2082	Cardiovascular/stroke risk prevention: A new machine learning framework integrating carotid ultrasound image-based phenotypes and its harmonics with conventional risk factors. <i>Indian Heart Journal</i> , 2020, 72, 258-264.	0.2	31
2083	Strategies for Improving Antimicrobial Properties of Stainless Steel. <i>Materials</i> , 2020, 13, 2944.	1.3	29
2084	Progress of research on dyslipidemia accompanied by nephrotic syndrome. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 182-187.	0.9	5
2085	Lipids and lipoproteins. , 2020, , 487-506.		4
2086	Sea Buckthorn and Grape Extract Might Be Helpful and Sustainable Phyto-Resources as Associated Hypolipidemic Agentsâ€”Preliminary Study. <i>Sustainability</i> , 2020, 12, 9297.	1.6	5
2087	Regulatory Mechanisms of Baicalin in Cardiovascular Diseases: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 583200.	1.6	42
2088	Regulation of microRNAs in high-fat diet induced hyperlipidemic hamsters. <i>Scientific Reports</i> , 2020, 10, 20549.	1.6	10
2089	Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis?. <i>International Journal of Neuroscience</i> , 2022, 132, 201-206.	0.8	7
2090	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 113.	1.1	4
2091	Correlations between Iron Metabolism Parameters, Inflammatory Markers and Lipid Profile Indicators in Patients with Type 1 and Type 2 Diabetes Mellitus. <i>Journal of Personalized Medicine</i> , 2020, 10, 70.	1.1	6
2092	The Effects and Potential Mechanism of Oil Palm Phenolics in Cardiovascular Health: A Review on Current Evidence. <i>Nutrients</i> , 2020, 12, 2055.	1.7	6
2093	Lycopene Inhibit IMQ-Induced Psoriasis-Like Inflammation by Inhibiting ICAM-1 Production in Mice. <i>Polymers</i> , 2020, 12, 1521.	2.0	11
2094	Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. <i>Current Therapeutic Research</i> , 2020, 93, 100595.	0.5	5
2095	Low-grade inflammation independently associates with cardiometabolic risk in children with overweight/obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1544-1553.	1.1	29
2096	Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. <i>Journal of Drug Assessment</i> , 2020, 9, 129-144.	1.1	17
2097	Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on â€œIntegrated Vascular Ageâ€•instead of â€œChronological Ageâ€•: a multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 939-954.	0.7	15
2098	Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. <i>Clinical Research in Cardiology</i> , 2022, 111, 243-252.	1.5	32

#	ARTICLE	IF	CITATIONS
2099	Assessment of Beliefs and Attitudes About Statins Posted on Twitter. <i>JAMA Network Open</i> , 2020, 3, e208953.	2.8	54
2100	Benefits of Home-Based Solutions for Diagnosis and Treatment of Acute Coronary Syndromes on Health Care Costs: A Systematic Review. <i>Sensors</i> , 2020, 20, 5006.	2.1	2
2101	Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1835-1845.	1.0	7
2102	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD011737.	1.5	65
2103	Performance and clinical utility of supervised machine-learning approaches in detecting familial hypercholesterolaemia in primary care. <i>Npj Digital Medicine</i> , 2020, 3, 142.	5.7	21
2104	Prevalence and management of hypercholesterolemia in France, the Esteban observational study. <i>Medicine (United States)</i> , 2020, 99, e23445.	0.4	13
2105	Non-Alcoholic Fatty Liver Disease Markers Associated with Fasting Serum Insulin and Urinary Albumin Excretion Independent of Fasting Plasma Glucose. <i>Journal of Clinical Medicine</i> , 2020, 9, 3161.	1.0	0
2106	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096584.	0.4	0
2107	Effective improvement of minimal change nephrotic syndrome with uncontrollable high low-density lipoprotein cholesterol level using evolocumab accompanied by the development of acute pancreatitis. <i>CEN Case Reports</i> , 2020, 9, 333-337.	0.5	2
2108	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 515-523.	1.3	2
2109	Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. <i>Diagnostics</i> , 2020, 10, 301.	1.3	11
2110	Reduction in saturated fat intake for cardiovascular disease. <i>The Cochrane Library</i> , 2020, 5, CD011737.	1.5	81
2111	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. <i>PLoS ONE</i> , 2020, 15, e0233230.	1.1	9
2112	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , 2020, 19, 117.	1.2	3
2113	Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2020, 32, 120-125.	0.1	2
2114	Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany. <i>Drugs and Aging</i> , 2020, 37, 521-527.	1.3	3
2115	Progress in the seasonal variations of blood lipids: a mini-review. <i>Lipids in Health and Disease</i> , 2020, 19, 108.	1.2	22
2116	Efficacy and tolerability of alirocumab in Austrian clinical practice – results of the non-interventional PEARL-AT study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1419-1425.	0.9	7

#	ARTICLE	IF	CITATIONS
2117	<p><p>Low Vitamin D Serum Level Is Associated with HDL-C Dyslipidemia and Increased Serum Thrombomodulin Levels of Insulin-Resistant Individuals</p></p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1599-1607.	1.1	14
2118	Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology, 2021, 28, 825-833.	0.8	21
2119	Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary healthcare facilities in Indonesia. BMJ Open, 2020, 10, e035098.	0.8	6
2120	Effect of Tree Nuts Consumption on Serum Lipid Profile in Hyperlipidemic Individuals: A Systematic Review. Nutrition and Metabolic Insights, 2020, 13, 117863882092652.	0.8	16
2121	Roles and Mechanisms of Hawthorn and Its Extracts on Atherosclerosis: A Review. Frontiers in Pharmacology, 2020, 11, 118.	1.6	51
2122	Association between the Non-high-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio and the Risk of Coronary Artery Disease. BioMed Research International, 2020, 2020, 1-9.	0.9	11
2123	Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus – Polish multicenter study POLASPIRE. Archives of Medical Science, 2023, 19, 305-312.	0.4	5
2124	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Advances in Therapy, 2020, 37, 1724-1736.	1.3	32
2125	Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial. Current Medical Research and Opinion, 2020, 36, 941-945.	0.9	3
2126	Statins for primary prevention: what is the regulator’s role?. BMJ Evidence-Based Medicine, 2020, , bmjebm-2019-111321.	1.7	3
2127	Effects of a novel nutraceutical combination (BruMeChol ₂) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial. Trials, 2020, 21, 616.	0.7	9
2128	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
2129	Baseline, delta, and achieved low-density lipoprotein cholesterol levels and cardiovascular risk in patients on statin therapy: A post-hoc resampling mediation analysis of treating new targets [TNT] trial. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1649-1658.	0.9	0
2130	The role of cystatin C and fetuin A in the determination of early atherosclerotic risk in psoriasis patients. Dermatologic Therapy, 2020, 33, e13898.	0.8	7
2132	Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 533-538.	0.4	7
2133	Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2020, 25, 6-11.	0.4	2
2134	Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. European Heart Journal, 2020, 41, 3900-3909.	1.0	75
2135	Plaque morphology assessed by optical coherence tomography in the culprit lesions of the first episode of acute myocardial infarction in patients with low low-density lipoprotein cholesterol level. Journal of Cardiology, 2020, 75, 485-493.	0.8	8

#	ARTICLE	IF	CITATIONS
2136	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22
2137	Usefulness of a Structured Adult Education Program in Modifying Markers of Cardiovascular Risk After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 125, 845-850.	0.7	5
2138	Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 88-97.e2.	0.6	12
2139	Pooled cohort risk equation and subclinical cerebrovascular diseases. <i>European Journal of Neurology</i> , 2020, 27, 793-799.	1.7	2
2140	Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 296, 4-10.	0.4	6
2141	A randomized controlled trial of the effects of non-surgical periodontal therapy on cardiac function assessed by echocardiography in type 2 diabetic patients. <i>Journal of Clinical Periodontology</i> , 2020, 47, 726-736.	2.3	16
2142	Diet, Lifestyle, Smoking. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	5
2143	Strategies to achieve a healthy diet and health: reduction of trans fat and saturated fatty acids. , 2020, , 103-121.		2
2144	Cardiotrophin-1 Deficiency Abrogates Atherosclerosis Progression. <i>Scientific Reports</i> , 2020, 10, 5791.	1.6	9
2145	The clinical and laboratory investigation of dysbetalipoproteinemia. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 458-469.	2.7	12
2146	Thyroid function and lipid profile in euthyroid adults: the TCLSIH cohort study. <i>Endocrine</i> , 2020, 70, 107-114.	1.1	3
2147	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	1.2	5
2148	Association of Cardiovascular Mortality and Deep Learning-Funduscopy Atherosclerosis Score derived from Retinal Fundus Images. <i>American Journal of Ophthalmology</i> , 2020, 217, 121-130.	1.7	52
2149	Olive oil consumption and its repercussions on lipid metabolism. <i>Nutrition Reviews</i> , 2020, 78, 952-968.	2.6	24
2150	Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International Cholesterol management Practice Study (ICLPS). <i>Lipids in Health and Disease</i> , 2020, 19, 64.	1.2	1
2151	Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-2017. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 59-67.	1.8	10
2152	Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels—a Danish registry-based study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 181-188.	1.8	3
2153	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 51-58.	1.0	3

#	ARTICLE	IF	CITATIONS
2154	The effect of omega-3 fatty acids on coronary atherosclerosis quantified by coronary computed tomography angiography. <i>Clinical Nutrition</i> , 2021, 40, 1123-1129.	2.3	10
2155	Sirtuin 6: A potential therapeutic target for cardiovascular diseases. <i>Pharmacological Research</i> , 2021, 163, 105214.	3.1	29
2156	Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 134-142.	0.7	6
2157	Association between the 10-year predicted risk of atherosclerotic cardiovascular disease and dietary patterns among Canadian adults 40-79 years. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 636-644.	1.3	2
2158	Statin use and new-onset of inflammatory bowel disease: A systematic review and meta-analysis of over ten million participants. <i>European Journal of Pharmacology</i> , 2021, 891, 173750.	1.7	4
2159	Chronic kidney disease prevalence and cardiovascular risk in a cohort of patients with type 2 diabetes followed for 10 years in Badajoz (Spain). An observational study. <i>Primary Care Diabetes</i> , 2021, 15, 391-396.	0.9	7
2160	Recent updates on novel therapeutic targets of cardiovascular diseases. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 145-155.	1.4	12
2162	Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 608-638.	0.9	18
2163	Polyphenols and their effects on metabolic syndromes and other CVD risk factors. , 2021, , 253-267.		0
2164	Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 19.	0.7	9
2165	Practical Dyslipidemia Management in Stroke-Specific Situations. <i>Stroke Revisited</i> , 2021, , 165-172.	0.2	0
2166	Development and Implementation of a Decision Support System to Improve Control of Hypertension and Diabetes in a Resource-Constrained Area in Brazil: Mixed Methods Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e18872.	2.1	22
2167	Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia. <i>Journal of Translational Medicine</i> , 2021, 19, 19.	1.8	8
2168	The Prevalence of Probable Familial Chylomicronemia Syndrome in a Southern California Population. <i>Endocrine Practice</i> , 2021, 27, 71-76.	1.1	3
2169	Racionalidad científica para la evolución de las metas de LDL-c. , 2021, 32, 182-191.		0
2170	Dyslipidemia and Cardiometabolic Syndrome. <i>Cardiometabolic Syndrome Journal</i> , 2021, 1, 18.	1.0	3
2171	Overview of olive oil in vascular dysfunction. , 2021, , 165-174.		2
2172	Correlation between left ventricular diastolic dysfunction and dyslipidaemia in asymptomatic patients with new-onset type 2 diabetes mellitus. <i>The Egyptian Journal of Internal Medicine</i> , 2021, 33, .	0.3	4

#	ARTICLE	IF	CITATIONS
2173	Biomarker and Invasive Hemodynamic Assessment of Cardiac Damage Class in Aortic Stenosis. <i>Structural Heart</i> , 2021, 5, 208-217.	0.2	1
2174	The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. <i>Journal of Personalized Medicine</i> , 2021, 11, 103.	1.1	16
2175	Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. <i>Nutrients</i> , 2021, 13, 672.	1.7	40
2176	Circulating vascular endothelial growth factor receptor 2 levels and their association with lipid abnormalities in patients on hemodialysis. <i>Biomedical Reports</i> , 2021, 14, 37.	0.9	1
2177	Dietary fat intakes and cardiovascular disease risk in adults with type 2 diabetes: a systematic review and meta-analysis. <i>European Journal of Nutrition</i> , 2021, 60, 3355-3363.	1.8	19
2178	AF-React study: atrial fibrillation management strategies in clinical practiceâ€”retrospective longitudinal study from real-world data in Northern Portugal. <i>BMJ Open</i> , 2021, 11, e040404.	0.8	2
2179	Management of high and very high-risk patients â€” how to achieve the best advantage?. <i>AkademiÄt Medicyny I Sporta</i> , 2021, 2, 23-27.	0.0	0
2180	The Impact of Olive Oil and Mediterranean Diet on the Prevention of Cardiovascular Diseases. , 0, , .		0
2181	Dyslipidemia and rupture risk of intracranial aneurysmsâ€”a systematic review. <i>Neurosurgical Review</i> , 2021, 44, 3143-3150.	1.2	7
2182	Mitochondrial impairments in aetiopathology of multifactorial diseases: common origin but individual outcomes in context of 3P medicine. <i>EPMA Journal</i> , 2021, 12, 27-40.	3.3	44
2183	Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation. <i>Advances in Therapy</i> , 2021, 38, 2323-2338.	1.3	5
2184	Updates in bariatric surgery guidelines: what's new?. <i>Minerva Surgery</i> , 2021, 76, .	0.1	2
2185	Registry of the Egyptian specialized hypertension clinics: Sexâ€”related differences in clinical characteristics and hypertension management among low socioeconomic hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1120-1128.	1.0	2
2186	Impact of cardiovascular risk factors on myocardial workâ€”insights from the STAAB cohort study. <i>Journal of Human Hypertension</i> , 2022, 36, 235-245.	1.0	13
2187	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021, 107, 1369-1375.	1.2	53
2188	Systematic Identification of Familial Hypercholesterolaemia in Primary Careâ€”A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 302.	1.1	4
2189	Early Prevention of Atherosclerosis: Detection and Management of Hypercholesterolaemia in Children and Adolescents. <i>Life</i> , 2021, 11, 345.	1.1	22
2190	Metabolic syndrome and coronary artery disease in adults with congenital heart disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 563-576.	0.7	8

#	ARTICLE	IF	CITATIONS
2191	Dietary Macronutrient Composition in Relation to Circulating HDL and Non-HDL Cholesterol: A Federated Individual-Level Analysis of Cross-Sectional Data from Adolescents and Adults in 8 European Studies. <i>Journal of Nutrition</i> , 2021, 151, 2317-2329.	1.3	8
2192	Clinical approach to chronic wound management in older adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2327-2334.	1.3	49
2193	Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology – A new chance for causative therapy?. <i>Journal of Controlled Release</i> , 2021, 333, 536-559.	4.8	18
2194	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. <i>Menopause</i> , 2021, 28, 610-618.	0.8	13
2195	Secondary Causes of Hypertriglyceridemia are Prevalent Among Patients Presenting With Hypertriglyceridemia Induced Acute Pancreatitis. <i>American Journal of the Medical Sciences</i> , 2021, 361, 616-623.	0.4	4
2196	Lipids and lipid-modifying therapy. <i>Trends in Urology & Men's Health</i> , 2021, 12, 23-28.	0.2	0
2197	Metabolic Syndrome and Myocardial Infarction in Women. <i>Current Pharmaceutical Design</i> , 2021, 27, 3786-3794.	0.9	4
2199	Fluorescent CdSe/ZnS quantum dots incorporated poly (styrene-co-maleic anhydride) nanospheres for high-sensitive C-reaction protein detection. <i>Surfaces and Interfaces</i> , 2021, 24, 101057.	1.5	5
2200	Evaluation of selected risk factors for cardiovascular diseases and diabetes as a background for the prevention program in occupational healthcare. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2021, 34, 403-413.	0.6	3
2201	Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. <i>Clinical Cardiology</i> , 2021, 44, 955-962.	0.7	5
2202	Two RECK Splice Variants (Long and Short) Are Differentially Expressed in Patients with Stable and Unstable Coronary Artery Disease: A Pilot Study. <i>Genes</i> , 2021, 12, 939.	1.0	3
2203	The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations ≥ 70 mg/dL. <i>BMC Medicine</i> , 2021, 19, 142.	2.3	11
2204	Association of long-term exposure to ambient air pollutants with blood lipids in Chinese adults: The China Multi-Ethnic Cohort study. <i>Environmental Research</i> , 2021, 197, 111174.	3.7	49
2205	Peripheral Artery Disease as a Risk Factor for Myocardial Infarction. <i>Cureus</i> , 2021, 13, e15655.	0.2	2
2206	Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2021, 16, e0253298.	1.1	4
2207	Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. <i>JAMA Network Open</i> , 2021, 4, e2113186.	2.8	43
2208	The Role of Essential Oils and Their Main Compounds in the Management of Cardiovascular Disease Risk Factors. <i>Molecules</i> , 2021, 26, 3506.	1.7	18
2209	Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. <i>Thrombosis Journal</i> , 2021, 19, 45.	0.9	8

#	ARTICLE	IF	CITATIONS
2210	The Role of C-reactive Protein in Patient Risk Stratification and Treatment. <i>European Cardiology Review</i> , 2021, 16, e28.	0.7	7
2211	The Tacrolimus Metabolism Rate and Dyslipidemia after Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3066.	1.0	8
2212	Acute Stress-Induced Blood Lipid Reactivity in Hypertensive and Normotensive Men and Prospective Associations with Future Cardiovascular Risk. <i>Journal of Clinical Medicine</i> , 2021, 10, 3400.	1.0	5
2213	Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women as a Potential Prevention Factor in Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2021, 13, 2531.	1.7	14
2214	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.4	19
2215	Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 991-1001.	0.7	1
2216	Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 57.	2.0	51
2217	Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis. <i>Scientific Reports</i> , 2021, 11, 15599.	1.6	9
2218	Cardiac CT findings in patients with family history of premature CAD: an observational study. <i>Acta Cardiologica</i> , 2021, , 1-6.	0.3	0
2219	Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 674446.	1.1	3
2220	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-11.	1.0	5
2221	The scientific basis and future of lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 32-36.	0.4	16
2222	Temporal trends of lipid control in very high cardiovascular risk patients. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 641-648.	0.2	4
2223	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	11
2224	Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis. <i>Frontiers in Genetics</i> , 2021, 12, 724149.	1.1	8
2225	A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin. <i>Current Diabetes Reviews</i> , 2021, 17, e122820189541.	0.6	2
2226	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
2227	Low prevalence of diabetic retinopathy in patients with long-term type 1 diabetes and current good glycemic control - one-center retrospective assessment. <i>Endocrine</i> , 2022, 75, 427-436.	1.1	3

#	ARTICLE	IF	CITATIONS
2228	Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 538-548.	1.8	11
2229	Temporal trends of lipid control in very high cardiovascular risk patients. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 641-648.	0.2	0
2230	Functional versus morphological assessment of vascular age in patients with coronary heart disease. <i>Scientific Reports</i> , 2021, 11, 18164.	1.6	6
2231	Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes. <i>Tzu Chi Medical Journal</i> , 2021, 33, 135.	0.4	9
2232	Strategies for identifying familial hypercholesterolaemia in non-specialist clinical settings. <i>The Cochrane Library</i> , 0, , .	1.5	1
2234	Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. , 2015, , 1-10.		2
2235	Clinical Case 3: Patient with Essential Hypertension and Familial Hypercholesterolaemia. <i>Practical Case Studies in Hypertension Management</i> , 2016, , 33-50.	0.0	1
2236	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1695-1718.		2
2237	Lipidsenkende Mittel. , 2015, , 745-756.		1
2238	Hyperlipidemia. , 2014, , 295-302.		6
2239	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
2240	Somatic assessment of one hundred inpatients in a psychiatric crisis unit: A retrospective observational study. <i>L'Encephale</i> , 2020, 46, 173-176.	0.3	2
2241	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol $\leq 70 \text{ mg/dL}$ compared with a novel low-density lipoprotein estimation method. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1065-1072.	0.6	37
2243	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMII/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic“therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017, 19, D3-D54.	0.0	19
2244	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1991-2000.	0.8	44
2245	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1864-1872.	0.8	19
2247	Estatinas en enfermedad renal cr3nica. <i>Ars Medica</i> , 2017, 42, .	0.1	2
2248	Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study. <i>Singapore Medical Journal</i> , 2017, 58, 535-542.	0.3	21

#	ARTICLE	IF	CITATIONS
2249	PDE5 inhibitor efficacy is estrogen dependent in female heart disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 2464-2471.	3.9	67
2250	Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 402-9.	0.2	12
2251	2016 Chinese guidelines for the management of dyslipidemia in adults. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 1-29.	0.2	226
2252	The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 344-353.	0.2	2
2253	Heart Transplantation and Risk of Cardiac Vasculopathy Development: What Factors Are Important?. <i>Annals of Transplantation</i> , 2017, 22, 682-688.	0.5	8
2254	Statin non-adherence: clinical consequences and proposed solutions. <i>F1000Research</i> , 2016, 5, 714.	0.8	11
2255	Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 242.	1.1	10
2256	Hypercholesterolemia and prevention of cardiovascular diseases in the light of preventive medical examinations of employees in Poland. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2019, 32, 865-872.	0.6	7
2257	State of the Science on Cardiometabolic Risk After Spinal Cord Injury: Recap of the 2013 ASIA Pre-Conference on Cardiometabolic Disease. <i>Topics in Spinal Cord Injury Rehabilitation</i> , 2014, 20, 105-112.	0.8	6
2258	Cascade Screening for Familial Hypercholesterolemia (FH). <i>PLOS Currents</i> , 2011, 3, RRN1238.	1.4	61
2259	An Equation to Estimate the Concentration of Serum Apolipoprotein B. <i>PLoS ONE</i> , 2012, 7, e51607.	1.1	10
2260	Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e52828.	1.1	43
2261	Nitrosylated Hemoglobin Levels in Human Venous Erythrocytes Correlate with Vascular Endothelial Function Measured by Digital Reactive Hyperemia. <i>PLoS ONE</i> , 2013, 8, e76457.	1.1	31
2262	A Cluster Randomised Controlled Trial of a Pharmacist-Led Collaborative Intervention to Improve Statin Prescribing and Attainment of Cholesterol Targets in Primary Care. <i>PLoS ONE</i> , 2014, 9, e113370.	1.1	35
2263	Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. <i>PLoS ONE</i> , 2015, 10, e0115270.	1.1	25
2264	Serum Lipid Levels and Dyslipidaemia Prevalence among 10 Year-Old Northern Mexican Children. <i>PLoS ONE</i> , 2015, 10, e0119877.	1.1	18
2265	Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study. <i>PLoS ONE</i> , 2015, 10, e0130946.	1.1	41
2266	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. <i>PLoS ONE</i> , 2015, 10, e0138092.	1.1	32

#	ARTICLE	IF	CITATIONS
2267	Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure. PLoS ONE, 2015, 10, e0144602.	1.1	3
2268	Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PLoS ONE, 2016, 11, e0155228.	1.1	37
2269	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. PLoS ONE, 2016, 11, e0166246.	1.1	9
2270	Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. PLoS ONE, 2017, 12, e0181077.	1.1	11
2271	Trends in disease-free life expectancy at age 65 in Spain: Diverging patterns by sex, region and disease. PLoS ONE, 2020, 15, e0240923.	1.1	18
2272	Plant sterols for adults with hypercholesterolemia treated with or without medication (statins). Revista Espanola De Nutricion Humana Y Dietetica, 2015, 19, 105.	0.1	2
2273	Reduced Heart Function Predicts Drug-Taking Compliance and Two-Year Prognosis in Chinese Patients With Stable Premature Coronary Artery Disease. Journal of Clinical Medicine Research, 2015, 7, 154-160.	0.6	2
2274	Comparisons of microbiota-generated metabolites in patients with young and elderly acute coronary syndrome. Anatolian Journal of Cardiology, 2020, 24, 175-182.	0.5	4
2275	Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. European Journal of Endocrinology, 2019, 181, 579-590.	1.9	6
2276	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38
2277	Secondary hyperlipidemias: etiology and pathogenesis. Russian Journal of Cardiology, 2019, , 74-81.	0.4	10
2278	Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	28
2279	APPROACHES TO STATIN THERAPY ADHERENCE IMPROVEMENT. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 81-87.	0.4	2
2280	Methodological aspects of the identification and correction of nutrition-dependent risk factors for cardiovascular diseases during screening of certain adult population groups of Russia. Profilakticheskaya Meditsina, 2015, 18, 3.	0.2	11
2281	Quality of lipid-lowering therapy in outpatient practice: RECVAS Register data. Profilakticheskaya Meditsina, 2016, 19, 9.	0.2	5
2283	Akut koroner sendromda kontrast nefropati geliÅyimi ile Syntax Skoru arasÄ±ndaki iliÅyki. Cukurova Medical Journal, 2019, 44, 1181-1188.	0.1	2
2284	Lifestyle and Comorbidities: Do We Take Enough Care of Preconception Health in Assisted Reproduction?. Journal of Family & Reproductive Health, 2020, 14, 150-157.	0.4	3
2285	Radial artery intima-media thickness regresses after secondary prevention interventions in patientsâ€™ post-acute coronary syndrome and is associated with cardiac and kidney biomarkers. Oncotarget, 2017, 8, 53419-53431.	0.8	3

#	ARTICLE	IF	CITATIONS
2286	Consensus statement on the assessment of comorbidities in people living with HIV in Romania. <i>Germs</i> , 2019, 9, 198-210.	0.5	13
2287	Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials. <i>Review of Diabetic Studies</i> , 2013, 10, 191-203.	0.5	11
2288	LIPID PROFILE AND HEMORHEOLOGY DYNAMICS IN PATIENTS WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE IN THE PREOPERATIVE AND POSTOPERATIVE PERIOD. <i>Russian Archives of Internal Medicine</i> , 2019, 9, 206-212.	0.0	2
2289	Biological markers in risk stratification and progression of cardiovascular disease: present and future. <i>Bulletin of Siberian Medicine</i> , 2018, 17, 264-280.	0.1	18
2290	Is it time to break the fast?â€”a paradigm shift in clinical lipidology. <i>Annals of Translational Medicine</i> , 2016, 4, 430-430.	0.7	1
2291	Re-assessing the role of non-fasting lipids; a change in perspective. <i>Annals of Translational Medicine</i> , 2016, 4, 431-431.	0.7	16
2292	Prevalence of lifestyle and cardiovascular risk factors in a group of medical students. <i>Central European Journal of Public Health</i> , 2018, 26, S12-S18.	0.4	6
2293	Modern strategy of diagnosis and treatment of children with heterozygous familial hypercholesterolemia. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2020, 65, 27-40.	0.1	4
2294	Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 5-9.	0.3	1
2295	Pharmacological Effects of Niacin on Acute Hyperlipemia. <i>Current Medicinal Chemistry</i> , 2016, 23, 2826-2835.	1.2	12
2296	Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. <i>Current Medicinal Chemistry</i> , 2016, 23, 1460-1476.	1.2	76
2297	Impact of Red Wine Consumption on Cardiovascular Health. <i>Current Medicinal Chemistry</i> , 2019, 26, 3542-3566.	1.2	44
2298	Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 6299-6305.	0.9	21
2299	Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol. <i>Current Pharmaceutical Design</i> , 2014, 20, 6238-6248.	0.9	15
2300	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. <i>Current Pharmaceutical Design</i> , 2014, 20, 6350-6357.	0.9	9
2301	Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances. <i>Current Drug Targets</i> , 2019, 20, 879-890.	1.0	3
2302	Protective Effects of Phenylpropanoids and Phenylpropanoid-rich Essential Oils on the Cardiovascular System. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 1459-1471.	1.1	10
2303	Metabolic Syndrome and Cardiometabolic Risk Factors. <i>Current Vascular Pharmacology</i> , 2014, 11, 858-879.	0.8	49

#	ARTICLE	IF	CITATIONS
2304	Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview. <i>Current Vascular Pharmacology</i> , 2014, 12, 627-641.	0.8	48
2305	Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. <i>Current Vascular Pharmacology</i> , 2016, 14, 523-533.	0.8	12
2306	Non-Traditional Cardiovascular Risk Markers in the Era of Established Major Risk Factors and Multiple Guidelines. <i>Current Vascular Pharmacology</i> , 2019, 17, 270-277.	0.8	10
2307	The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study. <i>Current Vascular Pharmacology</i> , 2020, 18, 193-199.	0.8	2
2308	Global Cardiovascular Risk Management in Primary Prevention. <i>Current Vascular Pharmacology</i> , 2012, 10, 709-711.	0.8	3
2309	Primary Hypertriglyceridemia: A Look Back on the Clinical Classification and Genetics of the Disease. <i>Current Diabetes Reviews</i> , 2020, 16, 521-531.	0.6	11
2310	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. <i>Current Diabetes Reviews</i> , 2020, 16, 949-956.	0.6	2
2311	Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies. <i>Current Cardiology Reviews</i> , 2018, 14, 67-76.	0.6	33
2312	Management of Measurable Variable Cardiovascular Disease' Risk Factors. <i>Current Cardiology Reviews</i> , 2018, 14, 153-163.	0.6	199
2313	Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 226-230.	0.6	6
2314	Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 122-125.	0.6	5
2315	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 55-60.	0.6	18
2316	Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease. <i>Open Hypertension Journal</i> , 2013, 5, 18-22.	0.8	9
2317	Clinical Evaluation of the Measurement Performance of the Philips Health Watch: A Within-Person Comparative Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e10.	1.8	18
2318	Development and Evaluation of a Mobile Decision Support System for Hypertension Management in the Primary Care Setting in Brazil: Mixed-Methods Field Study on Usability, Feasibility, and Utility. <i>JMIR MHealth and UHealth</i> , 2019, 7, e9869.	1.8	37
2319	Recent updates in dyslipidemia management: perspectives in stroke-specific situation. <i>Precision and Future Medicine</i> , 2020, 4, 9-20.	0.5	3
2320	The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis. <i>Blood Transfusion</i> , 2017, 15, 1-3.	0.3	14
2321	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 845-859.	0.6	12

#	ARTICLE	IF	CITATIONS
2322	The Treatment of Disorders of Lipid Metabolism. Deutsches Ärzteblatt International, 2016, 113, 261-8.	0.6	55
2323	The Labile Iron Pool in Monocytes Reflects the Activity of the Atherosclerotic Process in Men With Chronic Cardiovascular Disease. Physiological Research, 2017, 66, 49-61.	0.4	10
2324	Hypolipidemic treatment and target values of lipids. Interni Medicina Pro Praxi, 2018, 20, 82-84.	0.0	1
2325	The current state of lipid modifying therapy in the Czech population. Intervencni A Akutni Kardiologie, 2016, 15, 81-84.	0.0	1
2326	Anti-Obesity Property of Lichen Thamnolia vermicularis Extract in 3T3-L1 Cells and Diet-Induced Obese Mice. Preventive Nutrition and Food Science, 2017, 22, 285-292.	0.7	4
2327	Lipids in liver transplant recipients. World Journal of Gastroenterology, 2016, 22, 3315-3324.	1.4	34
2330	Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation. Korean Journal of Internal Medicine, 2014, 29, 210.	0.7	2
2331	Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry. Korean Journal of Internal Medicine, 2020, 35, 342-350.	0.7	2
2332	Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases. Korean Journal of Internal Medicine, 2020, 35, 593-604.	0.7	8
2333	Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians. Journal of Anaesthesiology Clinical Pharmacology, 2016, 32, 440.	0.2	8
2334	Asymptomatic left ventricular dysfunction and metabolic syndrome: Results from an Italian multicenter study. Journal of Cardiovascular Echography, 2013, 23, 96.	0.1	4
2335	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates. Heart Views, 2019, 20, 37.	0.1	5
2336	Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. Journal of Family Medicine and Primary Care, 2019, 8, 2249.	0.3	1
2337	Dietary Fibers and Nutraceuticals for Primary Cardiovascular Prevention in Children and Adolescents: A Critical Review. Food and Nutrition Sciences (Print), 2013, 04, 39-47.	0.2	4
2338	Replacement Meal: Effectiveness of a Soluble Powder Rich in Fibers and at Low Glycemic Index in Overweight but Not in Obese Patients. Food and Nutrition Sciences (Print), 2017, 08, 591-597.	0.2	1
2339	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World Journal of Diabetes, 2014, 5, 165.	1.3	16
2340	Proximal protection with the Gore PAES can reduce DWI lesion size in high-grade stenosis during carotid stenting. EuroIntervention, 2014, 10, 271-276.	1.4	11
2341	Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 738.	0.8	15

#	ARTICLE	IF	CITATIONS
2342	Trend in prevalence of uncontrolled total serum cholesterol for cardio-cerebro-vascular disease in a mediterranean area, 1988/89-2008/09. World Journal of Cardiology, 2013, 5, 420.	0.5	4
2343	Diabetes care among older adults in primary care in Austria - a cross-sectional study. Swiss Medical Weekly, 2012, 142, w13646.	0.8	5
2344	Check-up examination: recommendations in adults. Swiss Medical Weekly, 2015, 145, w14075.	0.8	17
2345	Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome. Oman Medical Journal, 2015, 30, 403-405.	0.3	1
2346	Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Archives of Medical Science, 2015, 11, 915-26.	0.4	24
2347	Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients. Annals of Saudi Medicine, 2017, 37, 366-374.	0.5	6
2348	The assessment of the relationship between variations in the apelin gene and coronary artery disease in Turkish population. Anatolian Journal of Cardiology, 2015, 15, 716-721.	0.5	2
2349	Absolute Risk of Cardiovascular Disease and Lipid Management Targets. Journal of Atherosclerosis and Thrombosis, 2013, 20, 689-697.	0.9	11
2350	Diabetes Mellitus. Journal of Atherosclerosis and Thrombosis, 2014, 21, 93-98.	0.9	16
2351	Subclinical Carotid Atherosclerosis Burden in the Japanese: Comparison between Okinawa and Nagano Residents. Journal of Atherosclerosis and Thrombosis, 2015, 22, 854-868.	0.9	10
2352	Intima-media thickness correlates with features of metabolic syndrome in young people with a clinical diagnosis of familial hypercholesterolaemia. Kardiologia Polska, 2013, 71, 566-572.	0.3	9
2353	Management of severe hypertriglyceridaemia. Kardiologia Polska, 2013, 71, 1007-1012.	0.3	5
2354	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. Kardiologia Polska, 2015, 73, 471-477.	0.3	4
2355	Does heart failure determine the nutrition of patients?. Kardiologia Polska, 2014, 72, 56-63.	0.3	5
2356	Flow-mediated dilatation (FMD) and prevalence of cardiovascular risk factors: the value of FMD assessment in high risk patients is limited. Kardiologia Polska, 2014, 72, 254-261.	0.3	6
2357	Prevalence of dyslipidaemia in statin-treated patients in South Africa : results of the DYSlipidaemia International Study (DYSIS). Cardiovascular Journal of Africa, 2013, 24, 330-338.	0.2	16
2360	Comparison of Secondary Prevention Status between Percutaneous Coronary Intervention and Coronary Artery Bypass Patients. Arquivos Brasileiros De Cardiologia, 2017, 109, 466-474.	0.3	2
2361	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.3	102

#	ARTICLE	IF	CITATIONS
2362	The Relationship between Serum Apelin Levels and the Severity of Calcific Aortic Stenosis. <i>Acta Cardiologica Sinica</i> , 2018, 34, 259-266.	0.1	10
2363	Statin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan. <i>Acta Cardiologica Sinica</i> , 2016, 32, 23-30.	0.1	9
2364	Statin Therapy: Review of Safety and Potential Side Effects. <i>Acta Cardiologica Sinica</i> , 2016, 32, 631-639.	0.1	203
2365	Preprocedural Lp(a) level and ApoB/ApoA-1™ ratio and the risk for contrast-induced acute kidney injury in patients undergoing emergency PCI. <i>Lipids in Health and Disease</i> , 2021, 20, 130.	1.2	2
2366	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
2367	Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome. <i>Journal of Cardiology</i> , 2022, 79, 391-399.	0.8	1
2368	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	1.0	12
2369	Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. <i>The Cochrane Library</i> , 2021, 2021, CD012985.	1.5	2
2370	Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study <sc>II</sc>. <i>Clinical Cardiology</i> , 2021, 44, 1575-1585.	0.7	9
2371	Short-Term Intake of Yellowstripe Scad versus Salmon Did Not Induce Similar Effects on Lipid Profile and Inflammatory Markers among Healthy Overweight Adults despite Their Comparable EPA+DHA Content. <i>Nutrients</i> , 2021, 13, 3524.	1.7	2
2372	Statins: Side effects and drug interactions. <i>Scripta Medica</i> , 2011, 42, 84-91.	0.0	0
2373	Cardiovascular risk and lipid control in secondary prevention. <i>Srce I Krvni Sudovi</i> , 2011, 30, 210-219.	0.1	0
2375	Small Dense Low-density Lipoprotein and Cardiovascular Disease. <i>Journal of Lipid and Atherosclerosis</i> , 2012, 1, 1.	1.1	0
2376	Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. <i>Southern Medical Journal</i> , 2012, 105, 48-55.	0.3	3
2377	RECOMENDACIONES EN PREVENCIÓN DEL RIESGO VASCULAR. , 2012, , 29-61.		0
2378	Lipidsenkende Mittel. , 2012, , 697-711.		0
2379	Two male study groups with adiposity and hypertriglyceridemia were at risk for hypertension and alcohol use declined renal endothelium. <i>Health</i> , 2012, 04, 1390-1395.	0.1	2
2381	Optimization of primary and secondary prevention. , 2012, , 259-277.		0

#	ARTICLE	IF	CITATIONS
2382	Discovery and Validation Case Studies, Recommendations: Discovery and Development of Multimarker Panels for Improved Prediction of Near-Term Myocardial Infarction. RSC Drug Discovery Series, 2013, , 315-333.	0.2	1
2383	Stoffwechselerkrankungen. , 2013, , 279-315.		0
2384	Umsatzveränderungen in einzelnen Indikationsgruppen. , 2013, , 43-376.		0
2385	Fettstoffwechsel; Lipidsenker - Pharmakotherapie bei Fettstoffwechselstörungen. , 2013, , 569-583.		0
2387	Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings. Pharmacology & Pharmacy, 2013, 04, 318-324.	0.2	0
2389	Lipidsenkende Mittel. , 2013, , 687-702.		0
2390	Kardiologische Therapie bei Hochbetagten. , 2013, , 433-446.		0
2391	Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients. Swiss Medical Weekly, 2013, 143, w13828.	0.8	9
2392	How to asses and improve cardiopulmonary risk prior to vascular surgery?. Vasa - European Journal of Vascular Medicine, 2013, 42, 323-330.	0.6	0
2393	Lipideverlagende geneesmiddelen. , 2014, , 291-304.		0
2394	Dyslipoproteinemie. , 2014, , 35-52.		0
2395	Editorial: Sailing across the sea of guidelines. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2013, 20, 361-367.	0.3	0
2396	Homozygous Familial Hypercholesterolemia: Case report and Review of Literature. American Journal of Internal Medicine, 2014, 2, 34.	0.1	1
2397	Fettstoffwechsel und Hypertonie bei Diabetes. , 2014, , 217-237.		0
2398	Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. Journal of the Japanese Coronary Association, 2014, 20, 282-294.	0.0	0
2399	Correlation Between Serum Uric Acid and Renal Function in Patients With Stable Coronary Artery Disease and Type 2 Diabetes. Journal of Clinical Medicine Research, 2014, 6, 443-50.	0.6	10
2401	Non-statin Therapies for CKD with Dyslipidemia. , 2014, , 153-178.		0
2403	Statin. Journal of the Nihon University Medical Association, 2014, 73, 81-84.	0.0	0

#	ARTICLE	IF	CITATIONS
2404	Nuevas guías ACC / AHA 2013 en el manejo del colesterol: "Una mirada crítica del Departamento de Prevención Cardiovascular de la Sociedad Chilena de Cardiología y Cirugía Cardiovascular". Revista Chilena De Cardiología, 2014, 33, 136-141.	0.0	0
2405	Fenofibrate Therapy and Change of Renal Function: Management, What and How?. Korean Journal of Medicine, 2014, 86, 698.	0.1	0
2406	Statins: Practical Considerations – A Review. European Cardiology Review, 2014, 9, 71.	0.7	5
2407	Alteraciones del metabolismo de las lipoproteínas. , 2014, , 44-65.		0
2408	Dyslipidemia Treatment in Diabetes Mellitus Patients. Korean Journal of Medicine, 2014, 87, 686.	0.1	0
2409	The ideal management of blood cholesterol: a review of the updated 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk. Journal of the Korean Medical Association, 2014, 57, 857.	0.1	0
2410	Women with overweight, mixed hyperlipidemia, intolerance to glucose and diastolic hypertension. Health, 2014, 06, 454-467.	0.1	2
2411	Nutrición. , 2014, , 117-147.		0
2412	Relevance of Target-Organ Lesions as Predictors of Mortality in Patients with Diabetes Mellitus. Arquivos Brasileiros De Cardiologia, 2014, 103, 272-81.	0.3	1
2413	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-29.		0
2415	Management of elevated blood cholesterol in the psychiatric patient: What's new in the guidelines?. Mental Health Clinician, 2014, 4, 100-106.	0.5	0
2416	PENGARUH PEMBERIAN SUP JAMUR TIRAM PUTIH (Pleurotus ostreatus) TERHADAP KADAR TRIGLISERIDA PADA SUBJEK OBESITAS. Journal of Nutrition College, 2014, 3, 943-950.	0.1	0
2417	PENGARUH PEMBERIAN SUP JAMUR TIRAM PUTIH (Pleurotus Ostreatus) TERHADAP KADAR KOLESTEROL TOTAL SUBJEK OBESITAS. Journal of Nutrition College, 2014, 3, 465-472.	0.1	1
2418	Interrelation of blood lipid spectrum, level of systemic inflammation and mass of body in patients with coronary heart disease in combination with nonalcoholic fatty liver disease and their dynamics in terms of secondary prevention.. Medicni Perspektivi, 2014, 19, 103-111.	0.1	2
2419	Which One to Endorse Among the Multitude of Lipid Guidelines?. European Endocrinology, 2015, 11, 32.	0.8	0
2420	Effects of cardiopulmonary bypass on mediastinal drainage and the use of blood products in the intensive care unit in 60- to 80-year-old patients who have undergone coronary artery bypass grafting. Brazilian Journal of Cardiovascular Surgery, 2015, 30, 597-604.	0.2	0
2421	Statins and Fibrates: Should They Be Recommended?. , 2015, , 11-23.		1
2422	Fettstoffwechselstörungen: Diagnostik. , 2015, , 1-11.		0

#	ARTICLE	IF	CITATIONS
2423	Statins and PCSK9 Inhibitors: Defining the Correct Patients. , 2015, , 99-117.		1
2425	Influence of a Regular, Standardized Meal on Lipid Profile of People with Diabetes. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2015, 09, .	0.1	0
2426	Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression. Arquivos Brasileiros De Cardiologia, 2015, 105, 11-9.	0.3	11
2427	Participants with Treated Hyperlipidemia may be More Health Conscious. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1025-1026.	0.9	0
2428	Strategies of Hyperglycemia Management among Patients with Diabetic Nephropathy, Renal Impairment, Hypertension and Lipid Disorders. Journal of Endocrinology and Diabetes, 2015, 2, .	0.2	0
2429	Update on the Pharmacologic Agents for Dyslipidemia. Journal of Korean Diabetes, 2015, 16, 269.	0.1	0
2430	Lipidsenkertherapie. , 2015, , 1-11.		0
2431	Fibra dietĂ©tica e gordura saturada: relaĂ§Ăo entre marcadores bioquĂmicos da sĂndrome metabĂlica. Scientia Medica, 2015, 25, 18236.	0.1	0
2432	Cardiovascular Risk Factors, Diet and Lifestyle among a Group of Italian Young Adults Students. International Journal of Clinical Cardiology, 2015, 2, .	0.1	2
2435	Modern strategy of treatment hypercholesterolemia. ScienceRise, 2015, 3, 66.	0.1	0
2436	What do we know about lipoprotein(a)?. Kardiologia Polska, 2015, 73, 235-239.	0.3	1
2437	The occurrence of risk factors of cardiovascular diseases and the effect of selected dietary habits on the lipid profile and body mass index. Potravinarstvo, 2015, 9, 330-336.	0.5	2
2438	Modern management of dyslipidemia in general medical practice: practical issues of lipid-lowering pharmacotherapy. LĂki UkraĂni, 2015, .	0.0	0
2439	Using a standardized follow-up program to improve coronary heart disease secondary prevention. Anatolian Journal of Cardiology, 2015, 16, 84-91.	0.5	4
2440	Dietary gender differences in terms of the risk of atherogenesis in Poland. Acta Scientiarum Polonorum, Technologia Alimentaria, 2015, 14, 257-267.	0.2	2
2441	Four-year imaging follow-up of a homozygous familial hypercholesterolaemia patient: atherosclerosis ingravescence and coronary flow velocity reserve reduced gradually. Case report. Medical Ultrasonography, 2015, 17, 401.	0.4	0
2442	From Framingham to Hunt 2: 60 Years Blaming the Wrong Culprit?. Journal of Cardiology & Current Research, 2015, 4, .	0.1	0
2443	Is there a relation between statin use and glycemic control in type 2 diabetic patients?. TĂrkiye Aile HekimliĂi Dergisi, 2015, 19, 179-186.	0.4	0

#	ARTICLE	IF	CITATIONS
2444	Management of Dyslipidemia according to the 2015 Treatment Guideline for Diabetes: Controversies and Issues to Resolve. <i>Journal of Korean Diabetes</i> , 2016, 17, 96.	0.1	0
2445	Articropathie oblit�rante des membres inf�rieurs : principes de prise en charge m�dicale. , 2016, , 259-261.		0
2446	Cardio-vascular comorbidity: Focus on correcting tissue ischemia and energy shortage. <i>Kardiologiya i Serdechno-Sosudistaya Khirurgiya</i> , 2016, 9, 68.	0.1	0
2448	Dietary Practices. , 2016, , 413-417.		0
2450	Quantitative Measurement of Effect of Short-term Life Style Modification on Lipid Profiles in Korean Patients with Hyperlipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2016, 5, 79.	1.1	0
2452	Statin Myopathy. , 2016, , 113-122.		0
2453	Statins for All Patients with Hypertension��It is still not Prime Time!. <i>Hypertension Journal</i> , 2016, 2, 44-50.	0.1	0
2454	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 217-227.	0.0	0
2455	Cap�tulo 4 - Estratifica��o de Risco Cardiovascular. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 107, 18-24.	0.3	3
2456	Pharmaka mit Wirkung auf den Lipidstoffwechsel. <i>Springer-Lehrbuch</i> , 2016, , 489-508.	0.1	0
2457	A Critical Evaluation of the Role of Routine Uses of Statin as a Tool for Primary Prevention of Cardiovascular Diseases. <i>Open Journal of Preventive Medicine</i> , 2016, 06, 133-142.	0.2	0
2458	Vascular Disease in Young Indians (20-40 years): Role of Dyslipidemia. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, OE01-5.	0.8	6
2459	14. Familial hypercholesterolemia. <i>Human Health Handbooks</i> , 2016, , 243-266.	0.1	0
2460	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	0.9	7
2461	Do we use statins enough? News in the combination treatment by statins �nd ezetimibe. <i>Interni Medicina Pro Praxi</i> , 2016, 18, 71-73.	0.0	0
2462	Statins, Targets and Chronic Kidney Disease. <i>Journal of Cardiology & Current Research</i> , 2016, 6, .	0.1	0
2464	ASGR1 - a new target for lowering non-HDL cholesterol. <i>Global Cardiology Science & Practice</i> , 2016, 2016, e201614.	0.3	1
2465	The family hypercholesterolemia. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2016, 22, 272-276.	0.1	0

#	ARTICLE	IF	CITATIONS
2466	Interconnections between lipid metabolism indices and inflammation biomarkers in patients with unstable angina depending on age. <i>Medical and Clinical Chemistry</i> , 2016, , .	0.1	0
2467	What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital. <i>PLoS ONE</i> , 2016, 11, e0167258.	1.1	2
2469	The Cardiovascular System and the Coronary Circulation. , 2017, , 13-59.		1
2470	Stoffwechselerkrankungen. , 2017, , 285-322.		0
2471	Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort. <i>Anatolian Journal of Cardiology</i> , 2017, 17, 92-96.	0.5	0
2472	Kardiologie. , 2017, , 61-143.		0
2473	Peripheral Arterial Disease in CKD: Disease Burden, Outcomes and Interventional Strategies. , 2017, , 337-346.		0
2475	Treatment of Patients with Risk Factors: Compliance and Adherence. <i>Acta Facultatis Medicae Naissensis</i> , 2017, 34, 5-11.	0.1	1
2476	The changing paradigm of dyslipidaemia management. <i>Universa Medicina</i> , 2017, 36, 1.	0.1	0
2477	What has changed in treatment of patients with dyslipidemia?. <i>Interni Medicina Pro Praxi</i> , 2017, 19, 106-108.	0.0	0
2478	Dyslipoproteinemia. , 2018, , 227-243.		0
2479	Modern recommendations on diagnostics and treatment of lower extremity arteries diseases in the family doctors practice (review of the literature). <i>Family Medicine</i> , 2017, .	0.1	1
2481	A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry). <i>Journal of Clinical Medicine of Kazakhstan</i> , 2017, 4, 20-25.	0.1	0
2482	Side effects of statins in patient with compensated hypothyroidism and SLCO1B1 *5 (c.521T>C) polymorphism. <i>Kliničeskā Iksperimentalnā Tireoidologiā</i> , 2017, 13, 36-44.	0.1	1
2483	Dislipidemia and Serum Level of Interleukin-22 in Hypertensive Patients with Concomitant Excessive Body Weight or Obesity. <i>Lviv Clinical Bulletin</i> , 2017, 4, 8-14.	0.1	0
2484	Secondary Dyslipidemia In Obese Children - Is There Evidence For Pharmacological Treatment?. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 362-363.	0.3	0
2485	Role of antioxidants in treatment and prevention of patients with high risk of cardiovascular complications. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2018, 11, 31.	0.1	1
2487	Lysosomal acid lipase deficiency - underestimated cause of dislipidemia. what's new?. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2018, 7, 65.	0.3	0

#	ARTICLE	IF	CITATIONS
2488	Counterpoint: Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?. Arquivos Brasileiros De Cardiologia, 2018, 111, 750-752.	0.3	0
2489	SYNTAX and Logistic Clinic SYNTAX Score as a Predictor of Atrial Fibrillation after Isolated Coronary Artery Bypass. Angiology: Open Access, 2018, 06, .	0.1	0
2490	Traitement des dyslipidÃ©mies. , 2018, , 123-139.e1.		0
2491	Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?. Arquivos Brasileiros De Cardiologia, 2018, 111, 747-749.	0.3	3
2493	Chronic Kidney Disease Ð's a Common Medical Problem. UkraÃ­nsË¹kij Å¼urnal Medicini BÃ­ologÃ­-Ã­ Ta Sportu, 2018, 3, 185-193.	0.0	0
2494	Features of the Lipid Profile in Patients with Arterial Hypertension and Cardiovascular Diseases According to Smoking Status. Open Hypertension Journal, 2018, 10, 8-14.	0.8	1
2495	Features of Diagnosis and Treatment of Coronary Syndrome X. UkraÃ­nsË¹kij Å¼urnal Medicini BÃ­ologÃ­-Ã­ Ta Sportu, 2018, 3, 275-278.	0.0	0
2496	Prevalence of risk factors in cardiovascular diseases in selected population of the Czech Republic. Central European Journal of Public Health, 2018, 26, 118-123.	0.4	3
2497	Vascular biomarkers: research methods, indicators, clinical, prognostic value and perspectives. UMJ Heart & Vessels, 2018, .	0.0	0
2499	Are risk factors of cerebral small vessel disease differ from those in patients with high atherothrombotic risk without cerebrovascular disease?. Journal of Medical Science, 2018, 87, 145-153.	0.2	0
2500	Akut miyokard infarktÃ¼sÃ¼nde yeni geliÅen atriyal fibrilasyon ile SYNTAX skoru arasÃ±ndaki iliÅki. SdÃ¢e SaÅljik BÃlÃmlerÅ° DergÃ°sÃ°, 2018, 9, 7-14.	0.1	1
2501	Performance and Egg Yolk Profile of Duck Feed a Diet Supplemented with Garlic Powder and Shrimp Waste. Jurnal Ilmu Pertanian Indonesia, 2018, 23, 227-232.	0.1	2
2502	Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 112, 649-705.	0.3	12
2503	Statins in real clinical practice: current guidelines, possibilities of new schemes for their use. Profilakticheskaya Meditsina, 2019, 22, 86.	0.2	0
2504	Metabolic syndrome: contemporary views and danger in pregnancy. PerinatologiÃ I PediatriÃ, 2019, , 74-78.	0.0	1
2505	GLIMEPIRIDE â€” ASSISTANT TESTED BY TIME. Problemi Endokrinnoi Patologii, 2019, 69, 121-127.	0.0	0
2506	Chemical and Functional Properties of Cavendish Jepara 30 (Musa cavendishii) Banana Pseudostem Flour after Blanching and Soaking in Sodium Bisulphite Solution. Pakistan Journal of Nutrition, 2019, 18, 936-945.	0.2	0
2507	Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. Singapore Medical Journal, 2019, 60, 454-462.	0.3	4

#	ARTICLE	IF	CITATIONS
2508	Hyperlipidemia management in Slovakia: observational study. <i>Vnitřní Lékařství</i> , 2019, 65, 761-769.	0.1	0
2509	Lipid disorders. , 2020, , 2055-2097.		0
2511	Effect of M-Health Application: “Chicken LOF”(Low Fat in 90 Days) on Lipid Profile and Body Composition Among Dyslipidemia Healthcare Workers: A Randomized Controlled Trial. <i>Open Public Health Journal</i> , 2020, 14, 341-349.	0.1	2
2514	Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 890-902.	1.1	13
2515	Impact of Baseline LDL-C and Lp(a) Elevation on Coronary Revascularization in Patients with Acute Coronary Syndrome One-Year after First Percutaneous Coronary Intervention. <i>World Journal of Cardiovascular Diseases</i> , 2020, 10, 102-115.	0.0	0
2516	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 615-636.	0.0	0
2518	SOME FEATURES OF PERIPHERAL BLOOD COMPOSITION IN PATIENTS WITH CORONARY ARTERY DISEASE AND ARTERIAL HYPERTENSION. , 2020, , 383-389.		1
2519	The prevalence of major cardiovascular risk factors in rural population of the Chui region of Kyrgyzstan: results of an epidemiological study. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 183-191.	0.5	2
2520	Changes in Target Achievement Rates after Statin Prescription Changes at a Single University Hospital. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020, 2, 103.	0.0	1
2521	Analysis of Susceptibility Factors and Related Predictors of the Coronary Artery Triple-Vessel Lesion. <i>Advances in Clinical Medicine</i> , 2020, 10, 1450-1456.	0.0	0
2522	MECHANISM OF AN ACUTE INCREASE OF INTRACRANIAL PRESSURE AND ITS HARMFUL INFLUENCE ON BRAIN TISSUE. <i>Nejrohirurgi i Nevrologi Kazahstana</i> , 2020, , 3-18.	0.0	0
2523	Correlations of lipid metabolism with bone remodeling. <i>Medic Ro</i> , 2020, 6, 28.	0.0	0
2524	Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an Observational Study of Treatment Patterns and Lipid Control. <i>Acta Clinica Croatica</i> , 2020, 59, 641-649.	0.1	1
2526	Statin therapy and low-density lipoprotein cholesterol reduction after acute coronary syndrome: Insights from the United Arab Emirates. <i>Heart Views</i> , 2020, 21, 80.	0.1	0
2527	FIBERPASTA “ Scientific Study on Obese Patients and FIBERPASTA “ Scientific Report - San Camillo Forlanini Diabetes Department. , 2020, 02, .		0
2528	Can We Improve the Evaluation of Cardiovascular Risk in Obese Children? A Possible Study Protocol. <i>Acta Medica Transilvanica</i> , 2020, 25, 14-19.	0.1	0
2529	Lipid Lowering Treatment and Follow Up in Recent Post Acute Coronary Syndrome Patients: Real-World Evidence from the Multicenter Observational Prospective - Post Acute Coronary Syndrome Italian Study (PACSI). <i>International Cardiovascular Forum Journal</i> , 0, 19, .	1.1	1
2530	Bariatric surgery and cardiovascular outcome. <i>Egyptian Heart Journal</i> , 2020, 72, 67.	0.4	12

#	ARTICLE	IF	CITATIONS
2531	Termination of the ESH-CHL-SHOT trial. <i>Journal of Hypertension</i> , 2020, 38, 2542-2543.	0.3	5
2532	Possibilities in the Prediction of Cardiac Arrhythmias and Conductivity Disorders in Former Athletes. <i>Advances in Gerontology</i> , 2020, 10, 363-367.	0.1	0
2533	Management of the Diabetic Patient in the Diagnostic Care Pathway. <i>IFMBE Proceedings</i> , 2021, , 784-792.	0.2	23
2534	Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101114.	0.9	8
2535	A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. <i>Clinical Biochemist Reviews</i> , 2012, 33, 25-31.	3.3	13
2536	Cholesterol and cardiovascular disease in the elderly. <i>Facts and gaps.</i> , 2013, 4, 154-69.		41
2537	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. <i>Canadian Family Physician</i> , 2013, 59, 1169-80.	0.1	38
2538	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. <i>Indian Journal of Medical Research</i> , 2013, 138, 461-91.	0.4	14
2539	Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia. <i>American Journal of Cardiovascular Disease</i> , 2014, 4, 58-69.	0.5	1
2540	Family history of cardiovascular disease. <i>Canadian Family Physician</i> , 2014, 60, 1016.	0.1	19
2541	Utility of different cardiovascular disease prediction models in rheumatoid arthritis. <i>Journal of Medicine and Life</i> , 2014, 7, 588-94.	0.4	3
2542	Interdisciplinary Approach in a Complex Case of STEMI. <i>MÃ dica</i> , 2014, 9, 382-6.	0.4	0
2543	Mean platelet volume variability in young patients with non-ST elevation acute myocardial infarction. <i>Journal of Medicine and Life</i> , 2014, 7 Spec No. 3, 107-13.	0.4	3
2544	Attainment of multifactorial treatment targets among the elderly in a lipid clinic. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 239-45.	0.2	4
2545	Non-High-Density Lipoproteins Cholesterol and Cardio-Metabolic Risk. <i>MÃ dica</i> , 2015, 10, 33-8.	0.4	1
2546	Associations of common SNPs in the SORT1, GCKR, LPL, APOA1, CETP, LDLR, APOE genes with lipid trait levels in an Algerian population sample. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7358-63.	0.5	6
2547	Frequency of Testing for Dyslipidemia: A Systematic Review and Budget Impact Analysis. <i>Ontario Health Technology Assessment Series</i> , 2014, 14, 1-27.	3.0	2
2549	Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care. <i>Canadian Family Physician</i> , 2015, 61, 857-67, e439-50.	0.1	47

#	ARTICLE	IF	CITATIONS
2550	Statin therapy for heart failure: to prescribe or not?. <i>Journal of Thoracic Disease</i> , 2015, 7, 1702-3.	0.6	0
2551	The Effect of Intensified Low Density Lipoprotein Cholesterol Reduction on Recurrent Myocardial Infarction and Cardiovascular Mortality. <i>Acta Cardiologica Sinica</i> , 2013, 29, 404-12.	0.1	11
2552	Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent. <i>Acta Cardiologica Sinica</i> , 2014, 30, 325-32.	0.1	2
2553	Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?. <i>Hippokratia</i> , 2015, 19, 332-7.	0.3	4
2554	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. <i>European Heart Journal Supplements</i> , 2017, 19, D163-D189.	0.0	0
2555	Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 89-96.	0.5	3
2556	Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 290-297.	0.2	0
2557	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. <i>BMJ Open</i> , 2020, 10, e036769.	0.8	1
2558	Plasma circulating microRNAs in patients with stable coronary artery disease - Impact of different cardiovascular risk profiles and glomerular filtration rates. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 270-276.	0.3	0
2559	Assessment of the Influence of Cardiovascular Risk Factors on the Prevalence of Arterial Hypertension in an Organized Population. <i>Problemy ZdorovĀ I Ākologii</i> , 2019, , 53-61.	0.0	0
2560	The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. <i>Pharmacological Research</i> , 2022, 175, 105986.	3.1	29
2561	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGram 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	1.0	9
2562	Pharmacodynamic Evaluation of the Gexia Zhuyu Decoction in the Treatment of NAFLD and the Molecular Mechanism Underlying the TRPM4 Pathway Regulation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15.	0.5	5
2563	Cardiovascular disease risk and key anthropometrics: a trend analysis. <i>British Journal of Cardiac Nursing</i> , 2021, 16, 1-16.	0.0	0
2565	Prevention and Influence of PCSK9 Inhibitors in Atherosclerotic (AS) Diseases. <i>Advances in Clinical Medicine</i> , 2021, 11, 5735-5739.	0.0	0
2566	Chronic fine particulate matter exposure, habitual exercise, and dyslipidemia: A longitudinal cohort study. <i>Environmental Epidemiology</i> , 2022, 6, e190.	1.4	2
2567	Awareness and Related Factors of Dyslipidemia in Menopausal Women in Korea. <i>Healthcare (Switzerland)</i> , 2022, 10, 112.	1.0	5
2568	Four-year changes in central fatness, risk of diabetes, and metabolic control in older adults: a cohort study with mediation analysis. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 230-240.	0.7	3

#	ARTICLE	IF	CITATIONS
2569	Long-term body composition improvement in post-menopausal women following bariatric surgery: a cross-sectional and case-control study. <i>European Journal of Endocrinology</i> , 2022, 186, 255-263.	1.9	2
2570	Akutes Koronarsyndrom: Wie geht es nach der Akutphase weiter?. , 0, , .		0
2571	Young Fatal Case of Familial Hypercholesterolemia: A Case Report. <i>Journal of Cardiovascular Medicine and Cardiology</i> , 0, , 016-017.	0.1	0
2572	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. <i>BMJ Open</i> , 2020, 10, e036769.	0.8	3
2573	Exploring the Role of Nutraceuticals (Red Yeast Rice) in Secondary Prevention: A New Pathway Can Be Opened. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 24-29.	0.0	0
2574	Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 822626.	1.1	1
2575	Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	9
2576	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. <i>Atherosclerosis</i> , 2022, 343, 28-50.	0.4	12
2577	Development of an Optimized Tetra-Amplification Refractory Mutation System PCR for Detection of 12 Pathogenic Familial Hypercholesterolemia Variants in the Asian Population. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 120-130.	1.2	0
2578	Artificial neuronal network analysis in investigating the relationship between oxidative stress and endoplasmic reticulum stress to address blocked vessels in cardiovascular disease. <i>Journal of Medical Biochemistry</i> , 2022, 41, 518-525.	0.7	1
2579	A very rare case of chylomicronemia revealed by cerebral thrombophlebitis in a 4-month-old infant. <i>Annals of Medicine and Surgery</i> , 2022, 75, 103276.	0.5	0
2580	Vascular dysfunction and dyslipidemia in multiple sclerosis: are they correlated with disease duration and disability status?. <i>Egyptian Heart Journal</i> , 2022, 74, 9.	0.4	6
2581	Impact of lowering low-density lipoprotein cholesterol thresholds on the proportion of adults requiring an intervention: Application of the 2019 ESC/EAS guidelines for the management of dyslipidaemia to the French population. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 106-108.	0.7	2
2582	EgÅ©szsÅ©gpszicholÅ©giai szempontok a szÅ©v- Å©s Å©rendszeri betegek kezelÅ©sÅ©ben. , 2022, , 57-79.		0
2583	Benefits of adherence to the Korea Healthy Eating Index on the risk factors and incidence of the metabolic syndrome: analysis of the 7th (2016-2018) Korea National Health and Nutrition Examination Survey. <i>Journal of Nutrition and Health</i> , 2022, 55, 120.	0.2	7
2584	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization. <i>JTCVS Open</i> , 2022, , .	0.2	4
2585	Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 451-465.	1.1	4
2586	A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021. <i>Current Problems in Cardiology</i> , 2023, 48, 101151.	1.1	13

#	ARTICLE	IF	CITATIONS
2587	Relationship between continuity of care and clinical outcomes in patients with dyslipidemia in Korea: a real world claims database study. <i>Scientific Reports</i> , 2022, 12, 3062.	1.6	2
2588	Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women. <i>Nutrients</i> , 2022, 14, 1082.	1.7	5
2589	Proteomic Analysis of Serum Lysine Acetylation in Uyghur Patients With T2DM. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 787885.	1.6	1
2590	Efficacy of Plant Sterol-Enriched Food for Primary Prevention and Treatment of Hypercholesterolemia: A Systematic Literature Review. <i>Foods</i> , 2022, 11, 839.	1.9	11
2591	Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 15-24.	1.1	6
2592	Association between Gout and Dyslipidemia: A Nested Caseâ€“Control Study Using a National Health Screening Cohort. <i>Journal of Personalized Medicine</i> , 2022, 12, 605.	1.1	4
2593	Effectiveness of bisoprolol versus other β -blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 423-436.	0.6	2
2594	RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. <i>International Journal of Diabetes in Developing Countries</i> , 0, , 1.	0.3	1
2595	Sonographic Tophi and Inflammation Are Associated With Carotid Atheroma Plaques in Gout. <i>Frontiers in Medicine</i> , 2021, 8, 795984.	1.2	10
2596	ST-elevation myocardial infarction complicated by cardiac arrest in a young patient with familial dyslipidemia. <i>Tap Chi Nghien Cuu Y Hoc</i> , 2022, 148, 141-145.	0.0	0
2597	Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 294-301.	1.0	8
2603	Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective. <i>Nestle Nutrition Institute Workshop Series</i> , 2015, 82, 61-73.	1.5	0
2606	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. , 2022, 13, 491.		17
2609	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014, 34 Suppl 2, 1-81.	0.2	8
2612	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9
2613	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. <i>BMJ Open</i> , 2022, 12, e055015.	0.8	0
2614	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	3.0	3
2615	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	5

#	ARTICLE	IF	CITATIONS
2616	A Pilot Study of whether or Not Vegetable and Fruit Juice Containing <i>Lactobacillus paracasei</i> Lowers Blood Lipid Levels and Oxidative Stress Markers in Thai Patients with Dyslipidemia: A Randomized Controlled Clinical Trial. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4913.	1.3	3
2617	Updating obesity management strategies: an audit of Italian specialists. <i>Eating and Weight Disorders</i> , 2022, 27, 2653-2663.	1.2	1
2619	A simultaneous pancreas-kidney transplantation for type 1 diabetes mellitus after a long-term of receiving hemodialysis renal replacement therapy. <i>Clinical Nese. Diabetes Mellitus</i> , 2022, 25, 192-198.	0.5	1
2620	Chia Flour (<i>Salvia hispanica</i> L.) Intake Does Not Affect Weight Loss and Lipid Profile but Improve Systolic Blood Pressure Control in Obesity. , 2023, 42, 403-410.		2
2621	Phyto-Enrichment of Yogurt to Control Hypercholesterolemia: A Functional Approach. <i>Molecules</i> , 2022, 27, 3479.	1.7	4
2622	Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. <i>American Heart Journal</i> , 2022, 251, 78-90.	1.2	7
2623	A Mobile Health-Based Disease Management Program Improves Blood Pressure in People With Multiple Lifestyle-Related Diseases at Risk of Developing Vascular Diseaseâ€• A Retrospective Observational Study â€•. <i>Circulation Reports</i> , 2022, 4, 322-329.	0.4	1
2624	Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	5
2625	Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper.. <i>Archives of Medical Science</i> , 0, , .	0.4	5
2626	The Effect of Anthropometric Measurements on the Incidence of Atrial Fibrillation in Patients With Acute Myocardial Infarction. <i>Cureus</i> , 2022, , .	0.2	0
2627	The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Populationâ€•A Review. <i>Life</i> , 2022, 12, 839.	1.1	3
2628	Demographics and Characteristics of Patients Admitted With Acute Coronary Syndrome to the Coronary Care Unit at King Abdulaziz University. <i>Cureus</i> , 2022, , .	0.2	1
2629	Hypertriglyceridemia induced acute pancreatitis: 4 years' experience from a tertiary care institute and quick literature review. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 3360.	0.3	2
2630	Lipid-lowering therapy in patients with peripheral artery disease â€• a call for action. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, 51, 193-195.	0.6	1
2631	C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. <i>European Journal of Internal Medicine</i> , 2022, 104, 49-54.	1.0	14
2632	Intensity of and Adherence to Lipidâ€•Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	13
2633	Plasma lipoprotein (a) and tissue plasminogen activator are associated with increased risk of atherosclerotic cardiovascular disease. <i>Heliyon</i> , 2022, 8, e09836.	1.4	4
2634	Effect of Low High-Density Lipoprotein Level on Endothelial Activation and Prothrombotic Processes in Coronary Artery Diseaseâ€•A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8637.	1.2	2

#	ARTICLE	IF	CITATIONS
2635	TG/HDL-C Ratio Is a Risk Factor Associated with CKD: Use in Assessing the Risk of Progression of CKD. <i>Pathophysiology</i> , 2022, 29, 374-382.	1.0	3
2637	Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality. <i>Pharmaceuticals</i> , 2022, 15, 919.	1.7	6
2638	Efficacy and Safety Differences between Domestic Paclitaxel Drug-Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral-Popliteal Arteries Type IIAâ€“C. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-5.	0.4	1
2639	Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1483-1489.	1.2	1
2640	Anti-hypercholesterolemic activity of standardized fermented <i>Allium cepa</i> L. var <i><i>aggregatum</i></i> extract: <i><i>In vitro</i></i> and <i><i>in vivo</i></i> studies. <i>Journal of HerbMed Pharmacology</i> , 2022, 11, 383-388.	0.4	0
2641	Artificial Scaffolds in Cardiac Tissue Engineering. <i>Life</i> , 2022, 12, 1117.	1.1	19
2642	The monomeric C-reactive protein level is associated with the increase in carotid plaque number in patients with subclinical carotid atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
2643	Early flattening of the oxygen pulse during the cardiopulmonary exercise test in asymptomatic adults and its association with cardiovascular risk factors. <i>International Journal of Cardiology</i> , 2022, 367, 65-73.	0.8	4
2644	<i>Gynostemma pentaphyllum</i> for dyslipidemia: A systematic review of randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2645	Pharmacoepidemiological analysis of the effect of lipid-lowering therapy on cardiovascular mortality in the regions of the Russian Federation. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022, , 45-54.	0.2	0
2646	Assessment of cardiovascular risk with C-reactive protein in rheumatoid arthritis patients. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
2647	The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis. <i>BioMed Research International</i> , 2022, 2022, 1-14.	0.9	8
2648	Heat maps of cardiovascular disease risk factor clustering among community-dwelling older people in Xinjiang: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e058400.	0.8	1
2649	Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8686.	1.8	9
2650	Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study. <i>Clinical Therapeutics</i> , 2022, 44, 1272-1281.	1.1	3
2651	EVOOâ€™s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10120.	1.8	2
2652	Lipid nutritional value and bioaccessibility of novel <i><scp>readyâ€™toâ€™eat</scp></i> seafood products with encapsulated bioactives. <i>International Journal of Food Science and Technology</i> , 2023, 58, 2722-2734.	1.3	0
2653	Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. <i>Pharmacological Research</i> , 2022, 184, 106439.	3.1	10

#	ARTICLE	IF	CITATIONS
2654	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. , 2022, , 133-198.		0
2655	Associations between Individual Exposure to Fine Particulate Matter Elemental Constituent Mixtures and Blood Lipid Profiles: A Panel Study in Chinese People Aged 60â€“69 Years. Environmental Science & Technology, 2022, 56, 13160-13168.	4.6	6
2656	Characteristics and outcomes of COVID-19 in heart transplantation recipients in the Netherlands. Netherlands Heart Journal, 2022, 30, 519-525.	0.3	2
2657	Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study. Cardiovascular Drugs and Therapy, 2024, 38, 119-129.	1.3	0
2658	Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. Clinical Research in Cardiology, 2023, 112, 299-311.	1.5	7
2659	Cardiovascular disease risk among male workers of a regional electricity distribution company in Brazil. Work, 2022, , 1-8.	0.6	0
2660	Statin Myopathy. , 2022, , 137-147.		0
2661	Mediterranean Diet Adherence and Serum Markers of Lipids. Biomarkers in Disease, 2022, , 329-357.	0.0	0
2663	Consumo de azÃ³car y eventos cardiovasculares mayores: revisiÃ³n sistemÃ¡tica. Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo, 2022, 9, .	0.1	1
2664	Low grade intravascular hemolysis associates with peripheral nerve injury in type 2 diabetes. PLoS ONE, 2022, 17, e0275337.	1.1	3
2665	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 100513.		3
2666	Twenty-first century epidemiology of dyslipidemia in Greece: EMENO national epidemiological study. Hellenic Journal of Cardiology, 2023, 69, 1-8.	0.4	6
2667	Exploring the Novelty in Lipid Profiling of Patients: A Non-fasting Approach from Eastern India. Journal of Laboratory Physicians, 0, , .	0.4	0
2668	Association between sedentary behavior, physical activity, and cardiovascular disease-related outcomes in adultsâ€”A meta-analysis and systematic review. Frontiers in Public Health, 0, 10, .	1.3	16
2669	Effect of Atorvastatin on Serial ChangesÃn Coronary Physiology andÃn Plaque Parameters. JACC Asia, 2022, , .	0.5	0
2670	Familial chylomicronemia syndrome caused by compound heterozygous mutation of lipoprotein lipase gene: A case report and review of literature. Clinica Chimica Acta, 2022, 537, 112-117.	0.5	0
2671	Sorption of bile salts from aqueous solutions by MCM-41 silica with chemically immobilized steroid groups. Applied Nanoscience (Switzerland), 0, , .	1.6	0
2673	Characteristics of Rheoencephalography and some associated factors on menopausal women. Journal of Electrical Bioimpedance, 2022, 13, 78-87.	0.5	0

#	ARTICLE	IF	CITATIONS
2674	Current issues of lipid-lowering therapy in patients with high-risk hypertension. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 42.	0.2	0
2675	Evaluation of rs1748195 <scp>ANGPTL3</scp> gene polymorphism in patients with angiographic coronary artery disease compared to healthy individuals. <i>Molecular Genetics & Genomic Medicine</i> , 2023, 11, .	0.6	5
2676	Recommended and observed statin use among U.S. adults â€“ National Health and Nutrition Examination Survey, 2011-2018. <i>Journal of Clinical Lipidology</i> , 2023, 17, 225-235.	0.6	3
2677	Marked weight loss on liraglutide 3.0Âµg: Real-life experience of a <scp>S</scp>wiss cohort with obesity. <i>Obesity</i> , 2023, 31, 74-82.	1.5	7
2678	Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100663.	1.3	1
2679	INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 42-46.	0.3	0
2680	Pediatric Population with Down Syndrome: Obesity and the Risk of Cardiovascular Disease and Their Assessment Using Omics Techniquesâ€”Review. <i>Biomedicines</i> , 2022, 10, 3219.	1.4	1
2681	Effect of ApoE Îµ4 gene polymorphism on the correlation between serum uric acid and left ventricular hypertrophy remodeling in patients with coronary heart disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
2682	Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study. <i>EJHaem</i> , 2023, 4, 3-12.	0.4	0
2683	Hyperlipidemia in children: Unsolved problems. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2023, 67, 40-45.	0.1	0
2684	How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases. <i>Therapeutic Advances in Chronic Disease</i> , 2023, 14, 204062232211432.	1.1	1
2685	Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (â€œJena auf Zielâ€). <i>Clinical Research in Cardiology</i> , 2023, 112, 1212-1219.	1.5	8
2686	The TELE-DD Randomised Controlled Trial on Treatment Adherence in Patients with Type 2 Diabetes and Comorbid Depression: Clinical Outcomes after 18-Month Follow-Up. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 328.	1.2	2
2687	National Trends in Statin Use in Lithuania from 2010 to 2021. <i>Medicina (Lithuania)</i> , 2023, 59, 37.	0.8	2
2688	Real-World Use of Alirocumab: Experience from a Large Healthcare Provider. <i>Journal of Clinical Medicine</i> , 2023, 12, 1084.	1.0	0
2689	Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event. <i>Leukemia Research</i> , 2023, 127, 107023.	0.4	1
2690	Cardiovascular and lipid-lowering effects of a marine lipoprotein extract in a high-fat diet-induced obesity mouse model. <i>International Journal of Medical Sciences</i> , 2023, 20, 292-306.	1.1	4
2691	Correlation between red cell distribution width and coronary artery disease in patients undergoing elective coronary angiography. <i>International Journal of Research in Medical Sciences</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
2692	Inclisiran – A Revolutionary Addition to a Cholesterol-Lowering Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6858.	1.8	3
2693	Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses. <i>Atherosclerosis</i> , 2023, 367, 24-33.	0.4	9
2694	New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. <i>Nutrients</i> , 2023, 15, 640.	1.7	26
2695	Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. <i>Phytomedicine</i> , 2023, 112, 154716.	2.3	3
2696	The Impact of Novel Reconstruction Algorithms on Calcium Scoring: Results on a Dedicated Cardiac CT Scanner. <i>Diagnostics</i> , 2023, 13, 789.	1.3	0
2698	The Role of Certain Polymorphic Variants in Genes, Previously Associated with Blood Pressure Values, with Reference to the Risk of Development of Coronary Artery Disease. <i>Acta Medica Bulgarica</i> , 2022, 49, 5-11.	0.0	0
2699	Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease. <i>Chest</i> , 2023, 164, 637-649.	0.4	6
2700	Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1078.	3.8	16
2701	Efficacy of Mobile-Based Cognitive Behavioral Therapy on Lowering Low-density Lipoprotein Cholesterol Levels in Patients With Atherosclerotic Cardiovascular Disease: Multicenter, Prospective Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 0, 25, e44939.	2.1	2
2702	The Challenges of Implementing a Text Message Intervention to Promote Behavioral Change in Primary Care Patients With Hypertension and Diabetes. <i>International Journal of Cardiovascular Sciences</i> , 2023, 36, .	0.0	0
2704	Long-term Effectiveness of Myocardial Revascularization in Patients After the Transferred Syndrome (Literature Review with Own Research Results). <i>Lviv Clinical Bulletin</i> , 2023, 1, 73-79.	0.1	0
2705	Mortality across the spectrum of hemoglobin level in patients undergoing surgical coronary revascularization. <i>Clinical Cardiology</i> , 2023, 46, 535-542.	0.7	1
2706	Efficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot study. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 67, 15-20.	0.4	0
2707	Relationship Between Rotating Night Shift Work and Anthropometric Markers of Overall and Central Adiposity. <i>Risk Management and Healthcare Policy</i> , 0, Volume 16, 537-549.	1.2	0
2708	Assessing Effects of Diet Alteration on Carbohydrate – Lipid Metabolism of Antipsychotic-Treated Schizophrenia Patients in Interventional Study. <i>Nutrients</i> , 2023, 15, 1871.	1.7	0
2709	Evidence-based European recommendations for the dietary management of diabetes. <i>Diabetologia</i> , 2023, 66, 965-985.	2.9	32
2710	A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
2711	Nutraceutical alternatives to red yeast rice extract/monacolin K for moderate hypercholesterolaemia: Current evidence and knowledge gaps: Nutraceuticals and hypercholesterolaemia. , 2022, 1, .		0

#	ARTICLE	IF	CITATIONS
2716	Development and therapeutic applications of monoclonal antibodies. , 2023, , 99-114.		0
2717	Special Patient Populations. , 2024, , 336-344.e2.		1
2724	Nutraceuticals and Functional Foods for Cholesterol Reduction. , 2024, , 236-245.e3.		0
2755	Pulsed-field ablation of atrial fibrillation: kinetics of release of multiple cardiac biomarkers. Journal of Interventional Cardiac Electrophysiology, 0, , .	0.6	0